ECLAMPSIA A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R EFERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright ©2004 by ICON Group International, Inc. Copyright ©2004 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1 Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Eclampsia: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-84403-8 1. Eclampsia-Popular works.I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International, Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on eclampsia. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes&Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON ECLAMPSIA ............................................................................................... 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Eclampsia ...................................................................................... 7 E-Journals: PubMed Central ....................................................................................................... 29 The National Library of Medicine: PubMed ................................................................................ 30 CHAPTER 2. NUTRITION AND ECLAMPSIA ..................................................................................... 77 Overview...................................................................................................................................... 77 Finding Nutrition Studies on Eclampsia..................................................................................... 77 Federal Resources on Nutrition ................................................................................................... 83 Additional Web Resources ........................................................................................................... 83 CHAPTER 3. ALTERNATIVE MEDICINE AND ECLAMPSIA ............................................................... 87 Overview...................................................................................................................................... 87 National Center for Complementary and Alternative Medicine.................................................. 87 Additional Web Resources ........................................................................................................... 94 General References ....................................................................................................................... 96 CHAPTER 4. PATENTS ON ECLAMPSIA ............................................................................................ 97 Overview...................................................................................................................................... 97 Patents on Eclampsia ................................................................................................................... 97 Patent Applications on Eclampsia ............................................................................................. 104 Keeping Current ........................................................................................................................ 113 CHAPTER 5. BOOKS ON ECLAMPSIA.............................................................................................. 115 Overview.................................................................................................................................... 115 Book Summaries: Online Booksellers......................................................................................... 115 Chapters on Eclampsia............................................................................................................... 116 CHAPTER 6. PERIODICALS AND NEWS ON ECLAMPSIA ................................................................ 117 Overview.................................................................................................................................... 117 News Services and Press Releases.............................................................................................. 117 Academic Periodicals covering Eclampsia ................................................................................. 121 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 125 Overview.................................................................................................................................... 125 NIH Guidelines.......................................................................................................................... 125 NIH Databases........................................................................................................................... 127 Other Commercial Databases..................................................................................................... 129 The Genome Project and Eclampsia ........................................................................................... 129 APPENDIX B. PATIENT RESOURCES ............................................................................................... 133 Overview.................................................................................................................................... 133 Patient Guideline Sources.......................................................................................................... 133 Finding Associations.................................................................................................................. 137 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 139 Overview.................................................................................................................................... 139 Preparation................................................................................................................................. 139 Finding a Local Medical Library................................................................................................ 139 Medical Libraries in the U.S. and Canada ................................................................................. 139 ONLINE GLOSSARIES................................................................................................................ 145 Online Dictionary Directories ................................................................................................... 148 ECLAMPSIA DICTIONARY ....................................................................................................... 149
viii Contents
INDEX .............................................................................................................................................. 217
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with eclampsia is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about eclampsia, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to eclampsia, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on eclampsia. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to eclampsia, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on eclampsia. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON ECLAMPSIA Overview In this chapter, we will show you how to locate peer-reviewed references and studies on eclampsia.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and eclampsia, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “eclampsia” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Prepregnancy Weight and the Risk of Pregnancy Complications Source: Healthy Weight Journal. 15(6): 83. November/December 2001. Summary: A study initially published in the American Journal of Public Health found that both overweight and obese women appear to have an increased risk of developing pregnancy complications. Researchers categorized 96,801 women by body mass index (BMI) using data obtained from Washington State birth certificates and driver licenses issued between 1992 and 1996. Findings indicated that when compared with thin women, both overweight and obese women were at a significantly higher risk for developing gestational diabetes, preeclampsia, and eclampsia. The risk of these diseases and Cesarean delivery increased consistently for women with a prepregnancy BMI of 20 or greater. Women who were overweight or obese were also at greater risk for delivering at or before 32 weeks gestation. Moreover, infants of obese women had a
4
Eclampsia
nearly twofold increased risk of death within the first year of life. The researchers emphasized that women should avoid excessive weight gain during adolescence and young adulthood. •
Part 2: Rationale for a Wellness Approach to Obesity Source: Healthy Weight Journal. 14(2):20-24. March-April 2000. Summary: Based on a review of studies comparing body mass index (BMI) and mortality, the authors conclude that extremes of weight, both overweight and underweight, result in excess mortality. The excess mortality among the underweight cannot be attributed to smoking, as is sometimes done, because the smokers who are at the highest risk for disease are not especially lean. In the elderly, leanness is an indicator for increased mortality; obesity is not a risk factor until it reaches the extremes of a BMI greater than 35. Obesity can actually be beneficial in terms of risk for some diseases. This is true for cancer, infectious diseases, chronic obstructive pulmonary disease, osteoporosis, eclampsia, peptic ulcer, and suicide, among others. In other diseases, patients were are classified as obese have a better survival rate than leaner patients. Examples are hypertension, high cholesterol, and diabetes type II. The authors caution that this does not mean that patients with these conditions should try to gain weight, but that patients who are overweight do not have as dire a prognosis as leaner patients. More dangerous in the view of the authors are the ineffective methods of weight loss attempted by many overweight patients. None have proved effective and weight cycling (repeated loss and gain of weight) has been shown to be hazardous. The authors call for a change of focus, to healthy lifestyles, rather than a focus on weight loss.
•
Hypertension in Pregnancy Source: Nephron. 76(3): 254-263. July 1997. Contact: Available from S. Karger Publishers, Inc. 26 West Avon Road, P.O. Box 529, Farmington, CT 06085. Summary: Normal pregnancy is characterized by a marked reduction in peripheral vascular resistance. Blood pressure is diminished, while cardiac output, blood volume, renal blood flow, and the glomerular filtration rate (GFR) are increased. These hemodynamic changes are reversed in preeclampsia eclampsia (PE E), a condition considered to be related to a dysfunction of the endothelium. This article discusses hypertension in pregnancy, notable PE E. The author hypothesizes that decreases in the production of nitric oxide (NO) and prostacyclin (in association with an increased synthesis of thromboxane A2) may play a role in the pathogenesis of PE E. Recent reports have supported the concept that an imbalance between vasodilators and vasoconstrictors may explain the clinical, laboratory, and hemodynamic disturbances observed in PE E. The control of hypertension, rest, and close clinical and laboratory surveillance remain the gold standard to minimize the severity of the complications of PE E. However, on the basis of its physiology and pathophysiology, low dose aspirin has been recommended in pregnancies at risk to prevent or, at least, delay the occurrence of PE E. Although initial reports showed promising results, recent conclusions from large trials have moderated this optimism. The use of supplemental L arginine may be considered another possibility of treatment, and experimental data have given convincing results, but there are no reports on PE E. The author concludes that the practical management of PE E requires prudence, careful followup and prompt decisions on the precise moment for delivery (which remains the most effective
Studies
5
therapeutic procedure). The article concludes with a roundtable discussion of the practical issues that arise in managing these patients. 54 references. •
Malignant Hypertension and Hypertensive Emergencies Source: JASN. Journal of the American Society of Nephrology. 9(1): 133-142. January 1998. Contact: Available from Williams and Wilkins. 428 E. Preston Street, Baltimore, MD 21202. (800) 638-6423. Summary: This article discusses hypertensive crises, defined as a syndrome characterized by severe blood pressure (BP) elevation associated with imminent risks to the patient. It is a common clinical problem and accounts for 27.5 percent of all medical emergencies presenting to the emergency department. The most important determinant for the urgency of treatment is deterioration of vital organ function secondary to the hypertension. The authors consider both the presence of Keith-Wagener grade IV retinal changes (papilledema) and grade III retinopathy (hemorrhages, cotton wool spots, and hard exudates without papilledema) as malignant hypertension. The authors outline the incidence, etiology, pathology, clinical presentation (including renal involvement), and prognosis of malignant hypertension. The next section of the article considers drugs of choice for hypertensive emergencies and urgencies, including sodium nitroprusside, labetalol, nitroglycerin, beta-adrenergic blockers, diazoxide, trimethaphan camsylate, phentolamine and phenoxybenzamine, antiotensin-converting enzyme (ACE) inhibitors, hydralazine, minoxidil, calcium channel blockers, and clonidine. The final section of the article discusses special situations, including acute renal failure, hypertensive encephalopathy, cerebrovascular accidents (stroke), left ventricular failure and pulmonary edema, myocardial infarction and unstable angina, dissecting aortic aneurysm, adrenergic crises, postoperative hypertension, and eclampsia. The authors conclude that the effects of hypertension on target organ function need to be balanced against the risks of excessive BP lowering. 1 figure. 4 tables. 31 references.
•
HELLP Syndrome: Hemolysis, Elevated Liver Enzymes, and Low Platelets Source: JAMA. Journal of the American Medical Association. 280(6): 559-562. August 12, 1998. Summary: This article presents a detailed case study and discussion of HELLP syndrome, which consists of hemolysis, elevated liver enzymes, and low platelets. The HELLP syndrome is one of the hypertensive disorders of pregnancy, which also include preeclampsia and eclampsia. The multi-organ dysfunction in HELLP can lead to acute tubular necrosis and renal failure. Preeclampsia is associated with glomerular endotheliosis, whose pathologic hallmark is a thickening of the basement membranes; a similar renal lesion may account for the proteinuria in HELLP. With proper supportive care, most patients fully recover kidney function. The author emphasizes that all physicians should know that a cardinal symptom of the HELLP syndrome is right upper quadrant pain. Clinicians examining pregnant women in a primary care or subspecialty setting should have a low threshold for ordering a complete blood count, urinalysis, and liver function tests, even if the patients complaints are nonspecific. Finally, pregnant women need regular, accurate blood pressure measurement. A blood pressure of 140 over 90 mm Hg, normal in most nonpregnant patients, may indicate serious disease in pregnant women. 28 references.
6
•
Eclampsia
Jaundice in Pregnancy Source: European Journal of Gastroenterology and Hepatology. 3(12): 892-896. December 1991. Summary: This article presents an overview of the occurrence of jaundice in pregnancy. Topics include the causes of jaundice; disorders specific to pregnancy, including hyperemesis gravidarum, benign recurrent intrahepatic cholestasis of pregnancy, HELLP syndrome (hemolysis, elevated liver enzymes and low platelets), toxemia/eclampsia and liver disease, biliary disease and pregnancy, infections of the liver during pregnancy, hepatocellular disorders and pregnancy, vascular hepatic disorders and pregnancy, and hepatic tumors and pregnancy. The author stresses that knowledge of the biochemical changes that are physiological and that occur in normal pregnancy is imperative in order to avoid mistaken interpretation of the biochemical tests during pregnancy. 1 table. 30 annotated references.
•
Liver Disease in Pregnancy Source: New England Journal of Medicine. 335(8): 569-576. August 22, 1996. Summary: This article reviews liver disease in pregnancy. Topics include diagnosis; cholestatic liver disease, including hyperemesis gravidarum, and intrahepatic cholestasis of pregnancy; hepatocellular disease, including viral hepatitis, liver diseases of late pregnancy, acute fatty liver of pregnancy, preeclampsia and eclampsia, and the HELLP syndrome; and the differential diagnosis of liver disease in pregnancy, including the changes in laboratory values, and the use of ultrasound and liver biopsy. The authors emphasize that liver disease is a rare complication of pregnancy, but when it occurs it may do so in a dramatic and tragic fashion for both mother and infant. 3 figures. 2 tables. 60 references.
•
Diagnosing and Managing Liver Abnormalities in Pregnancy Source: IM. Internal Medicine. 20(5): 31-32, 35-40. May 1999. Contact: Available from Medical Economics. 5 Paragon Drive, Montvale, NJ 07645. (800) 432-4570. Summary: This article reviews the diagnosis and management of liver abnormalities in pregnancy. The authors note that certain effects of pregnancy can create the impression of liver disease where none exists. However neither serum transaminase nor bilirubin is altered during normal pregnancy; therefore, these tests are reliable indicators of liver disease. When a pregnant patient presents with evidence of liver disease, there are three options to consider. She may have one of the liver problems that are unique to pregnancy, which include abnormalities associated with hyperemesis gravidarum, intrahepatic cholestasis of pregnancy (IHCP), preeclampsia eclampsia HELLP syndrome, and acute fatty liver of pregnancy (AFLP). Or she could have a liver disease for which pregnancy is a predisposing factor, such as Budd Chiari syndrome or herpes hepatitis. If neither is the case, then she either has underlying liver disease or has acquired it coincidentally. Some of these latter situations, such as hepatitis B during pregnancy, may also have important implications for the infant. The author concludes that while corrective treatment is often not possible, timely detection and control of liver disease in pregnancy are always important to an optimal outcome. The article includes a diagnostic algorithm for liver disease in pregnancy. 1 figure. 1 table. 17 references.
Studies
•
7
Liver Diseases in Pregnancy Source: Practical Gastroenterology. 20(7): 14, 16-18, 20, 25-26, 28, 30-32, 37. July 1996. Contact: Available from Shugar Publishing, Inc. 99B Main Street, Westhampton Beach, NY 11978. (631) 288-4404. Fax (631) 288-4435. E-Mail:
[email protected]. Summary: This article, one in a series on gastrointestinal (GI) disorders during pregnancy, reviews liver diseases in pregnancy. Liver diseases during pregnancy range from benign to fatal, and from diagnostically straightforward to challenging. In this review article, the authors discuss the pathophysiology, diagnosis, and management of some important hepatobiliary disease that may affect pregnant patients. First, they review the entities peculiar to pregnancy, such as cholestasis of pregnancy, hyperemesis gravidarum, preclampsia and eclampsia, and acute fatty liver of pregnancy. In the second section, they discuss a number of important hepatobiliary diseases that may be coincidental with pregnancy, including viral hepatitis, the portal hypertensive state, autoimmune hepatitis, primary biliary cirrhosis, Wilson's disease, hemochromatosis, gallstones, Budd-Chiari syndrome, Dubin-Johnson syndrome, acute porphyrias, and liver mass lesions. The authors focus in particular on the diagnostic approach to the pregnant patient, as well as outcome for the fetus and the afflicted mother. Finally, they briefly consider the role of liver transplantation in pregnancy. 71 references. (AA-M).
Federally Funded Research on Eclampsia The U.S. Government supports a variety of research studies relating to eclampsia. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to eclampsia. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore eclampsia. The following is typical of the type of information found when searching the CRISP database for eclampsia: •
Project Title: ANGIOGENIC & PREMEABILITY PREECLAMPSIA
GROWTH
FACTORS
IN
Principal Investigator & Institution: Johnson, Donna D.; Obstetrics and Gynecology; Medical University of South Carolina 171 Ashley Ave Charleston, Sc 29425 Timing: Fiscal Year 2002; Project Start 28-AUG-2001; Project End 30-JUN-2004 Summary: (provided by applicant): Pre-eclampsia is a multisystem disorder that complicates 10 percent of pregnancies. This disease leads to increased morbidity and mortality for both the mother and baby. Although the clinical presentation of the disease 2 Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
8
Eclampsia
is well described, the pathophysiologic mechanisms for the clinical manifestations are not. The overall hypothesis of this application is that vascular endothelial growth factor (VEGF) and placental growth factor (PIGE) are likely mediators of some of the clinical features of preeclampsia and the placenta is the site for the altered production of these growth factors. VEGF and PIGF are specific mitogen for endothelial cells and are potent stimuli for angiogenesis and vascular permeability. The biological activity of these related growth factors is modified depending on the concentration of each. This proposal will examine their relationship to the clinical manifestations of preeclampsia in two specific aims. In specific aim one, the hypothesis to be tested is that maternal serum levels of PIGE and VEGF are altered in preeclamptic patients and these alterations correlate to increased vascular permeability and subsequently clinical manifestations of the disease, such as proteinuria and pulmonary edema. Maternal serum levels of VEGF and PIGE will be measured by enzyme-linked immunosorbent assay (ELISA) in pregnancies complicated by pre-eclampsia and then compared to those found in normal pregnancies. We will follow patients longitudinally to determine if the alterations of VEGF and PIGF change as the disease progresses. PIGF is an important modulator of VEGF activity. We predict that PIGE levels decrease but VEGF levels remain unchanged or increase. As PIGF levels become more depressed, the clinical manifestations of preeclampsia will progress. In specific aim two, the hypothesis to be tested is that alterations in maternal serum levels of PIGF and VEGF will be reflected in the placenta at the level of gene expression. Maternal serum levels of VEGF and PIGE will be measured by ELISA in normal pregnancies and pregnancies complicated by preeclampsia and correlated with the expression VEGF and PIGE mRNA in the placenta determined by Northern blot. The placenta is likely the major source for these growth factors in pregnancy and any changes in the serum levels will be reflected in the placenta. In other words PIGF gene expression will be reduced and VEGF gene expression will be unchanged or increased. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BIOLOGY OF HUMAN UTERINE NK CELLS Principal Investigator & Institution: Moffett, Ashley; University of Cambridge Cambridge, England Cambridge, Timing: Fiscal Year 2003; Project Start 21-SEP-2001; Project End 30-NOV-2004 Summary: In human pregnancy normal implantation and development of the fetoplacental unit is dependent on transformation of the uterine lining from endometrium to decidua. The formation of decidua is essential for normal pregnancy. In a non-pregnant cycle the endometrium breaks down at menstruation and a similar process occurs in a failing pregnancy at miscarriage. The cellular and molecular processes responsible for formation of decidua or endometrial breakdown are largely unknown. The hypothesis underlying this proposal is that the unusual population of uterine mucosal leucocytes, uterine Natural Killer (N K) cells, play a pivotal role in the critical decision that the secretory endometrium must make either to decidualise or undergo menstruation. The functions of uterine NK cells are unknown, but they are most abundant in species which undergo mucosal decidualisation and they are an integral part of decidua. In nonpregnant cycles they undergo apoptosis 2-3 days preceding menstrual breakdown before there are no other morphological features of menstruation. The specific questions are: 1) Are the NK cells in the uterine mucosa recruited from the blood? 2) What factors in the uterine microenvironment are responsible for triggering NK cell apoptosis or maintaining NK cell survival? 3) Can uterine NK cells influence the process of decidualisation? This work will increase understanding of two crucial processes in
Studies
9
human reproductive physiology - decidualisation and menstruation. Therefore this work will have a major impact on women's health. It could lead to novel therapeutic approaches in a wide range of disorders including infertility, miscarriage, disorders due to defective placentation (pre-eclampsia and IUGR) and menstrual disorders. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CANCER IN THE JERUSALEM PERINATAL STUDY COHORT Principal Investigator & Institution: Harlap, Susan; Research Professor; Obstetrics and Gynecology; New York University School of Medicine 550 1St Ave New York, Ny 10016 Timing: Fiscal Year 2002; Project Start 15-JUN-1999; Project End 31-MAY-2003 Summary: The Jerusalem Perinatal Study is a population-based research data bank based on mothers, fathers and offspring. In 1964-76 all Jewish births were surveyed, as were all births to Arab residents of West Jerusalem. Demographic data were recorded on the parents, infant deaths and congenital malformations, admissions to hospitals and obstetric complications. Approximately two thirds of the Jews were refugees, or their offspring, from Morocco, Algeria, Tunisia, Egypt, Iraq, Iran, Turkey, Yemen, Syria or Lebanon. Specific subsets of the mothers were interviewed in 1966-68 and 1975-76, adding information on consanguinity, antenatal health, body size, smoking, fertility, gynecologic variables and contraceptive use. After an average of 27 years (range 21-33) most offspring have completed their compulsory military service. This cohort may be one of the largest to include ethnic ancestry with obstetric and social data, which can link siblings and parents. We propose to link this database with Israel's Cancer Registry for follow-up studies of malignancies, as the parents and offspring age, and to prepare for the potential use of this cohort for cancer prevention trials. In this initial 4-year project we will undertake the checking and corrections needed for record linkage, describe losses to follow up, identify deaths and update the record linkage annually. Linkage in 1999 will identify malignancies diagnosed to the end of 1996, including an estimated 1846 cases in the 34,900 mothers and 485 in the 92,500 male and female offspring. We estimate there will be 440 cancers of breast and 122 of ovary, half of them to women of non-European origin. Focussing on breast cancer in mothers we will test for effects of gender of first offspring and explore ethnic differences in the effects of these and conventional risk factors. We will question whether changes in incidence of breast cancer and or other cancers can be predicted by births of offspring with major or minor birth defects, including neural tube defects and Down's syndrome, or by certain obstetric outcomes, including pre-eclampsia. The results may identify women who would benefit from intensive screening or provide new clues to the etiology of breast cancer. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CEREBROVASCULAR HYPERTENSION
CHANGES
IN
PREGNANCY
AND
Principal Investigator & Institution: Cipolla, Marilyn J.; Neurology; University of Vermont & St Agric College 340 Waterman Building Burlington, Vt 05405 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2007 Summary: (provided by applicant): Eclampsia is a serious complication of pregnancy that occurs when hypertension develops with neurologic symptoms, including headaches, nausea, visual disturbances and convulsions. While numerous organs are affected by hypertension in pregnancy, cerebrovascular involvement is the direct cause of death in approximately 40 percent of patients. The major cerebrovascular changes
10
Eclampsia
that occur have been shown to be similar to hypertensive encephalopathy in which acute elevations in blood pressure (i.e., acute hypertension) overcome the myogenic vasoconstriction of the cerebral arteries and arterioles causing autoregulatory failure, hyperperfusion and edema. Because women who develop eclampsia in general are normotensive prior to pregnancy, there is evidence that pregnancy affects the cerebral circulation in a way that makes the vessels susceptible to autoregulatory failure and hyperperfusion during acute hypertension. The long-term objective of this proposal is to investigate how pregnancy affects the structure and function of the cerebral circulation focusing on diameter regulation in response to changes in pressure (myogenic reactivity) and how those changes affect vascular permeability that promotes edema. Aim 1 will use isolated and pressurized posterior cerebral arteries from pregnant and nonpregnant rats to determine the pressure at which forced dilatation occurs and investigate underlying mechanisms of pregnancy-induced alterations in diameter regulation, including vascular smooth muscle actin and endothelial cell influences (e.g., nitric oxide and prostaglandins). In addition, since hypertension alone has been shown to cause significant remodeling and reactivity changes in the cerebral circulation, Aim 1 will also investigate how elevated mean arterial pressure during pregnancy affects myogenic activity and diameter regulation in a rat model of hypertension in pregnancy (nitric oxide inhibition). Acute hypertension and eclampsia are associated with significant edema formation due to disruption of the normally impermeable cerebral endothelium. Therefore, Aim 2 will investigate pregnancy-induced changes in endothelial cell permeability during acute hypertension, including enhanced fluid phase endocytosis (transcellular flux) and tight junction disruption (paracellular flux). The influence of pregnancy on permeability during forced dilatation will be determined using a combination of techniques, including clearance of fluorescent tracers and transmission electron microscopy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CHRONIC HYPOXIA, UTERINE ARTERY VASOREGULATION & GROWTH Principal Investigator & Institution: Moore, Lorna G.; Professor; Medicine; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, Co 800450508 Timing: Fiscal Year 2002; Project Start 01-JAN-1999; Project End 31-DEC-2003 Summary: (Adapted from applicant's abstract) The investigator proposes to determine the mechanisms by which pregnancy and chronic hypoxia influence uterine artery vasoregulation and growth, and thus contribute to fetal growth restriction and possibly pre-eclampsia. The central working hypothesis is that chronic hypoxia impairs vasoregulatory and growth related responses of the uterine artery. The hypothesis will be tested by experiments performed in three specific aims. (1) Determine the effects of pregnancy and chronic hypoxia on uterine artery vasodilators/constrictor responses to the physiological stimuli of flow, pressure, and pharmacological agents; (2) Determine the effect of pregnancy and/or chronic hypoxia on uterine artery growth; and (3) Determine the effect of pregnancy and/or chronic hypoxia on the relationship of indices of impaired uterine artery vasoregulation and growth to uterine artery blood flow, intrauterine growth restriction, and pre-eclampsia. Aims #1 and #2 are to be conducted on pregnant and non-pregnant guinea pigs kept at 1600m and 3962m throughout pregnancy. Aim #3 focuses on women residing at either low or high altitude in whom Doppler flow velocimetry and ultrasound imaging will be used to measure uterine artery blood flow. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
11
Project Title: COMPARTMENTALIZATION OF ACROGRANIN SIGNALING IN EMBRYOS Principal Investigator & Institution: Gerton, George L.; Research Professor; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2002; Project Start 10-JUL-2002; Project End 30-JUN-2007 Summary: (provided by applicant): The preimplantation phase of mammalian embryo development proceeds in several stages. Starting with the one-cell zygote, mitosis gives rise to a multicellular embryo that differentiates into a morula and then to the blastocyst. The blastocyst is characterized by the differentiation into two different compartments, the inner cell mass (ICM) and the trophectoderm. The development and function of the trophoblasts giving rise to the placenta are under the control of maternal and embryonic factors. Steroid hormones and other factors help to modulate the responsiveness of the uterus to implantation. Studies of mammalian embryos in culture have provided evidence for the production of autocrine growth factors as well as paracrine interactions between the ICM and trophectoderm. One of these factors, acrogranin (the granulin/epithelin precursor) has an important role in the development of preimplantation mouse embryos in culture. In this proposal, the broad, long-term objective is to determine the role of the acrogranin gene in regulating the development of pre- and peri-implantation mammalian embryos. The goals of this project are: Specific Aim 1. Characterize the role of acrogranin in preimplantation embryo development. Specific Aim 2. Examine the effects of acrogranin on the trophectoderm stem (TS) cell model. Specific Aim 3. Determine the signal transduction pathways used for acrogranin signaling in blastocysts. Specific Aim 4. Determine whether acrogranin is part of a paracrine loop regulating Oct4, leukemia inhibitory factor, and fibroblast growth factor4 signaling in mouse blastocysts. Studies on the role of acrogranin in trophoblast growth and differentiation will lead to a better understanding of the molecular bases of human placental disorders such as "missed abortions" (pregnancy losses in the first two months of gestation), some types of intrauterine growth retardation, and pre-eclampsia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: EFFECT OF LEPTIN ON TROPHOBLAST INVASIVENESS Principal Investigator & Institution: Schulz, Laura C.; Biology; Boston University Charles River Campus 881 Commonwealth Avenue Boston, Ma 02215 Timing: Fiscal Year 2004; Project Start 01-SEP-2004 Summary: (provided by applicant): I propose to investigate the relationship between leptin and trophobiast invasion. Invasion of the uterine epithelium by embryonic trophoblast ceils during early pregnancy is crucial for the establishment and development of the placenta, which is in turn necessary for healthy fetal development. Leptin is a hormone produced by adipose tissue, and in some species, the placenta, that acts as a signal of nutritional state to the reproductive system. The proposed project will attempt to characterize one of the mechanisms by which nutrition affects placental development, and increase our understanding of the role of leptin in pre-eclampsia, a common complication of pregnancy characterized by insufficient trophoblast invasion. The difference in invasivness between trophoblast ceils from early and late pregnancy will be used to study the effects of leptin. I will use primary mouse trophoblast ceils to test the hypotheses (1) that leptin promotes trophoblast invasion in placental ceils from early, but not late pregnancy and (2) that this invasion is mediated by an increase in MMP activity, which is (3) stimulated via the MAPK signaling pathway. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
12
•
Eclampsia
Project Title: FIRCA BREAST CANCER CASE-CONTROL STUDY IN SLOVAKIA Principal Investigator & Institution: Cerhan, James R.; Associate Professor; Mayo Clinic Rochester 200 1St St Sw Rochester, Mn 55905 Timing: Fiscal Year 2003; Project Start 01-FEB-2003; Project End 31-JAN-2006 Summary: (provided by applicant) This research will be done primarily in Slovakia as a FIRCA supplement to NIH grant # P01 CA82267 (Project 4). Breast cancer is the most commonly diagnosed cancer in women in SIovakia, and the leading cause of death. There are emerging data that fetal, early childhood and adolescent exposures related to growth, body mass and physical activity may be associated with the risk of breast cancer. We propose to evaluate these questions in a hospital-based case-control study in western Slovakia. Cases (N=250) will be women aged 20-70 years who are first diagnosed with invasive breast cancer from 1/1/2003 through 6/30/2005 and are residents of Trnava or Senica districts at the time of diagnosis. Cases will be rapidly ascertained through surveillance of the district hospitals in Trnava and Senica. Controls (N=250) will be women with no history of breast cancer, aged 20-70 years, and who are residents of Trnava or Senica district. Controls will be frequency matched to cases by age group and district, and will be randomly selected from the primary care medical practices in each district. Participants will complete a standardized in-person interview and provide a blood sample. Through interviews and abstraction of medical/population records, we will collect data on fetal exposures (birthweight, birth length, gestational age, twinning/zygosity, pre-eclampsia, etc.), childhood anthropometrics (height and weight at various ages), and adolescent exposures (anthropometrics, age at menarche). We will also collect data on other key breast cancer risk factors, including reproductive and adult anthropometric variables, in order to evaluate confounding. Genomic DNA will also be collected from peripheral blood, and banked in order to conduct future studies on the role of common genetic polymorphisms in candidate genes, as well as gene-environment interactions, in the etiology of breast cancer. There is sufficient statistical power to test the a priori hypotheses of interest. We have assembled an international research team for this study. This study will address an important scientific question in breast cancer etiology, and these data would be expected to better inform the primary prevention of the disease. This study will also develop infrastructure and experience in Slovakia for the conduct of cancer epidemiology studies, and generate the necessary preliminary data for expansion of this research effort. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GAP JUNCTIONS IN PLACENTAL DEVELOPMENT Principal Investigator & Institution: Lye, Stephen J.; Professor; Mount Sinai Hospital (Toronto) 600 University Ave Toronto, Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 31-JUL-2005 Summary: (provided by applicant): Failure of appropriate placental development, particularly in the first trimester, is associated with significant complications of pregnancy, including miscarriage, pre-eclampsia and intrauterine growth restriction (IUGR). During the first trimester, placental trophoblast cells undergo dynamic cellular events, including cell proliferation, differentiation, migration/invasion, and cell-cell interactions. These events are required for the formation of the anchoring villous and the invasion of extravillous trophoblast (EVT) deep into the uterine wall where they induce a remodelling of the maternal spiral arteries. In other tissues, intercellular communication via gap junctions is known to modulate these processes, though there is no information as to whether this occurs in the placenta. Therefore, the overall objective
Studies
13
of this project is to define the role of gap junctional intercellular communication (GJIC) in placental development. We hypothesize that a loss of GJIC is necessary for EVT to exit the proliferative phenotype of the anchoring villous and invade into the uterine wall. Furthermore, we hypothesize that re-expression of GJIC by populations of invasive EVT induces their terminal differentiation allowing them to associate with endothelial cells in spiral arteries during remodelling, and also, in EVT distant from vessels, to promote their aggregation and fusion to form large, multi-nucleated non-invasive trophoblast. Support for these hypotheses is provided by our preliminary data, using first trimester placental explants, in which we have shown that blockade of GJIC or antisense knock-down of the gap junction protein, connexin40, induces EVTs to differentiate from the proliferative to the invasive phenotype. We will address these hypotheses through 4 specific aims. In Aim I, we will use the explants to determine whether GJIC-blockade alone is sufficient to induce the invasive EVT phenotype and to identify putative upstream modifiers and downstream effectors of GJIC-mediated EVT differentiation. Complementary studies in Aim II will take advantage of the power of trophoblast stem cells to define connexins that modulate differentiation to invasive trophoblast, determine whether mutation of these connexins disrupts normal differentiation and use micro-array analysis to identify trophoblast genes whose expression is modified by GJIC. In Aim Ill, we will utilize a trophoblast-decidua explant co-culture system to determine how the decidua modifies GJICmediated EVT differentiation. In Aim IV, we will use primary trophoblasts and the Jeg-3 cell line (wild type or following stable transfection with connexin proteins) to investigate, in vitro and in vivo, the requirement for GJIC during EVT-endothelial coupling and vessel invasion. This novel investigation integrates the experience and efforts of three laboratories, each recognized internationally for their independent investigations on placental development. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: OUTCOMES
GESTATIONAL
DIABETES:
DIAGNOSTIC
CRITERIA
AND
Principal Investigator & Institution: Ferrara, Assiamira; Research Scientist Ii; Kaiser Foundation Research Institute 1800 Harrison St, 16Th Fl Oakland, Ca 946123433 Timing: Fiscal Year 2002; Project Start 01-SEP-2000; Project End 31-AUG-2004 Summary: (Adapted from Investigator's Abstract) Gestational diabetes mellitus (GDM) is associated with increased risk of several adverse infant and maternal outcomes and its clinical recognition can reduce these risks. There is concern that the current criteria for GDM may be to restrictive and that residual excess risk of perinatal complications exists below present cutoff values. The proposed study will evaluate whether among women without GDM (as defined by current criteria), increasing levels of maternal glycemia are associated with increased risk of selected perinatal complications: infant severe macrosomia, severe hyperbilirubinemia, hypoglycemia, respiratory distress syndrome, and maternal preeclampsia/eclampsia. To accomplish this, the investigators propose to conduct five nested case-control studies, one for each of the complications of interest, within a large multiethnic cohort of approximately 74,000 women who were screened at 24 to 28 weeks of gestation at Kaiser Permanente, Northern California between 1995 and 1998. In this setting nearly 94 percent of the pregnant women are screened for GDM by a 50 gm., 1 hr. oral glucose tolerance test (50 g, 1-h OGTT) and approximately 15 percent have are abnormal screening and go on to receive the diagnostic (100-g, 3-h OGTT) test. Potential cases of each type of complication will be identified by searching computerized hospitalization and laboratory databases. For each of the infant
14
Eclampsia
complications, 500 cases will be randomly selected without knowledge of the maternal glucose values. A single control group for the infant complication case groups will be 1,000 infants randomly selected from all births and frequency matched on gestational age to the distribution of the combined case group. Five hundred women with either preeclampsia or eclampsia and 500 age-matched controls will be randomly selected. The medical records of the 3,000 mother-infant pairs in the four case-control studies on infant complications, and 1,000 women for the case-control study of preeclampsia/eclampsia, will be abstracted to confirm eligibility, and, if so, to ascertain data on possible maternal and infant covariates. Logistic regression will be used to estimate the odds ratios associated with several levels of pregnancy glycemia and perinatal complications. The investigators state that the proposed study will provide important knowledge about the magnitude of the risk of severe perinatal complications associated with degrees of maternal hyperglycemia below the glucose cutpoints currently used to diagnose GDM. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GLOBAL NETWORK FOR WOMEN'S & CHILDREN'S HEALTH RESEARCH Principal Investigator & Institution: Spinnato, Joseph A.; Obstetrics and Gynecology; University of Cincinnati 2624 Clifton Ave Cincinnati, Oh 45221 Timing: Fiscal Year 2002; Project Start 17-SEP-2001; Project End 30-APR-2006 Summary: (Provided by applicant): The maternal, perinatal and neonatal morbidity and mortality rates for Brazil are five to ten-fold higher that that reported for developed countries. In Sao Paulo for the year 1998, 127 matemal deaths were recorded. The maternal death rate was 57 per 100,000 live births. Twenty-four of these deaths were directly attributable to complications of eclampsia and preeclampsia. An additional four deaths were related to chronic hypertension. Overall hypertensive complications of pregnancy were associated with 28 maternal deaths and ranked as the number one cause of maternal death (22%). As high as the Sao Paulo maternal mortality rate was, in Brazil for the same year the rate was 140 per 100,000. Complications of hypertensive disease were the most common cause of death (28.5%). The infrastructure and monies to train health professionals in the techniques of clinical research is inadequate in Brazil. As a result, outcomes-based research that might identify methods to eliminate the causes of morbidity and mortality that are specific to Brazil are not performed, or when performed, are likely to be flawed in one way or another, so that accurate conclusions cannot be made. By providing mentored experience in all phases of clinical research to Brazilian health professionals, well designed outcome-based research can be accomplished that will direct changes in clinical management and public policy that will reduce maternal and perinatal morbidity and mortality rates. The aims of this proposal are to: 1) study the efficacy of antioxidant therapy initiated at or before 20 weeks of gestation to reduce the incidence and severity of preeclampsia in a high risk obstetric population in Sao Paulo Brazil; 2) integrate this research effort with the training of a Brazilian scientist (concurrent application to the International Women?s and Children?s Health Research Training Grant TW-00-007); and 3) stimulate and facilitate international collaborative women?s and children?s health research that will reduce morbidity and mortality from conditions affecting women and children in developing countries. Obstetric patients with chronic hypertension, or preeclampsia in a prior pregnancy, presenting for care at or before 20 weeks of gestation will be randomized, in a masked, double-blinded fashion, to receive either Vitamin E (400 IU) and Vitamin C (1,000 mg) or placebo. The primary outcome assessed will be the incidence of preeclampsia. The
Studies
15
Research Committee of the Department of Obstetrics and Gynecology, University of Sao Paulo, and the U.S. investigators will assess the long-term impact of this program on women?s and children?s health research, health care in Brazil, and international research collaboration. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GONADAL PEPTIDE EFFECT ON FEMALE REPRODUCTION-ACTIVINS Principal Investigator & Institution: Lin, Yu-Wai P.; Barry University 11300 Ne 2Nd Ave Miami, Fl 331616695 Timing: Fiscal Year 2003; Project Start 01-MAY-2003; Project End 30-APR-2007 Summary: Folliculogenesis in vertebrates involves the developmental progression from a small primordial follicleto a large preovulatory follicle containing a fully competent oocyte arrested at the second meiotic metaphase by the time of ovulation. This entire process is regulated and coordinated by endocrine hormones such as the pituitary gonadotropins, and locally modulated by steroids and factors (inhibin/activin) acting in an autocrine/paracrine manner. The molecular nature of these factors is only now being elucidated. Gonadal peptides such as inhibin and activin are currently being recognized not only as regulators of the pituitary gonadotropins secretion, but also as multifunctional modulators in the ovary and in the utero-placental unit. In addition to their normal reproductive roles, inhibins and activins have been implicated in gonadal oncogenesis and pathologies of the reproductive system. In this regard, high levels of inhibin B are associated with granulosa cell carcinoma, and high levels of inhibin A are correlated with pre-eclampsia and Down syndrome during pregnancy. The understanding of the relationship of several gonadal peptides to the signals for gonadal function still has many unanswered questions. This proposal is designed to elucidate the molecular mechanisms underlying the expression and the paracrine and autocrine biological activities of inhibin/activin A and B. Although the different inhibin/activin isoforms (A and B) appear to have similar effects in the pituitary, there is also precedent suggesting that they may have distinct physiological roles in different tissues. The availability of recombinant inhibin/activin A and B now gives the possibility to assess the functions of the various inhibin/activin isoforms. In order to implement the above objectives, the following projects will be carried out:: a) Isolation and cloning of the inhibin/activin subunits (alpha,betaA,and betaB) from ovarian tissue, b) Antibodies against the inhibin/activin subunits will be generated to carry out western blot analysis, c) Expression of inhibin/activin subunits during follicle development and during the process of gonadotropic stimulation of oocyte maturation, d) Paracrine (local effect at neighboring cells) and autocrine (local effect in the same cells) biological activities (on steroidogenesis and oocyte maturation) of inhibin/activin A and B will be assessed using in vitro ovarian follicle cultures, to test the hypothesis that the various forms of the gonadal peptides may have distinct physiological roles in the ovary. The proposed research will furnish critically needed information about the molecular dynamics and actions of the inhibin/activin in the ovary. Understanding the physiology of inhibins and activins and the interplay of major endocrine and paracrine mechanisms involved in the ovary is essential to decipher the process of gonadal differentiation in both normal and disease conditions, and may ultimately help in the diagnosis and treatment of reproductive dysfunction in humans. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
16
•
Eclampsia
Project Title: HSF 1 REQUIREMENTS IN EXTRAEMBRYONIC DEVELOPMENT Principal Investigator & Institution: Benjamin, Ivor J.; Professor of Medicine, Chair and Chief; Internal Medicine; University of Texas Sw Med Ctr/Dallas Dallas, Tx 753909105 Timing: Fiscal Year 2002; Project Start 13-JUL-2001; Project End 30-JUN-2006 Summary: Induced genetic mutations in mice have provided unprecedented challenges and opportunities for biologists to characterize the physiological roles of targeted gene disruptions in important biological processes or specific pathways, which were neither suspected not predicted. The broad, long-term objectives of this proposal are to determine the physiological roles that heat shock transcription factor 1 (HSF1) plays in mammalian extra-embryonic development, and to define strategies by which the regulatory network involving HSF1 can be manipulated to enhance in utero survival and growth. Hsf1-/-knockout mice exhibit a complex phenotype including placental defects, reduced but variable survival depending on genetic background, and growth retardation. Importantly, we have determined that the key role(s) for HSF1 in mammalian placental function appears to be dissociated from its well-characterized properties as a major stress-inducible transactivator of heat shock protein genes under stressful conditions. The main hypothesis to be tested is whether or not the role played by the regulatory heat shock factor 1 (HSF1), in extra-embryonic development involves the control of the proliferation, differentiation or maintenance of the spongiotrophoblast layer through signaling pathways based on cross-talk between placental cells and maternal decidua. Two independent and unbiased approaches will be used as discovery platforms to identify, isolate, and characterize the molecular pathways influenced by HSF1. Expression profiling by microarrays will used to assess differential gene expression in maternal and fetal tissues (Specific Aim 1), and the relevant signaling pathways to be characterized in the context of placental function (Specific Aim 2). Separately, whole genome scanning based on marker linkage analyses will enable us to identify and localize the dominant modifier loci (Specific Aim 3) that confer increased survival of the placental traits in the most severely affect to isogenic 129, Hsf1 knockout mice (Specific aim 4). The major strength of these innovative approaches is that both discovery platforms will yield complementary information to plan rescue strategies aimed at transgenic expression HSF1 in specific cells and the creation of congenic strains (Specific aim 4). Our work will provide new insights about the physiological roles of HSF1 in mammalian placental function. We further propose such information can constitute a rational basis to interventions involving HSF1 in the diagnosis, prognosis, and therapy for conditions such as pre-eclampsia and intrauterine growth retardation in humans. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: IMPROVING PDC/MWRI INSTITUTIONAL ANIMAL RESOURCES Principal Investigator & Institution: Schatten, Gerald P.; Professor; Magee-Women's Health Corporation 204 Craft Ave Pittsburgh, Pa 15213 Timing: Fiscal Year 2003; Project Start 15-SEP-2003; Project End 14-SEP-2004 Summary: (provided by applicant): The MWRI is a multidisciplinary research institute dedicated to women and infants' health. The majority of its 70 members are from three Departments of the Medical School of the University of Pittsburgh: Obstetrics, Gynecology, and Reproductive Sciences; Pediatrics; and Pathology. The remaining members of the Institute are from other departments in the Medical, Nursing, and Pharmacy Schools and from the Graduate School of Public Health of the University of Pittsburgh. Membership includes investigators with M.D., Ph.D. or both, who have
Studies
17
expertise in clinical or basic research as well as epidemiology or health services research. The Institute emphasizes research and training in interactive, innovative, and translational research. On-going projects include studies in amenorrhea, pre-eclampsia, pregnancy loss, and sexually transmitted diseases. Currently, the investigators of the MWRI utilize mice, rats, and non-human primates as animal models of human disease. The PDC of the MWRI is actively researching contemporary topics of national importance including: the pluripotency of embryonic stem cells using non-human primates; the feasibility of a variety of transgenic approaches for disease modeling using primates; the outcome of Assisted Reproductive Technologies (ART) in macaque models; and the feasibility of cloning in non-human primates, either for production of identical research models or to evaluate 'therapeutic' cloning. All the non-human primate research performed at the MWRI is performed under the auspices of the PDC. This application requests funds to: 1) provide the PDC and MWRI vivarium with stateof-the-art non-human primate enclosures that exceed all new United States Department of Agriculture (USDA) directives for psychological enrichment; and 2) modernize the PDC and MWRI vivarium with a steam sterilizer. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INSULIN RESISTANCE IN PATHOGENESIS OF PRE ECLAMPSIA Principal Investigator & Institution: Kauma, Scott; Virginia Commonwealth University Richmond, Va 232980568 Timing: Fiscal Year 2003 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MENTORED DEVELOPMENT AW
PATIENT
ORIENTED
RESEARCH
CAREER
Principal Investigator & Institution: Barry-Carr, Darcy; Obstetrics and Gynecology; University of Washington Grant & Contract Services Seattle, Wa 98105 Timing: Fiscal Year 2002; Project Start 01-AUG-2000; Project End 31-JUL-2005 Summary: PROPOSAL (Adapted from the applicant's abstract): Pre-eclampsia, a hypertensive disorder unique to pregnancy, is a leading cause of maternal and neonatal morbidity and mortality. Endothelial dysfunction is a central feature in the pathophysiology of pre-eclampsia. Mechanisms that have been suggested to contribute to the endothelial dysfunction of pre-eclampsia include insulin resistance and a hyperdynamic circulation (high cardiac output). Insulin resistance and high cardiac output persist postpartum, suggesting that these women have an underlying disorder. However, it is unclear whether these abnormalities are related and whether insulin resistance has a role in producing hemodynamic alterations and endothelial dysfunction in these women. The investigator hypothesizes that postpartum women who have a history of pre- eclampsia are insulin resistant and have associated alterations in hemodynamics and endothelial function. Furthermore, she hypothesizes that insulin resistance has a causal role in producing these changes. Two specific aims have been identified to address these hypotheses: 1) to determine whether the insulin resistance present in postpartum women with a history of pre-eclampsia is associated with altered hemodynamics and endothelial dysfunction; and 2) to determine whether reversing insulin resistance in women with a history of pre-eclampsia, is associated with improvements in hemodynamics and endothelial function, thus suggesting that insulin resistance is a causative factor in women with these abnormalities. A case-control study
18
Eclampsia
will address the first specific aim. A double-blind, placebo-controlled, randomized study will address the second specific aim by using an insulin sensitizing agent, rosiglitazone, as an interventional tool. The results of these studies could provide a rationale for future investigations aimed at determining whether treating insulin resistance in women with a history of pre-eclampsia will decrease the risk of recurrent pre- eclampsia in subsequent pregnancies and reduce the prevalence of the long-term metabolic and cardiovascular complications in these women as they age. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MENTORED DEVELOPMENT AW
PATIENT-ORIENTED
RESEARCH
CAREER
Principal Investigator & Institution: Funai, Edmund F.; Obstetrics and Gynecology; Yale University 47 College Street, Suite 203 New Haven, Ct 065208047 Timing: Fiscal Year 2002; Project Start 01-JUL-2000; Project End 30-JUN-2005 Summary: PROPOSAL (Adapted from the applicant's abstract): The aim of this grant application is to test the hypothesis that in normal pregnancy soluble GPx expressed by the placenta and released into the maternal compartment, catalyzes liberation of NO from S-nitrosothiols (SNOs), such as S-nitroso- glutathione (SNO-Glu). This contributes to the decrease in BP seen as a normal pregnancy progresses. The investigators propose that disturbances in placenta GPx expression or release may be responsible for the various manifestations of pre-eclampsia. In addition, a hypoxic environment, as may be found in the intervillous space early in gestation, may contribute to an increase in endothelial nitric oxide synthase (eNOS) expression, mediated through vascular endothelial growth factor (VEGF). Elevated plasma VEGF levels in the first trimester of women destined to develop pre-eclampsia may suggest an early compensatory mechanism to promote both increased angiogenesis and blood flow. They anticipate that the results of this study will extend their understanding of the pathogenesis of preeclampsia and contribute to strategies for early diagnosis and treatment. A comparison of GPx levels in plasma from normal pregnant, pre-eclamptic pregnant and nonpregnant women will indicate whether GPx is secreted by the placenta into the maternal circulation at levels high enough to support a role for placental GPx in the transport and bioavailability of NO. Northern blot analysis and immunoassay will be used to confirm that expression of GPx messenger ribonucleic acid (mRNA) and release of GPx protein is reduced in placentas from term pre-eclamptic pregnancies as compared to normal pregnancies. NO and SNO-Glu levels in blood from nonpregnant, normal pregnant and pre-eclamptic women will indicate whether there is a relative increase in SNO-Glu in pre-eclampsia, at the expense of bioavailable NO. SNO-hemoglobin levels in venous blood from the three groups will be compared, as one would anticipate higher levels in normal pregnant women. Preliminary data suggest that VEGF levels rise significantly in the first trimester in those patients destined to develop pre-eclampsia, and VEGF may serve as an early marker to identify those patients at risk. They will investigate potential relationships between hypoxia and the expression of VEGF, GPx and eNOS. In addition, plasma VEGF levels will be measured serially throughout gestation during normal and pre-eclamptic pregnancies, and the value of VEGF and its inhibitor, Soluble Flt-1 (sFIt1), as early and reproducible markers of preeclampsia will be explored. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
19
Project Title: MIDCAREER AWARD IN PATIENT ORIENTED OBSTETRIC RESEARCH Principal Investigator & Institution: Rouse, Dwight J.; Obstetrics and Gynecology; University of Alabama at Birmingham Uab Station Birmingham, Al 35294 Timing: Fiscal Year 2002; Project Start 28-AUG-2000; Project End 30-JUN-2005 Summary: (Adapted from applicant's description): The purpose of this Midcareer Investigator Award in Patient-Oriented Research is to provide Dwight J. Rouse, Associate Professor of Obstetrics and Gynecology in the School of Medicine at the University of Alabama at Birmingham (UAB) with sufficient protected time to: 1) continue and expand his ongoing patient oriented research activities including serving as protocol chairman of a jointly funded NINDS and NICHD randomized clinical trial and as principal investigator of a funded RO1 randomized clinical trial of intrapartum chlorhexidine vaginal cleansing, and through the continued performance of decision and cost-effectiveness analyses of obstetric screening technologies and practices; 2) to enhance his activities and capabilities as a mentor, especially through the UAB NIH Women's Reproductive Health Research Center Career Development Program, and 3) to develop new patient oriented research skills. For this award, his new skill acquisition will be focused on "pragmatic" clinical trials, i.e., trials in which the intervention to be tested is overlaid on the background of local usual clinical practice, with a minimum of study-related practice constraints, liberal inclusion and few exclusion criteria The design and conduct of these pragmatic clinical trials poses distinct challenges, from devising an implementable intervention to coordinating communication across centers often not otherwise organized into a formal research network. Through formal epidemiologic (and economic analysis) training (obtaining an M.P.H.) and planned visits to internationally-renowned trial coordinating units, he will substantially enhance his abilities as a perinatal clinical trialist (and his ability to conduct economic analyses alongside clinical trials), especially in the area of pragmatic, multi-centered national and international trials which, for at least three reasons, are likely to take on increasing importance in defining optimal obstetric care. First, the declining patient populations of many academic obstetric units in this country make it difficult to conduct single center trials with adequate sample sizes and expeditious patient accrual. Second, the incidence of some severe but preventable obstetric outcomes (e.g., eclampsia) is quite low, but even for such low incidence conditions, it is often desirable to evaluate interventions which may offer only modest protection. Thus, to achieve adequate statistical power, large sample sizes are necessary. Finally, the effectiveness of an intervention (how it would perform under conditions of actual clinical practice) is an attribute that, in many situations, is as important as its efficacy (how it performs under ideal conditions). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MINORITY PREDOCTORAL FELLOWSHIP PROGRAM Principal Investigator & Institution: Ho-Chen, Jennifer K.; Molecular & Integrative Phys; University of Kansas Medical Center Msn 1039 Kansas City, Ks 66160 Timing: Fiscal Year 2003; Project Start 06-JUL-2003; Project End 05-JUL-2007 Summary: (provided by applicant): "No thesis selected". My research interests are in understanding the regulation and function of trophoblast invasion as well as the maternal adaptations that occur during pregnancy. Studies will be done to better understand the relationship between trophoblast cells and the maternal vasculature, cells of the immune system, and prolactin family members. By deciphering how trophoblast invasion into the uterus is regulated, and what causes their disappearance,
20
Eclampsia
more can be discovered about the maternal-fetal environment during pregnancy. The significance of focusing on trophoblast invasion is to better understand and potentially prevent pregnancy-associated conditions such as pre-eclampsia and intrauterine growth restriction. Both are correlated with shallow trophoblast invasion and lead to pathologies in the mother and fetus. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR GENETICS OF PREECLAMPSIA/ECLAMPSIA Principal Investigator & Institution: Williamson, Roger A.; University of Iowa Iowa City, Ia 52242 Timing: Fiscal Year 2002 Summary: The goals of this study are to elucidate the genetic importance of leading candidate genes in the pathogenesis of preeclampsia/eclampsia, conduct a genomewide search for chromosomal regions that may be linked to preeclampsia, and identify and evaluate candidate genes within the linked chromosomal regions in women who have had a previous pregnancy complicated by preeclampsia or eclampsia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NITRIC OXIDE METABOLIC CONTROL IN PREGNANCY Principal Investigator & Institution: Hintze, Thomas H.; Professor; Physiology; New York Medical College Valhalla, Ny 10595 Timing: Fiscal Year 2003; Project Start 15-DEC-1993; Project End 31-DEC-2006 Summary: (provided by applicant): The cardiovascular adjustments that occur during pregnancy include chronic increases in cardiac output, falls in total peripheral vascular resistance and tachycardia. There is an upregulation of endothelial nitric oxide synthase in almost all vascular beds studied in the gravid female including skeletal muscle, kidney and utems or placenta. The upregulation of eNOS directly contributes to the fall in TPR which is not confined to the placenta. Many studies have investigated the role of NO in the control of vascular resistance or how NO may buffer vasoconstriction and that a defect in NO production may be involved in pre-eclampsia. Despite increasing evidence that NO also modulates mitochondrial metabolism and substrate uptake by the heart, i.e. prevents glucose uptake and facilitates fatty acid uptake, there are literally no studies that have investigated the role of increased eNOS in the control of substrate uptake and organ oxygen consumption at all. We have previously shown that NO by interacting with cytochrome oxidase in heart, kidney and skeletal muscle serves to maximize the ratio of oxygen consumed to external work performed ie. increases efficiency. We have also shown that when eNOS produces NO in the heart and elsewhere, glucose uptake is prevented. It is important to re-emphasize that pregnancy is characterized by increased eNOS gene expression and increased NO production in every vascular bed of the mother. Furthermore, glucose uptake by the mother is low even insulin insensitive and this is thought to increase the amount of glucose available for uptake through the placenta to support fetal metabolism, since the placenta does not take up fatty acids. In addition a small but significant number of mothers go on to have a post-partum cardiomyopathy often leading to heart transplantation, perhaps when adjustments that occur during pregnancy do not regress after parturition. Thus the focus of this competitive renewal application will be the role of NO in the control of oxygen and substrate use during pregnancy with particular reference to the heart and coronary circulation. In the first specific aim, we will examine the role of NO in the control or metabolism in aged eNOS KO mice. The second aim will focus on the role of NO in the
Studies
21
pregnant eNOS KO mouse whereas the third specific aim will focus on the role of NO in cardiac glucose and oxygen uptake in the rat heart during pregnancy. Finally aim 4 will use chronically instrumented conscious pregnant dogs to address the role of NO in the control of cardiac function, substrate use and oxygen consumption during pregnancy and after parturition. For the first time we wilt perform a systematic mechanistic investigation into the role of NO in the control of cardiac oxygen and substrate use during pregnancy. These studies have direct application to the physiology of pregnancy and to the potential mechanisms resulting in post partum cardiac dysfunction. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NOVEL 3-D MODEL OF PLACENTAL CYTOMEGALOVIRUS INFECTION Principal Investigator & Institution: Morris, Cindy A.; Microbiology and Immunology; Tulane University of Louisiana New Orleans, La New Orleans, La 70112 Timing: Fiscal Year 2004; Project Start 01-DEC-2003; Project End 30-NOV-2005 Summary: (provided by applicant): The overall objective of this proposal is to develop an improved tissue model for the study of human cytomegalovirus infection (CMV) during pregnancy. Specifically, rotating wall vessels (RWVs) will be utilized to establish this advanced model system. CMV is the leading cause of congenital viral infection, and intrauterine transmission of the virus occurs in approximately 50% of pregnant women with primary CMV infection. CMV infection during pregnancy can have catastrophic consequences not only on the neonate, but also on pregnancy outcome, including spontaneous abortion, intrauterine growth restriction and pre-eclampsia. Despite the significant morbidity and mortality associated with congenital CMV infection, little is known about how the virus infects the conceptus. RWV technology offers a unique approach not previously applied toward the study of placental tissues and provides a novel model system to explore intrauterine CMV infection. The culture conditions of these bioreactors provide a low-shear and low-turbulence growth environment, similar to that required for normal in vivo fetal and placental development. Such an environment allows cells to co-localize spatially, grow three-dimensionally, and differentiate into highly specialized tissues. Preliminary data presented in this proposal demonstrate that the RWV supports the growth of a first trimester cytotrophoblast cell line. Importantly, we have shown that the environment created within the bioreactor promotes cytotrophoblast differentiation and allows for the formation of complex, multi-layered three-dimensional (3-D) aggregates that are functionally similar to in utero trophoblast cells. The hypothesis to be tested within this proposal is that placental epithelial cells cultured in the RWV are functionally similar to the developing in utero placenta and that the 3-D growth of these cells will provide an improved model system for the study of the molecular details involved in intrauterine CMV infection. The longterm research goals of this proposal are to utilize the 3-D model to study and understand 1) the molecular details of normal placental development, 2) CMV pathogenesis, 3) host-pathogen interactions that occur at the maternal-fetal interface during pregnancy, and 4) the molecular mechanism(s) that regulate the effect of CMV on placentation and pregnancy outcome. The specific aims are: 1) to further characterize the 3-D model of human placentation, and 2) to apply the placental 3-D model toward the study of intrauterine CMV infection. This novel model system will contribute to advanced studies of human placentation, ultimately leading to new therapeutic strategies for the prevention and treatment of placental and congenital CMV infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
22
•
Eclampsia
Project Title: PEPTIDE PROCESSING ENZYMES IN THE PLACENTA Principal Investigator & Institution: Reznik, Sandra E.; Montefiore Medical Center (Bronx, Ny) Bronx, Ny 104672490 Timing: Fiscal Year 2002; Project Start 01-APR-1998; Project End 31-DEC-2004 Summary: (Adapted from applicant's description): This K08 award will allow the candidate to obtain the scientific expertise and to conduct studies that will advance understanding of the functions of selected placental peptidases. Specifically, she will test hypotheses about the mechanisms by which alterations in the enzymes that process and metabolize Endothelin-1 are related to the pathogenesis of pre-eclampsia and pre-term labor and by which alterations in the carboxypeptidases that process a variety of peptide hormones and growth restriction. Specific aim 1 will test the hypothesis that two closely related metalloendopeptidases, endothelin converting enzyme-1 (ECE-1) and neutral endopeptidase (NEP), function in the regulation of levels of endothelin-1 (ET-1) in the placenta and that ET-1 functions as a common pathway in the pathogenesis of preeclampsia and pre-term labor. Aim 2 will test the hypothesis that recently identified members of the carboxypeptidase E family, highly concentrated in the rat placenta, also function as peptide processing enzymes in the human placenta. Specific aim 3 will test the hypothesis that the novel placental proteins also have nonenzymatic functions. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PERINATAL AND ADOLESCENT FACTORS IN BREAST CANCER Principal Investigator & Institution: Stuver, Sherri O.; Assistant Professor; Epidemiology; Harvard University (Sch of Public Hlth) Public Health Campus Boston, Ma 02115 Timing: Fiscal Year 2002; Project Start 16-FEB-2001; Project End 31-JAN-2003 Summary: The epidemiology of breast cancer is complicated and only partially understood, despite a concerted research effort in this area. The primary goal of the proposed study is to examine the association between, on the one hand, perinatal factors that exhibit their hypothesized carcinogenic action during early life and, on the other established breast cancer risk factors that operate during the perimenarcheal years. Our objective will be to explore whether certain perinatal factors may share a common biologic mechanism of action with perimenarcheal risk factors, with respect to breast carcinogenesis. The meet this objective, the following specific aims will be addressed to investigate if there is an association between birth size and indicators of sexual maturity during adolescence, particularly age at menarche and breast development; to study the association between birth size and adolescent somatic growth; to examine the association between perinatal complications, such as pregnancy preeclampsia/eclampsia, jaundice, and prematurity, and indicators of sexual maturity and somatic growth during adolescence. To study these relationships, a retrospective cohort study of the association between perinatal and adolescent factors will be conducted among young girls in Nord Trondelag County in Norway. The population based for this study will be the nearly 5,000 girls, 13 to 19 years of age, who were born between 1977 and 1984 and who participated in general health survey for adolescents that took place in 1996 and 1997. Using the unique personal registration number assigned to all Norwegians, linkage will be made between the relevant information collected during the adolescent health survey and birth record information stored in the national Birth Registry. Access to data of such excellent quality will provide an important opportunity to examine the role of perinatal and perimenarcheal factors in the etiology of breast cancer.
Studies
23
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PLACENTAL ANGIOGENIC FACTORS & UAEC /PAEC NO PRODUCTION Principal Investigator & Institution: Magness, Ronald R.; Professor; Obstetrics and Gynecology; University of Wisconsin Madison 750 University Ave Madison, Wi 53706 Timing: Fiscal Year 2002; Project Start 01-JUL-2001; Project End 30-JUN-2006 Summary: The pregnant women faces a unique physiological challenge to reorganize the maternal uterine vascular network to accommodate the metabolic demands of the feto-placental and uteroplacental blood flow by angiogenic growth factors (with particular focus on bFGF and VEGF) and the vascular regulator nitric oxide. This grant has two overall Specific Aims: 1) to establish molecular and cellular models of the regulation of the vascular endothelium at the maternal-fetal interface; and 2) to investigate these basic mechanisms in clinical settings where changes in placental regulator factors are hypothesized to control vascular adaptation to pregnancy. To accomplish these overall Aims, we propose four integrated projects, two scientific cores, and one administrative core. Our first Aim will primarily be addressed by the first two projects: Project I: Signaling mechanisms controlling NO production and mitogenesis in Uterine Artery Endothelial Cells (UAEC) and Ovine Fetal Placental Artery Endothelial Cells (OFPAEC). Project II: Angiogenic factor (bFGF and VEGF) and shear stress mediated changes in placental and uterine artery nitric oxide production. In these two highly integrated projects, we will utilize well-established cell lines and experimental systems derived by the project leaders from pregnant sheep. We will identify in vitro the signaling pathways used by angiogenic factors as well as their modulation by pregnancy, and address the mechanisms by which flow/shear stress mediate changes in endothelial cell expression of eNOS and NO production. In parallel to these basic studies, we propose two projects to address how pathophysiological perturbation of angiogenic control contributes significantly to the degradation of fetal health and wellbeing. Project III: Ethanol exposure on nitric oxide production and angiogenesis in the human placenta. Project IV: Trophoblast regulation of angiogenesis in the diabetic placenta. In these two highly integrated projects, we will utilize established endothelial cell lines and experimental systems derived by the project leaders from pregnant sheep. We will identify in vitro the signaling pathways used by angiogenic factors as well as their modulation by pregnancy, and address the mechanisms by which flow/shear stress mediated changes in endothelial cell expression of eNOS and NO production. In parallel to these basic studies, we propose two projects to address how pathophysiological perturbation of angiogenic control contributes significantly to the degradation of fetal health and well-being. Project III: Ethanol exposure on nitric oxide production and angiogenesis in the human placenta. Project IV: Trophoblast regulation of angiogenesis in the diabetic placenta. Ultimately, Projects III and IV will converge with Projects I and II, in that intracellular signaling mechanisms uncovered in the latter can be explored as the underlying causes of pathophysiological changes in the former clinical settings. The overall goals and integrated operation of the four Projects will be assured by the Administrative Core, and through usage of standardized assays and methods in all four Projects of Experimental Cores, Molecular Culture/Angiogenesis. Data from these studies will further our understanding of the basic control of placental and uterine angiogenesis and mechanisms contributing to fetal pathophysiology in diabetes, ethanol exposure, as well as pre-eclampsia and IUGR. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
24
•
Eclampsia
Project Title: INFERTILITY
POOR
OBSTETRIC
AND
PEDIATRIC
OUTCOMES
AFTER
Principal Investigator & Institution: Croughan-Minihane, Mary; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 941222747 Timing: Fiscal Year 2002 Summary: The primary aim of this retrospective cohort study is to determine whether naturally and treatment-achieved pregnancies among infertility patients (infertile pregnancy cohort) are at higher risk for adverse outcomes as compared to naturally conceived pregnancies achieved by fertile women (fertile pregnancy cohort) and where these differences persist after controlling for maternal and infant factors such as maternal age, parity, and gestational age. The infertile pregnancy cohort (n=5160) will be comprised of 3 groups of women: (1) infertile women who conceived between 1/1/94-1/1/97 as a result of infertility treatments; (2) fertile women who conceived as a result of infertility treatment undertaken as a result of male factor infertility; and (3) infertile women who conceived naturally after presenting for infertility treatment. The fertile pregnancy cohort (n=5160) is the non-exposed comparison group composed of women frequency matched on date of conception and maternal age who do not have a history of infertility and who conceived naturally. The outcomes of interest include pregnancy complications (e.g., IUGR, placental complications, and pre-eclampsia), labor and delivery complications (e.g., operative delivery and still birth), neonatal complications (e.g., death, cerebral palsy, and mental retardation). We expect to have over 90% power to detect statistically significant differences been the infertile and fertile pregnancy cohorts in nearly all of these outcomes. Infertility, prenatal, L&D, and pediatric medical records will be reviewed and a maternal interview conducted to gather complete information on infertility and reproductive history, health status and outcomes, and care providers. The relationships will be analyzed using path analysis, considering differences in risk according to fertility status, infertility etiology, infertility treatments received, and other maternal characteristics. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PREGNANCY ESTROGENS, DIET, AND BREAST CANCER RISK Principal Investigator & Institution: Hilakivi-Clarke, Leena A.; Professor; V T Lombardi Cancer Res Center; Georgetown University Washington, Dc 20057 Timing: Fiscal Year 2002; Project Start 15-AUG-2001; Project End 31-JUL-2006 Summary: Estrogen levels are elevated by 50-100 -fold during pregnancy, and interindividual variability in pregnancy estrogen levels is 4-6 -fold. Women exhibiting highest pregnancy estrogen levels are suggested to be at a significantly increased risk to develop breast cancer, perhaps due to an estrogen-induced promotion of existing transformed cells. Diet, particularly dietary fats, may affect pregnancy estrogen levels and later breast cancer risk. In our animal study, a high fat intake significantly increased pregnancy estrogen levels and increased pregnancy-promoted mammary tumor incidence. Polymorphism in genes that metabolize estrogens and have been linked to increased breast cancer risk, may also affect pregnancy estrogen levels. Our proposed study has two general aims: (1) to study whether dietary fat intake affects pregnancy estrogen levels in women, perhaps by interacting with polymorphism in CYP17 and COMT, and (2) to study whether highest pregnancy estrogen levels might increase breast cancer risk by increasing growth factor levels. These growth factors could originate from mutated or already transformed mammary cells, which during pregnancy are stimulated by high estrogen levels. Growth factor levels will be measured
Studies
25
in nipple aspirate fluid (NAF) that can be obtained using a breast pump from nonlactating breast. Consequently, the following hypotheses will be tested: Hypothesis-1. We hypothesize that high dietary fat intake and weight gain increase pregnancy estrogen levels. We further hypothesize that polymorphism in CYP17 or COMT influences these interactions. Hypothesis-2. We hypothesize that higher circulating estradiol levels during pregnancy are associated with increased growth factor levels in nipple aspirate fluid, including EGF, TGFalpha and IGF-1/IGF binding protein 3. These aims will be studied in 200 pregnant women attending the Maternity Clinic at Solna in NAF will be obtained 12 months after giving birth. Our results may lead to modifications of pregnancy diet to reduce the risk to develop breast cancer. In particular, women who already are at high risk, for example, due to family history of breast cancer, age at first pregnancy (greater than 30 years), or other reproductive risk factors, may significantly benefit from pregnancy dietary modifications. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PRENATAL DIET EFFECTS ON MOTHER AND CHILD Principal Investigator & Institution: Gillman, Matthew W.; Associate Professor; Harvard Pilgrim Health Care, Inc. 93 Worcester St Wellesley, Ma 02481 Timing: Fiscal Year 2002; Project Start 01-JUL-1998; Project End 30-JUN-2004 Summary: (Adapted from Investigator's Abstract) The overall goal of this amended application is to examine the role of prenatal factors, particularly diet (specifically, trans fatty acids, n-3 fatty acids and calcium), in outcomes of pregnancy and infancy. A total of 6,000 women will be enrolled during their first 12 weeks of pregnancy into the Harvard Pilgrim Health Care Cohort and will be followed along with their offspring until six months postpartum. The influence of specific nutrients on pregnancy outcomes, including fetal growth, length of gestation, and incidence of pre-eclampsia will be assessed. In addition, the effects of these same exposures on infant development and cardiovascular risk factors during the first six months of life will be examined. Four hypotheses will be tested: 1) maternal intake of trans fatty acids is inversely associated with fetal growth, length of gestation, and infant cognitive development; 2) maternal intake of n-3 fatty acids is directly associated with fetal growth, length of gestation and infant cognitive development; 3) maternal intake of calcium is inversely associated with incidence of pre-eclampsia and blood pressure levels in infancy; and 4) maternal intake and red blood cell level of n-3 fatty acids are inversely associated with incidence of preeclampsia. Blood samples and detailed data on gestational diet at several times during pregnancy will be collected along with sociodemographic variables, health habits, medical and family history, reproductive history and psychosocial conditions. Fetal growth data will be assessed from ultrasound examinations. Birth weight, height and other anthropometric data and blood pressure will be obtained and the offspring will be followed for 6 months to assess growth, cognitive development and blood pressure. There are plans to provide new avenues for the prevention of common adverse conditions of pregnancy, childhood and, perhaps, adulthood with the prospective, longitudinal study. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PREPREGNANCY PHENOTYPE & PREDISPOSITION TO PREECLAMPSIA Principal Investigator & Institution: Bernstein, Ira M.; Associate Professor; Obstetrics and Gynecology; University of Vermont & St Agric College 340 Waterman Building Burlington, Vt 05405
26
Eclampsia
Timing: Fiscal Year 2004; Project Start 01-FEB-2004; Project End 31-JAN-2009 Summary: (provided by applicant): Preeclampsia affects 3-5% of pregnancies and contributes significantly to maternal and neonatal morbidity and mortality. We have generated a novel hypothesis regarding the development of pre-eclampsia that postulates that two primary features contribute independently to its development. One feature is a pre-pregnancy phenotype that includes reduced plasma volume, elevated sympathetic tone, reduced utenne blood flow and enhanced platelet activation. This feature has been suggested by the association of a specific genetic polymorphism of angiotensinogen (TT235) with an increased risk for pre-eclampsia. This polymorphism has been linked in our preliminary data to key pathophysiologic features of preeclampsia, previously thought to be exclusive to pregnancy, in women who are examined prior to pregnancy. The second feature is the physiologic volume expansion of pregnancy. We have theorized that the overt clinical manifestations of pre-eclampsia become apparent in late pregnancy as a result of either 1) a normal volume expansion in women unable to tolerate it due to a chronic adaptation to low intravascular volume (abnormal prepregnancy phenotype) or 2) an excessive volume expansion in women with a normal prepregnancy phenotype (i.e. twins, molar pregnancies). In this grant we propose to examine 3 primary specific aims, employing detailed whole body physiologic measurements in women, that will support this pathophysiologic view of the development of preeclampsia; 1) We will confirm that the angiotensinogen genotype that has been linked to preeclampsia in Caucasians and Asians is associated with reduced plasma volume in a nulligravid population and that this plasma volume constriction is associated with elevated sympathetic tone, reduced uterine blood flow and heightened platelet activation prior to pregnancy, 2) As we follow these women into pregnancy we will demonstrate; a) that low prepregnancy plasma volume is associated with elevated sympathetic tone and reduced uterine blood flow in early pregnancy (12 weeks) predisposing to abnormal placentation despite similar plasma volume expansion, and b) that prepregnancy plasma volume is indirectly related to both the change in mean arterial pressure (corrected for plasma volume expansion) and degree of platelet activation in the third trimester, 3) Finally, we will demonstrate that pregnancy results in an increase in both post-puerperal plasma volume and arterial compliance Iowering the risk for both preeclampsia in future pregnancies and hypertension in later life. This will be a controlled prospective longitudinal study examining an integrated pathophysiologic mechanism underlying the development of preeclampsia. This study proposes to evaluate a novel hypothesis that synthesizes apparently contradictory data into a single coherent theory. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ROLE INTERACTIONS
OF
IGF-II
IN
HUMAN
TROPHOBLAST-DECIDUA
Principal Investigator & Institution: Giudice, Linda C.; Professor; Gynecology and Obstetrics; Stanford University Stanford, Ca 94305 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2007 Summary: (provided by applicant): Over the past 14 years the applicants lab has investigated decidualization of human endometrial stromal interactions between the human trophoblast and the maternal decidua in an effort to understand paracrine mechanisms operating in the placental bed during the invasive phase of human implantation. In particular, they have focussed on the insulin-like growth factor (IGF) family and its role in human implantation. IGF-II is abundantly expressed by the invading trophoblast, and it regulates maternal decidual modulators of invasion [IGF
Studies
27
binding protein-l and tissue inhibitor of metalloproteinase-3,TMP-3]. In addition, the investigators have pursued a global approach to gene profiling of human endometrial stromal cells during the process of decidualization in response to progesterone and to cAMP, and gene profiling of human endometrial biopsies, obtained in the implantation window and timed to the LH surge, in search of potential markers of uterine receptivity. These studies have revealed marked upregulation of IGF signaling cascade members and candidate genes for uterine receptivity and stromal decidualization. The underlying hypothesis of this proposal is that trophoblast-derived IGF-II acts on neighboring maternal endometrial stromal cells and regulates maternal modulators of trophoblast invasion. The specific aim is to investigate mechanisms underlying IGF-II actions an human endometrial stromal cells with a focus on signaling pathways and gene expression relevant to human implantation. The investigators shall validate signaling pathway members in human endometrium and test the hypothesis that the PI3 kinase pathway and phosphodiesterase 3B (PDE3B) mediate IGF-II effects on decidualized endometrial stromal cell modulators of trophoblast invasiveness. Effects of IGF-II signaling inhibitors on trophoblast invasion in vitro will be investigated as "proof of principle" and as a model for targeted drug development to enhance or inhibit trophoblast invasion. Finally, the investigators propose a gene discovery approach to investigate IGF-II actions on human endometrial stromal cell global gene expression. This will provide the Cooperative UO1 Program with a database of genes clustered by function expressed in decidualized endometrial stromal cells that are regulated by IGFII. This information can be used to investigate trophoblast-decidual interactions and enable targeted drug development for therapeutic intervention or prevention of abnormalities in trophoblast invasion, including infertility, ectopic pregnancy, and preeclampsia. The investigators work with the human model because of the uniqueness of implantation in humans. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SIGNALING PROLIFERATION
PATHWAYS
MEDIATING
TROPHOBLAST
Principal Investigator & Institution: Rappolee, Daniel A.; Obstetrics and Gynecology; Wayne State University 656 W. Kirby Detroit, Mi 48202 Timing: Fiscal Year 2002; Project Start 01-AUG-2001; Project End 31-JUL-2006 Summary: (provided by applicant): It is important to make a healthy placenta. Insufficient trophoblast proliferation or an imbalance between proliferation and differentiation may lead to pre-edampsia, IUGR or spontaneous abortion early after implantation of the embryo into the uterus, the time when most human conceptuses are lost. Our long term goal is to understand the signal transduction pathways that transduce intercellular signals into the trophoblast and induce proliferation. We have previously found that FGF input is required to produce trophoblast in the implanting embryo. We propose here to define the signal transduction pathways mediating trophoblast proliferation by promoting FGF-induced trophoblast proliferation and then testing several inhibitors of candidate transduction pathways to find which pathway(s) mediate the proliferative signal. In addition, we will block FGF-induced proliferation and then test for which rate-limiting enzyme genes in several signal transduction pathways are sufficient to re-activate the cell cycle. We also intend to define the FGFinduced signaling pathways that lead to proliferation compared with morptiogenetic events/differentiation. Since the first IVF baby, only 300,000 of 1,500,000 IVF attempts have resulted in a successful pregnancy. The majority of loss of human embryos is near the time of implantation. Other later loss of embryo/fetus loss due to preeclampsia and
28
Eclampsia
IUGR may also begin early at the time of implantation. Much of the loss is due to improper growth and differentiation of the placenta. Improved IVF requires an understanding of the mechanisms that mediate growth in the trophoblast lineage that enables placental function. The mouse is an excellent model to study implantation in humans. Therefore, the proposed studies should lead to improvement in methods to facilitate placentation and improve IVF and produce protocols for remediation of common defects in pregnancy such as pre-eclampsia and IUGR. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SLEEP REGULATION AND TUMOR NECROSIS FACTOR Principal Investigator & Institution: Krueger, James M.; Professor of Neurobiology; Vet & Comp Anat/Pharm/Physiol; Washington State University 423 Neill Hall Pullman, Wa 99164 Timing: Fiscal Year 2002; Project Start 01-AUG-1993; Project End 31-JUL-2005 Summary: (provided by applicant): Sleep is of central importance to neurobiology because to understand how the brain works, we will have to decipher the mechanisms and functions of sleep. The function(s) of sleep remain unknown and the humoral and neural mechanisms of sleep are incompletely understood. Most people intuitively recognize that sleep increases after sleep loss or during the course of an infection. There is much evidence that those sleep responses, as well as physiological sleep, are regulated, in part, by humoral mechanisms. We hypothesize that tumor necrosis factor alpha (TNF-alpha) is one of the key substances in sleep regulation. This hypothesis is based on studies showing: 1) TNF-alpha induces non-rapid eye movement sleep (NREMS); 2) inhibition of TNF-alpha inhibits spontaneous sleep and sleep responses induced by sleep loss or bacterial products; 3) TNF mRNA and TNF brain levels correlate with sleep propensity; 4) in humans, circulating TNF levels correlate with electroencephalogram slow-wave activity and increase after sleep loss or during several pathologies with associated fatigue, e.g., sleep apnea, rheumatoid arthritis, preeclampsia, multiple sclerosis. The proposed experiments seek to understand in mechanistic detail how TNF-alpha is involved in sleep regulation. We will determine whether blocking TNF-alpha or TNF-alpha production centrally attenuates systemic TNF-alpha-induced sleep responses; preliminary data show that vagotomy attenuates systemic TNF-alpha-induced NREMS (Specific Aim #1). We will investigate TNF-alpha regulation of NREMS within specific TNF-active sites in brain (Specific Aim #2). Preliminary data indicate that microinjection of TNF-alpha into the preoptic area enhances NREMS, whereas microinjection of an inhibitor of TNF-alpha reduces NREMS. Pharmacologic blockage of prostaglandins, adenosine, and interleukin-1, and sleep manipulation using sleep deprivation and acute mild increases in ambient temperature to enhance sleep, will be combined with microinjections of TNF-alpha or TNF-alpha inhibitors. We will also use gene arrays to determine the time course of sleep-sensitive changes in brain for TNF and TNF superfamily member mRNAs. Anticipated results will provide molecular-mechanistic advances to understand sleep regulation as well as aid our general understanding of cytokine regulation in the brain. We anticipate that results will be directly relevant to therapeutics, e.g., a TNF soluble receptor has already been shown to reduce fatigue associated with rheumatoid arthritis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: THE PHYSIOLOGY OF PLACENTAL LACTOGEN Principal Investigator & Institution: Handwerger, Stuart; Professor of Pediatrics; Children's Hospital Med Ctr (Cincinnati) 3333 Burnet Ave Cincinnati, Oh 45229
Studies
29
Timing: Fiscal Year 2002; Project Start 01-JUN-1978; Project End 31-MAR-2007 Summary: (Provided By Applicant) During human trophoblast differentiation, mononuclear cytotrophoblast cells of the placental villous differentiate to form a multinucleated syncytium that synthesizes and secretes many growth factors and steroid hormones that are important maternal and fetal regulators. Our laboratory is studying the differentiation of primary cultures of villous cytotrophoblast cells, using the induction of human placental lactogen (hPL), human chorionic gonadotropin (hCG) and several other genes as fundamental markers of syncytiotrophoblast cell development. We have observed that there are two distinct phases of cytotrophoblast differentiation: morphological differentiation, during which the mononuclear cytotrophoblast cells fuse to form a syncytium, and biochemical differentiation, during which the syncytiotrophoblast cells develop differentiated functions such as hormone production. The overall hypothesis of this proposal is that morphological differentiation depends on transcription factors that induce syncytin, a protein known to be critical for syncytium formation in BeWo choriocarcinoma cells, and that biochemical differentiation depends on the activity of the transcription factor AP-2a, which we have shown to be critical for the induction of several syncytiotrophoblast genes. We postulate that the induction of AP-2a leads to transcriptional induction and repression of groups of downstream transcription factors and other target genes essential for syncytiotrophoblast function; and disruption of AP-2a action or syncytin expression may lead to placental disorders such as choriocarcinoma, hydatidiform mole and preeclampsia. The specific aims are to test the hypotheses that 1) the syncytin and AP-2cz genes are coordinately regulated during cytotrophoblast differentiation by cAMP, steroid hormones, and inflammatory cytokines; 2) the induction of syncytin expression is critical for syncytium formation during villous cytotrophoblast cell differentiation, and 3) AP- 2-dependent transcription factors and growth factors direct a genetic program that is critical for hormone production and other biochemical processes essential for human cytotrophoblast differentiation and function. Methodologies will include transfection studies, gel shift assays, and DNA microarray analyses. New knowledge about the genetic program that directs normal trophoblast differentiation may lead to the development of novel approaches for the treatment of placental tumors, pre-eclampsia, and other pathological conditions associated with abnormal placental development Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “eclampsia” (or synonyms) into the search box. This search gives you access to full-
3 4
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.
30
Eclampsia
text articles. The following is a sample of items found for eclampsia in the PubMed Central database: •
Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. by Duley L, Henderson-Smart D, Knight M, King J.; 2001 Feb 10; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=26574
•
Clinical risk management in obstetrics: eclampsia drills. by Thompson S, Neal S, Clark V.; 2004 Jan 31; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=324457
•
Critical pathways for the management of preeclampsia and severe preeclampsia in institutionalised health care settings. by Perez-Cuevas R, Fraser W, Reyes H, Reinharz D, Daftari A, Heinz CS, Roberts JM.; 2003; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=270024
•
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. by Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA.; 2003 Mar 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=151901
•
Fetal and maternal contributions to risk of pre-eclampsia: population based study. by Lie RT, Rasmussen S, Brunborg H, Gjessing HK, Lie-Nielsen E, Irgens LM.; 1998 May 2; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=28531
•
Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. by Irgens HU, Reisaeter L, Irgens LM, Lie RT.; 2001 Nov 24; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=59993
•
Risk of subsequent thromboembolism for patients with pre-eclampsia. by van Walraven C, Mamdani M, Cohn A, Katib Y, Walker M, Rodger MA.; 2003 Apr 12; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=153713
•
Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? by Luttun A, Carmeliet P.; 2003 Mar 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=151908
•
Use of anticonvulsants in eclampsia and pre-eclampsia: survey of obstetricians in the United Kingdom and Republic of Ireland. by Gulmezoglu AM, Duley L.; 1998 Mar 28; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=28500
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6 The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to
6 PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
Studies
31
sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with eclampsia, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “eclampsia” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for eclampsia (hyperlinks lead to article summaries): •
A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. Author(s): Belfort MA, Anthony J, Saade GR, Allen JC Jr; Nimodipine Study Group. Source: The New England Journal of Medicine. 2003 January 23; 348(4): 304-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12540643&dopt=Abstract
•
A longitudinal study of biochemical markers of bone turnover during normal pregnancy and pregnancies complicated by pre-eclampsia. Author(s): Anim-Nyame N, Sooranna SR, Jones J, Alaghband-Zadeh J, Steer PJ, Johnson MR. Source: Bjog : an International Journal of Obstetrics and Gynaecology. 2002 June; 109(6): 708-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12118652&dopt=Abstract
•
A long-term transdermal nitric oxide donor improves uteroplacental circulation in women with preeclampsia. Author(s): Nakatsuka M, Takata M, Tada K, Asagiri K, Habara T, Noguchi S, Kudo T. Source: Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine. 2002 August; 21(8): 831-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12164565&dopt=Abstract
•
A randomized trial of intrapartum analgesia in women with severe preeclampsia. Author(s): Head BB, Owen J, Vincent RD Jr, Shih G, Chestnut DH, Hauth JC. Source: Obstetrics and Gynecology. 2002 March; 99(3): 452-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11864673&dopt=Abstract
•
A review of eclampsia in Qatar. Author(s): Sharara HA, Othman SY. Source: International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics. 2002 February; 76(2): 177-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11818115&dopt=Abstract
•
Abdominal pain and preeclampsia: sonographic findings in the maternal liver. Author(s): Suarez B, Alves K, Senat MV, Fromageot J, Fischer C, Rosenberg P, Ville Y. Source: Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine. 2002 October; 21(10): 1077-83; Quiz 1085-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12369662&dopt=Abstract
32
Eclampsia
•
Abnormal iron parameters in the pregnancy syndrome preeclampsia. Author(s): Rayman MP, Barlis J, Evans RW, Redman CW, King LJ. Source: American Journal of Obstetrics and Gynecology. 2002 August; 187(2): 412-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12193935&dopt=Abstract
•
Abnormalities in intracellular Ca2+ regulation in fetal vascular smooth muscle in preeclampsia: enhanced sensitivity to arachidonic acid. Author(s): Steinert JR, Poston L, Mann GE, Jacob R. Source: The Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology. 2003 February; 17(2): 307-9. Epub 2002 December 17. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12490537&dopt=Abstract
•
Absence of enhanced systemic inflammatory response at 18 weeks of gestation in women with subsequent pre-eclampsia. Author(s): Djurovic S, Clausen T, Wergeland R, Brosstad F, Berg K, Henriksen T. Source: Bjog : an International Journal of Obstetrics and Gynaecology. 2002 July; 109(7): 759-64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12135211&dopt=Abstract
•
ACOG practice bulletin on diagnosing and managing preeclampsia and eclampsia. American College of Obstetricians and Gynecologists. Author(s): Schroeder BM; American College of Obstetricians and Gynecologists. Source: American Family Physician. 2002 July 15; 66(2): 330-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12152970&dopt=Abstract
•
Activated protein C for preeclampsia: tailoring the disease to the therapy. Author(s): Lapinsky SE, Mehta S. Source: Critical Care Medicine. 2002 August; 30(8): 1929-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12163831&dopt=Abstract
•
Activated protein C in normal human pregnancy and pregnancies complicated by severe preeclampsia: a therapeutic opportunity? Author(s): von Dadelszen P, Magee LA, Lee SK, Stewart SD, Simone C, Koren G, Walley KR, Russell JA. Source: Critical Care Medicine. 2002 August; 30(8): 1883-92. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12163810&dopt=Abstract
•
Activation of leukocytes during the uteroplacental passage in preeclampsia. Author(s): Mellembakken JR, Aukrust P, Olafsen MK, Ueland T, Hestdal K, Videm V. Source: Hypertension. 2002 January; 39(1): 155-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11799095&dopt=Abstract
Studies
33
•
Acute renal failure complicating severe preeclampsia requiring admission to an obstetric intensive care unit. Author(s): Drakeley AJ, Le Roux PA, Anthony J, Penny J. Source: American Journal of Obstetrics and Gynecology. 2002 February; 186(2): 253-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11854645&dopt=Abstract
•
Adhesion molecules expression in the placental bed of pregnancies with preeclampsia. Author(s): Tziotis J, Malamitsi-Puchner A, Vlachos G, Creatsas G, Michalas S. Source: Bjog : an International Journal of Obstetrics and Gynaecology. 2002 February; 109(2): 197-201. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11888102&dopt=Abstract
•
Adrenomedullin, calcitonin gene-related peptide and their receptors: evidence for a decreased placental mRNA content in preeclampsia and HELLP syndrome. Author(s): Knerr I, Dachert C, Beinder E, Metzler M, Dotsch J, Repp R, Rascher W. Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2002 February 10; 101(1): 47-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11905404&dopt=Abstract
•
Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. Author(s): Buchbinder A, Sibai BM, Caritis S, Macpherson C, Hauth J, Lindheimer MD, Klebanoff M, Vandorsten P, Landon M, Paul R, Miodovnik M, Meis P, Thurnau G; National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Source: American Journal of Obstetrics and Gynecology. 2002 January; 186(1): 66-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11810087&dopt=Abstract
•
Alpha-foetoprotein in umbilical cord in relation to severe pre-eclampsia, birth weight and future breast cancer risk. Author(s): Vatten LJ, Romundstad PR, Odegard RA, Nilsen ST, Trichopoulos D, Austgulen R. Source: British Journal of Cancer. 2002 March 4; 86(5): 728-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11875734&dopt=Abstract
•
Altered Na+/H+ exchanger isoform 1 activity in immortalized lymphoblasts from women with pre-eclampsia: evidence for an intermediate phenotype. Author(s): Lee VM, Quinn PA, Jennings SC, Halligan AW, Ng LL. Source: Clinical Science (London, England : 1979). 2002 November; 103(5): 503-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12401124&dopt=Abstract
34
Eclampsia
•
Altered sonographic umbilical cord morphometry in early-onset preeclampsia. Author(s): Raio L, Ghezzi F, Di Naro E, Franchi M, Bolla D, Schneider H. Source: Obstetrics and Gynecology. 2002 August; 100(2): 311-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12151155&dopt=Abstract
•
Ambulatory blood pressure as predictor of preeclampsia in diabetic pregnancies with respect to urinary albumin excretion rate and glycemic regulation. Author(s): Lauszus FF, Rasmussen OW, Lousen T, Klebe TM, Klebe JG. Source: Acta Obstetricia Et Gynecologica Scandinavica. 2001 December; 80(12): 1096-103. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11846705&dopt=Abstract
•
An association between maternal smoking and preeclampsia in Japanese women. Author(s): Kobashi G, Ohta K, Hata A, Shido K, Yamada H, Fujimoto S, Kondo K. Source: Seminars in Thrombosis and Hemostasis. 2002 December; 28(6): 507-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12536340&dopt=Abstract
•
Anesthesia and preeclampsia. Author(s): Mandal NG. Source: Jama : the Journal of the American Medical Association. 2002 October 16; 288(15): 1847; Author Reply 1847-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12377078&dopt=Abstract
•
Angiotensin-converting enzyme activity in pre-eclampsia. Author(s): Laskowska M, Laskowska K, Oleszczuk J. Source: International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics. 2002 April; 77(1): 33-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11929654&dopt=Abstract
•
Angiotensinogen gene M235T variant and pre-eclampsia in Romanian pregnant women. Author(s): Procopciuc L, Jebeleanu G, Surcel I, Puscas M. Source: Journal of Cellular and Molecular Medicine. 2002 July-September; 6(3): 383-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12417054&dopt=Abstract
•
Antibodies to oxidised low-density lipoproteins and cardiolipin in pre-eclampsia and eclampsia. Author(s): Bowen RS, Moodley J, Dutton MF, Fickl H. Source: Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology. 2002 March; 22(2): 123-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12521691&dopt=Abstract
Studies
35
•
Appropriate neurological evaluation and multimodality magnetic resonance imaging in eclampsia. Author(s): Hoffmann M, Keiseb J, Moodley J, Corr P. Source: Acta Neurologica Scandinavica. 2002 September; 106(3): 159-67. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12174176&dopt=Abstract
•
Association between fetal nuchal translucency thickness in first trimester and subsequent gestational hypertension and preeclampsia. Author(s): Tsai MS, Lee FK, Cheng CC, Hwa KY, Cheong ML, She BQ. Source: Prenatal Diagnosis. 2002 September; 22(9): 747-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12224064&dopt=Abstract
•
Association between folic acid food fortification and hypertension or preeclampsia in pregnancy. Author(s): Ray JG, Mamdani MM. Source: Archives of Internal Medicine. 2002 August 12-26; 162(15): 1776-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12153382&dopt=Abstract
•
Bilateral retinal occlusion progressing to long-lasting blindness in severe preeclampsia. Author(s): Lara-Torre E, Lee MS, Wolf MA, Shah DM. Source: Obstetrics and Gynecology. 2002 November; 100(5 Pt 1): 940-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12423856&dopt=Abstract
•
Bioactivity of serum hCG in preeclampsia. Author(s): Casart YC, Camejo MI, Proverbio F, Febres F. Source: Obstetrics and Gynecology. 2001 September; 98(3): 463-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11530130&dopt=Abstract
•
Blindness associated with severe preeclampsia/eclampsia. Author(s): Amata AO. Source: Anesthesia and Analgesia. 2001 October; 93(4): 1081. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11574394&dopt=Abstract
•
Calcium supplementation in pre-eclampsia. Author(s): Wanchu M, Malhotra S, Khullar M. Source: J Assoc Physicians India. 2001 August; 49: 795-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11837466&dopt=Abstract
36
Eclampsia
•
Cerebral haemodynamics in pregnancy and pre-eclampsia as assessed by transcranial Doppler ultrasonography. Author(s): Sherman RW, Bowie RA, Henfrey MM, Mahajan RP, Bogod D. Source: British Journal of Anaesthesia. 2002 November; 89(5): 687-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12393763&dopt=Abstract
•
Cerebral perfusion pressure, and not cerebral blood flow, may be the critical determinant of intracranial injury in preeclampsia: a new hypothesis. Author(s): Belfort MA, Varner MW, Dizon-Townson DS, Grunewald C, Nisell H. Source: American Journal of Obstetrics and Gynecology. 2002 September; 187(3): 626-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12237639&dopt=Abstract
•
Cervicovaginal fetal fibronectin levels in women with preeclampsia. Author(s): McKenna DS, Costa S, Iams JD, Samuels P. Source: Obstetrics and Gynecology. 2002 August; 100(2): 266-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12151148&dopt=Abstract
•
Change in brain size during and after pregnancy: study in healthy women and women with preeclampsia. Author(s): Oatridge A, Holdcroft A, Saeed N, Hajnal JV, Puri BK, Fusi L, Bydder GM. Source: Ajnr. American Journal of Neuroradiology. 2002 January; 23(1): 19-26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11827871&dopt=Abstract
•
Changes in blood macrophage colony-stimulating factor levels after cesarean section in normotensive pregnancy and preeclampsia. Author(s): Hayashi M, Hoshimoto K, Ohkura T. Source: The American Journal of the Medical Sciences. 2002 July; 324(1): 5-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12120825&dopt=Abstract
•
Changes in urinary excretion of six biochemical parameters in normotensive pregnancy and preeclampsia. Author(s): Hayashi M, Ueda Y, Hoshimoto K, Ota Y, Fukasawa I, Sumori K, Kaneko I, Abe S, Uno M, Ohkura T, Inaba N. Source: American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 2002 February; 39(2): 392-400. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11840382&dopt=Abstract
•
Changing paternity and time since last pregnancy; the impact on pre-eclampsia risk. A study of 547 238 women with and without previous pre-eclampsia. Author(s): Trogstad LI, Eskild A, Magnus P, Samuelsen SO, Nesheim BI. Source: International Journal of Epidemiology. 2001 December; 30(6): 1317-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11821338&dopt=Abstract
Studies
37
•
Characterization of five marker levels of the hemostatic system and endothelial status in normotensive pregnancy and pre-eclampsia. Author(s): Hayashi M, Inoue T, Hoshimoto K, Negishi H, Ohkura T, Inaba N. Source: European Journal of Haematology. 2002 November-December; 69(5-6): 297-302. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12460234&dopt=Abstract
•
Choroidal vascular abnormalities in preeclampsia. Author(s): Iida T, Kishi S. Source: Archives of Ophthalmology. 2002 October; 120(10): 1406-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12365932&dopt=Abstract
•
Coagulation index to distinguish severe preeclampsia from normal pregnancy. Author(s): Kobayashi T, Sumimoto K, Tokunaga N, Sugimura M, Nishiguchi T, Kanayama N, Terao T. Source: Seminars in Thrombosis and Hemostasis. 2002 December; 28(6): 495-500. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12536338&dopt=Abstract
•
Collagen of umbilical cord vein and its alterations in pre-eclampsia. Author(s): Romanowicz L, Jaworski S. Source: Acta Biochimica Polonica. 2002; 49(2): 451-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12362987&dopt=Abstract
•
Commentary: Revisiting the primipaternity theory of pre-eclampsia. Author(s): Eskenazi B, Harley K. Source: International Journal of Epidemiology. 2001 December; 30(6): 1323-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11821339&dopt=Abstract
•
Comparison of the efficacy of continuous furosemide and low-dose dopamine infusion in preeclampsia/eclampsia-related oliguria in the immediate postpartum period. Author(s): Keiseb J, Moodley J, Connolly CA. Source: Hypertension in Pregnancy : Official Journal of the International Society for the Study of Hypertension in Pregnancy. 2002; 21(3): 225-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12517329&dopt=Abstract
•
Concentrations of apolipoproteins E, C2, and C3 and lipid profile in preeclampsia. Author(s): Chalas J, Audibert F, Francoual J, Le Bihan B, Frydman R, Lindenbaum A. Source: Hypertension in Pregnancy : Official Journal of the International Society for the Study of Hypertension in Pregnancy. 2002; 21(3): 199-204. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12517327&dopt=Abstract
38
Eclampsia
•
Concentrations of estrogens in patients with preeclampsia. Author(s): Zeisler H, Jirecek S, Hohlagschwandtner M, Knofler M, Tempfer C, Livingston JC. Source: Wiener Klinische Wochenschrift. 2002 June 28; 114(12): 458-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12422581&dopt=Abstract
•
Conservative management of early-onset pre-eclampsia and fetomaternal outcome in Nigerians. Author(s): Onah HE, Iloabachie GC. Source: Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology. 2002 July; 22(4): 357-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12521453&dopt=Abstract
•
Cortical blindness--a warning symptom of impending eclampsia? Author(s): Gale A, Eyong E. Source: Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology. 2002 January; 22(1): 89. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12521742&dopt=Abstract
•
Could an infectious trigger explain the differential maternal response to the shared placental pathology of preeclampsia and normotensive intrauterine growth restriction? Author(s): von Dadelszen P, Magee LA. Source: Acta Obstetricia Et Gynecologica Scandinavica. 2002 July; 81(7): 642-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12190839&dopt=Abstract
•
Cytokine expression in peripheral blood lymphocytes indicates a switch to T(HELPER) cells in patients with preeclampsia. Author(s): Rein DT, Schondorf T, Gohring UJ, Kurbacher CM, Pinto I, Breidenbach M, Mallmann P, Kolhagen H, Engel H. Source: Journal of Reproductive Immunology. 2002 March; 54(1-2): 133-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11839400&dopt=Abstract
•
Decrease of elastic tissue fibres in stem villus blood vessels of the human placenta during IUGR and IUGR with concomitant pre-eclampsia. Author(s): Wilhelm D, Mansmann U, Neudeck H, Matejevic D, Vetter K, Graf R. Source: Anatomy and Embryology. 2002 October; 205(5-6): 393-400. Epub 2002 July 06. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12382142&dopt=Abstract
Studies
39
•
Decreased maternal serum leptin in pregnancies complicated by preeclampsia. Author(s): Laml T, Preyer O, Hartmann BW, Ruecklinger E, Soeregi G, Wagenbichler P. Source: Journal of the Society for Gynecologic Investigation. 2001 March-April; 8(2): 8993. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11336879&dopt=Abstract
•
Decreased maternal serum placenta growth factor in early second trimester and preeclampsia. Author(s): Su YN, Lee CN, Cheng WF, Shau WY, Chow SN, Hsieh FJ. Source: Obstetrics and Gynecology. 2001 June; 97(6): 898-904. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11384693&dopt=Abstract
•
Delivery of patients with early onset, severe pre-eclampsia. Author(s): Hall DR, Odendaal HJ, Steyn DW. Source: International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics. 2001 August; 74(2): 143-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11502293&dopt=Abstract
•
Differences in apoptotic susceptibility of cytotrophoblasts and syncytiotrophoblasts in normal pregnancy to those complicated with preeclampsia and intrauterine growth restriction. Author(s): Crocker IP, Cooper S, Ong SC, Baker PN. Source: American Journal of Pathology. 2003 February; 162(2): 637-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12547721&dopt=Abstract
•
Differential levels of interleukin 6 in maternal and cord sera and placenta in women with pre-eclampsia. Author(s): Al-Othman S, Omu AE, Diejomaoh FM, Al-Yatama M, Al-Qattan F. Source: Gynecologic and Obstetric Investigation. 2001; 52(1): 60-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11549867&dopt=Abstract
•
Differential mechanisms of endothelium-dependent vasodilator responses in human myometrial small arteries in normal pregnancy and pre-eclampsia. Author(s): Kenny LC, Baker PN, Kendall DA, Randall MD, Dunn WR. Source: Clinical Science (London, England : 1979). 2002 July; 103(1): 67-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12095405&dopt=Abstract
•
Diffusion-weighted imaging shows cytotoxic and vasogenic edema in eclampsia. Author(s): Koch S, Rabinstein A, Falcone S, Forteza A. Source: Ajnr. American Journal of Neuroradiology. 2001 June-July; 22(6): 1068-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11415899&dopt=Abstract
40
Eclampsia
•
Dilantin as anticonvulsant in eclampsia. Author(s): Bathla S, Suneja A, Guleria K, Agarwal N. Source: J Indian Med Assoc. 2002 September; 100(9): 561-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12455387&dopt=Abstract
•
Do acetylsalicylic acid and other antiplatelet drugs prevent preeclampsia? Author(s): Maharaj R. Source: Can Fam Physician. 2001 December; 47: 2480-2. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11785278&dopt=Abstract
•
Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Author(s): Magpie Trial Collaboration Group. Source: Lancet. 2002 June 1; 359(9321): 1877-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12057549&dopt=Abstract
•
Does a lean prepregnancy body mass index influence outcome in pregnancies complicated by mild preeclampsia remote from term? Author(s): Barton JR, O'Nan JM, Bergauer NK, Jacques DL, Sibai BM. Source: Hypertension in Pregnancy : Official Journal of the International Society for the Study of Hypertension in Pregnancy. 2001; 20(3): 283-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12044336&dopt=Abstract
•
Does antiplatelet therapy prevent preeclampsia and its complications? Author(s): Kruszka S, Kruszka P. Source: The Journal of Family Practice. 2001 May; 50(5): 468. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11350714&dopt=Abstract
•
Does nitric oxide play a role in the aetiology of pre-eclampsia? Author(s): Postovit LM, Adams MA, Graham CH. Source: Placenta. 2001 April; 22 Suppl A: S51-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11312629&dopt=Abstract
•
Does serum calcium in pre-eclampsia and normal pregnancy differ? Author(s): Malas NO, Shurideh ZM. Source: Saudi Med J. 2001 October; 22(10): 868-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11744944&dopt=Abstract
Studies
41
•
Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation? Author(s): Antovic JP, Rafik Hamad R, Antovic A, Blomback M, Bremme K. Source: Thrombosis and Haemostasis. 2002 October; 88(4): 644-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12362237&dopt=Abstract
•
Doppler assessment of the uterine circulation in the second trimester in twin pregnancies: prediction of pre-eclampsia, fetal growth restriction and birth weight discordance. Author(s): Geipel A, Berg C, Germer U, Katalinic A, Krapp M, Smrcek J, Gembruch U. Source: Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2002 December; 20(6): 541-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12493041&dopt=Abstract
•
Doppler velocimetry: is it useful in preeclampsia? Author(s): Ceres R, Modrono A, Ruiz S. Source: American Journal of Obstetrics and Gynecology. 2001 August; 185(2): 522-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11518921&dopt=Abstract
•
Downregulation of placental syncytin expression and abnormal protein localization in pre-eclampsia. Author(s): Lee X, Keith JC Jr, Stumm N, Moutsatsos I, McCoy JM, Crum CP, Genest D, Chin D, Ehrenfels C, Pijnenborg R, van Assche FA, Mi S. Source: Placenta. 2001 November; 22(10): 808-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11718567&dopt=Abstract
•
Dyslipidemia in early second trimester is mainly a feature of women with early onset pre-eclampsia. Author(s): Clausen T, Djurovic S, Henriksen T. Source: Bjog : an International Journal of Obstetrics and Gynaecology. 2001 October; 108(10): 1081-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11702841&dopt=Abstract
•
Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. Author(s): Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Source: The Journal of Clinical Endocrinology and Metabolism. 2002 April; 87(4): 1762-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11932314&dopt=Abstract
42
Eclampsia
•
Eclampsia in Kaduna State of Nigeria--a proposal for a better outcome. Author(s): Onwuhafua PI, Onwuhafua A, Adze J, Mairami Z. Source: Niger J Med. 2001 April-June; 10(2): 81-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11705065&dopt=Abstract
•
Eclampsia in Sweden. Author(s): Kullberg G, Lindeberg S, Hanson U. Source: Hypertension in Pregnancy : Official Journal of the International Society for the Study of Hypertension in Pregnancy. 2002; 21(1): 13-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12044340&dopt=Abstract
•
Eclampsia. Author(s): Morgan E. Source: Nursing. 2002 March; 32(3): 104. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11902030&dopt=Abstract
•
Eclampsia: a leading cause of maternal mortality. Author(s): Mahran M. Source: Journal of Perinatal Medicine. 2001; 29(3): 235-40. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11447928&dopt=Abstract
•
Effect of preeclampsia in the mother on the leucine metabolism in the newborn infant. Author(s): Saenz De Pipaon Marcos M, Wattimena DJ, Van Beek RH, Lotgering FK, Sauer PJ. Source: Biology of the Neonate. 2002 January; 81(1): 23-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11803173&dopt=Abstract
•
Effect of preeclampsia on umbilical cord blood hematopoietic progenitor-stem cells. Author(s): Surbek DV, Danzer E, Steinmann C, Tichelli A, Wodnar-Filipowicz A, Hahn S, Holzgreve W. Source: American Journal of Obstetrics and Gynecology. 2001 September; 185(3): 725-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11568804&dopt=Abstract
•
Elevated C-reactive protein and pro-inflammatory cytokines in Andean women with pre-eclampsia. Author(s): Teran E, Escudero C, Moya W, Flores M, Vallance P, Lopez-Jaramillo P. Source: International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics. 2001 December; 75(3): 243-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11728484&dopt=Abstract
Studies
43
•
Elevated plasma homocysteine in early pregnancy: a risk factor for the development of severe preeclampsia. Author(s): Levine RJ, England LJ, Sibai BM. Source: American Journal of Obstetrics and Gynecology. 2002 May; 186(5): 1107; Author Reply 1108. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12015548&dopt=Abstract
•
Elevated plasma homocysteine in early pregnancy: a risk factor for the development of severe preeclampsia. Author(s): Cotter AM, Molloy AM, Scott JM, Daly SF. Source: American Journal of Obstetrics and Gynecology. 2001 October; 185(4): 781-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11641651&dopt=Abstract
•
Elevated tissue plasminogen activator as a potential marker of endothelial dysfunction in pre-eclampsia: correlation with proteinuria. Author(s): Bel L, Santos-Silva A, Rumley A, Lowe G, Pereira-Leite L, Quintanilha A, Rebelo I. Source: Bjog : an International Journal of Obstetrics and Gynaecology. 2002 November; 109(11): 1250-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12452463&dopt=Abstract
•
Endothelial dysfunction in uterine circulation in preeclampsia: can estrogens improve it? Author(s): Svedas E, Nisell H, Vanwijk MJ, Nikas Y, Kublickiene KR. Source: American Journal of Obstetrics and Gynecology. 2002 December; 187(6): 1608-16. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12501072&dopt=Abstract
•
Endothelial junctional protein redistribution and increased monolayer permeability in human umbilical vein endothelial cells isolated during preeclampsia. Author(s): Wang Y, Gu Y, Granger DN, Roberts JM, Alexander JS. Source: American Journal of Obstetrics and Gynecology. 2002 February; 186(2): 214-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11854638&dopt=Abstract
•
Endothelin-mediated preeclampsia at high altitude. Author(s): Angerio AD. Source: Critical Care Nursing Quarterly. 2000 August; 23(2): 73-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11853029&dopt=Abstract
44
Eclampsia
•
Enhanced coagulation activation in preeclampsia: the role of APC resistance, microparticles and other plasma constituents. Author(s): VanWijk MJ, Boer K, Berckmans RJ, Meijers JC, van der Post JA, Sturk A, VanBavel E, Nieuwland R. Source: Thrombosis and Haemostasis. 2002 September; 88(3): 415-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12353069&dopt=Abstract
•
Evidence for an association of the R485K polymorphism in the coagulation factor V gene with severe preeclampsia from screening 35 polymorphisms in 27 candidate genes. Author(s): Watanabe H, Hamada H, Yamakawa-Kobayashi K, Yoshikawa H, Arinami T. Source: Thrombosis and Haemostasis. 2001 December; 86(6): 1594-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11776341&dopt=Abstract
•
Evidence of in vivo generation of thrombin in patients with small-for-gestational-age fetuses and pre-eclampsia. Author(s): Chaiworapongsa T, Yoshimatsu J, Espinoza J, Kim YM, Berman S, Edwin S, Yoon BH, Romero R. Source: J Matern Fetal Neonatal Med. 2002 June;11(6):362-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12389649&dopt=Abstract
•
Evolutionary adaptations to pre-eclampsia/eclampsia in humans: low fecundability rate, loss of oestrus, prohibitions of incest and systematic polyandry. Author(s): Robillard PY, Dekker GA, Hulsey TC. Source: American Journal of Reproductive Immunology (New York, N.Y. : 1989). 2002 February; 47(2): 104-11. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11900595&dopt=Abstract
•
Expansion of the fraction of Th1 cells in women with preeclampsia: inverse correlation between the percentage of Th1 cells and the plasma level of PAI-2. Author(s): Ohkuchi A, Minakami H, Aoya T, Haga T, Kimura H, Suzuki M, Sato I. Source: American Journal of Reproductive Immunology (New York, N.Y. : 1989). 2001 October; 46(4): 252-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11642673&dopt=Abstract
•
Expression of inflammatory cytokines in placentas from women with preeclampsia. Author(s): Benyo DF, Smarason A, Redman CW, Sims C, Conrad KP. Source: The Journal of Clinical Endocrinology and Metabolism. 2001 June; 86(6): 2505-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11397847&dopt=Abstract
Studies
45
•
Factor V Leiden and factor II G20210A in preeclampsia and HELLP syndrome. Author(s): Benedetto C, Marozio L, Salton L, Maula V, Chieppa G, Massobrio M. Source: Acta Obstetricia Et Gynecologica Scandinavica. 2002 December; 81(12): 1095-100. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12519104&dopt=Abstract
•
Factor V Leiden mutation and preeclampsia. Author(s): Rigo J Jr, Nagy B, Fintor L. Source: American Journal of Obstetrics and Gynecology. 2002 April; 186(4): 853; Author Reply 853-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11967524&dopt=Abstract
•
Familial risk of preeclampsia in Newfoundland: a population-based study. Author(s): Dawson LM, Parfrey PS, Hefferton D, Dicks EL, Cooper MJ, Young D, Marsden PA. Source: Journal of the American Society of Nephrology : Jasn. 2002 July; 13(7): 1901-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12089387&dopt=Abstract
•
Fas and Fas ligand expression in maternal blood and in umbilical cord blood in preeclampsia. Author(s): Kuntz TB, Christensen RD, Stegner J, Duff P, Koenig JM. Source: Pediatric Research. 2001 December; 50(6): 743-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11726734&dopt=Abstract
•
Fetal and maternal cardiovascular diurnal rhythms in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Author(s): Koenen SV, Franx A, Mulder EJ, Bruinse HW, Visser GH. Source: J Matern Fetal Neonatal Med. 2002 May;11(5):313-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12389672&dopt=Abstract
•
Fetal cells and cell-free fetal DNA in maternal blood: new insights into preeclampsia. Author(s): Hahn S, Holzgreve W. Source: Human Reproduction Update. 2002 November-December; 8(6): 501-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12498420&dopt=Abstract
•
Fetal DNA clearance from maternal plasma is impaired in preeclampsia. Author(s): Lau TW, Leung TN, Chan LY, Lau TK, Chan KC, Tam WH, Lo YM. Source: Clinical Chemistry. 2002 December; 48(12): 2141-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12446469&dopt=Abstract
46
Eclampsia
•
Fibrinogen and factor VII promoter polymorphisms in women with preeclampsia. Author(s): Laasanen J, Hiltunen M, Punnonen K, Mannermaa A, Heinonen S. Source: Obstetrics and Gynecology. 2002 August; 100(2): 317-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12151156&dopt=Abstract
•
Fibronectin is a marker for organ involvement and may reflect the severity of preeclampsia. Author(s): Ostlund E, Hansson LO, Bremme K. Source: Hypertension in Pregnancy : Official Journal of the International Society for the Study of Hypertension in Pregnancy. 2001; 20(1): 79-87. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12044316&dopt=Abstract
•
First trimester insulin resistance and subsequent preeclampsia: a prospective study. Author(s): Wolf M, Sandler L, Munoz K, Hsu K, Ecker JL, Thadhani R. Source: The Journal of Clinical Endocrinology and Metabolism. 2002 April; 87(4): 1563-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11932283&dopt=Abstract
•
First-trimester maternal serum levels of placenta growth factor as predictor of preeclampsia and fetal growth restriction. Author(s): Ong CY, Liao AW, Cacho AM, Spencer K, Nicolaides KH. Source: Obstetrics and Gynecology. 2001 October; 98(4): 608-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11576576&dopt=Abstract
•
Frequency of factor V, prothrombin and methylenetetrahydrofolate reductase gene variants in preeclampsia. Author(s): D'Elia AV, Driul L, Giacomello R, Colaone R, Fabbro D, Di Leonardo C, Florio P, Petraglia F, Marchesoni D, Damante G. Source: Gynecologic and Obstetric Investigation. 2002; 53(2): 84-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11961379&dopt=Abstract
•
Functional characteristics of chorionic plate placental arteries from normal pregnant women and women with pre-eclampsia. Author(s): Ong SS, Crocker IP, Warren AY, Baker PN. Source: Hypertension in Pregnancy : Official Journal of the International Society for the Study of Hypertension in Pregnancy. 2002; 21(3): 175-83. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12517325&dopt=Abstract
•
Gene analysis of the N-terminal region of the estrogen receptor alpha in preeclampsia. Author(s): Malamitsi-Puchner A, Tziotis J, Evangelopoulos D, Fountas L, Vlachos G, Creatsas G, Sekeris CE, Moutsatsou P. Source: Steroids. 2001 September; 66(9): 695-700. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11546557&dopt=Abstract
Studies
47
•
Genetic susceptibility to preeclampsia: roles of cytosineto-thymine substitution at nucleotide 677 of the gene for methylenetetrahydrofolate reductase, 68-base pair insertion at nucleotide 844 of the gene for cystathionine beta-synthase, and factor V Leiden mutation. Author(s): Kim YJ, Williamson RA, Murray JC, Andrews J, Pietscher JJ, Peraud PJ, Merrill DC. Source: American Journal of Obstetrics and Gynecology. 2001 May; 184(6): 1211-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11349190&dopt=Abstract
•
Glutathione levels and antioxidative status in pre-eclampsia. Author(s): Schulz M, Wacker J, Bastert G. Source: International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics. 2002 August; 78(2): 157-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12175718&dopt=Abstract
•
Heat shock protein 70 is not increased in women with severe preeclampsia. Author(s): Livingston JC, Ahokas R, Haddad B, Sibai BM, Awaads R. Source: Hypertension in Pregnancy : Official Journal of the International Society for the Study of Hypertension in Pregnancy. 2002; 21(2): 123-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12175440&dopt=Abstract
•
Hemodialysis for toxic hypermagnesemia caused by intravenous magnesium in a woman with eclampsia and renal insufficiency. A case report. Author(s): Hirose M, Kobayashi M, Sudo S, Nakanishi K, Noda Y. Source: J Reprod Med. 2002 December; 47(12): 1050-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12516329&dopt=Abstract
•
Hemodynamic responses to obstructive respiratory events during sleep are augmented in women with preeclampsia. Author(s): Edwards N, Blyton DM, Kirjavainen TT, Sullivan CE. Source: American Journal of Hypertension : Journal of the American Society of Hypertension. 2001 November; 14(11 Pt 1): 1090-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11724205&dopt=Abstract
•
Hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome as a complication of preeclampsia in pregnant women increases the amount of cell-free fetal and maternal DNA in maternal plasma and serum. Author(s): Swinkels DW, de Kok JB, Hendriks JC, Wiegerinck E, Zusterzeel PL, Steegers EA. Source: Clinical Chemistry. 2002; 48(4): 650-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11901066&dopt=Abstract
48
Eclampsia
•
High intake of energy, sucrose, and polyunsaturated fatty acids is associated with increased risk of preeclampsia. Author(s): Clausen T, Slott M, Solvoll K, Drevon CA, Vollset SE, Henriksen T. Source: American Journal of Obstetrics and Gynecology. 2001 August; 185(2): 451-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11518908&dopt=Abstract
•
High serum interleukin-8 levels in afro-caribbean women with pre-eclampsia. Relations with tumor necrosis factor-alpha, duffy negative phenotype and von Willebrand factor. Author(s): Velzing-Aarts FV, Muskiet FA, van der Dijs FP, Duits AJ. Source: American Journal of Reproductive Immunology (New York, N.Y. : 1989). 2002 November; 48(5): 319-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12516654&dopt=Abstract
•
Higher risk of pre-eclampsia after change of partner. An effect of longer interpregnancy intervals? Author(s): Basso O, Christensen K, Olsen J. Source: Epidemiology (Cambridge, Mass.). 2001 November; 12(6): 624-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11679788&dopt=Abstract
•
History of abortion, preterm, term birth, and risk of preeclampsia: a population-based study. Author(s): Xiong X, Fraser WD, Demianczuk NN. Source: American Journal of Obstetrics and Gynecology. 2002 October; 187(4): 1013-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12388998&dopt=Abstract
•
Home monitoring of blood pressure in pregnancy at high risk of pre-eclampsia. Author(s): Waugh J, Bosio P, Habiba M, Boyce T, Shennan A, Halligan A. Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2001 November; 99(1): 109-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11604197&dopt=Abstract
•
Homocysteine and cellular fibronectin are increased in preeclampsia, not transient hypertension of pregnancy. Author(s): Powers RW, Evans RW, Ness RB, Crombleholme WR, Roberts JM. Source: Hypertension in Pregnancy : Official Journal of the International Society for the Study of Hypertension in Pregnancy. 2001; 20(1): 69-77. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12044315&dopt=Abstract
Studies
49
•
Homonymous hemianopia following a triplet pregnancy: post-natal cerebral vasculitis or atypical eclampsia. Author(s): Keay SD, Carroll SG, Scrutton M, Kelly A, Ormerod I, Cahill DJ. Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2002 June 10; 103(1): 92-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12039474&dopt=Abstract
•
Hormone levels in pre-eclampsia. Author(s): James WH. Source: Acta Obstetricia Et Gynecologica Scandinavica. 2002 December; 81(12): 1152; Author Reply 1152. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12519112&dopt=Abstract
•
Hypertension and its relation to renal function 10 years after pregnancy complicated by pre-eclampsia and pregnancy induced hypertension. Author(s): Shammas AG, Maayah JF. Source: Saudi Med J. 2000 February; 21(2): 190-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11533780&dopt=Abstract
•
Hypertension in pregnancy and preeclampsia. Knowledge and clinical practice among obstetrician-gynecologists. Author(s): Repke JT, Power ML, Holzman GB, Schulkin J. Source: J Reprod Med. 2002 June; 47(6): 472-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12092016&dopt=Abstract
•
Hypertension/preeclampsia. Author(s): Odendaal H. Source: Cardiovasc J S Afr. 2002 January-February; 13(1): 5-8. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11875601&dopt=Abstract
•
Hypertensive diseases and eclampsia. Author(s): Myers JE, Baker PN. Source: Current Opinion in Obstetrics & Gynecology. 2002 April; 14(2): 119-25. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11914688&dopt=Abstract
•
Hypertensive retinopathy and pre-eclampsia. Author(s): Tadin I, Bojic L, Mimica M, Karelovic D, Dogas Z. Source: Coll Antropol. 2001; 25 Suppl: 77-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11817020&dopt=Abstract
50
Eclampsia
•
Hyperuricemia, oxidative stress in preeclampsia. Author(s): Kharb S, Singh GP. Source: Clinica Chimica Acta; International Journal of Clinical Chemistry. 2001 March; 305(1-2): 201-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11354030&dopt=Abstract
•
Hypothesis: preeclampsia as a maternal-fetal conflict. Author(s): Odent M. Source: Medgenmed [electronic Resource] : Medscape General Medicine. 2001 September 5; 3(5): 2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11976604&dopt=Abstract
•
Hypoxia-reoxygenation: a potent inducer of apoptotic changes in the human placenta and possible etiological factor in preeclampsia. Author(s): Hung TH, Skepper JN, Charnock-Jones DS, Burton GJ. Source: Circulation Research. 2002 June 28; 90(12): 1274-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12089065&dopt=Abstract
•
ICAM-1 in maternal serum and amniotic fluid as an early marker of preeclampsia and IUGR. Author(s): Baviera G, D'Anna R, Corrado F, Ruello A, Buemi M, Jasonni VM. Source: J Reprod Med. 2002 March; 47(3): 191-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11933682&dopt=Abstract
•
Impact of preeclampsia and gestational hypertension on birth weight by gestational age. Author(s): Xiong X, Demianczuk NN, Saunders LD, Wang FL, Fraser WD. Source: American Journal of Epidemiology. 2002 February 1; 155(3): 203-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11821244&dopt=Abstract
•
Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either preeclampsia or intrauterine growth retardation. Author(s): Ishihara N, Matsuo H, Murakoshi H, Laoag-Fernandez JB, Samoto T, Maruo T. Source: American Journal of Obstetrics and Gynecology. 2002 January; 186(1): 158-66. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11810103&dopt=Abstract
•
Increased concentrations of soluble CD40 ligand, RANTES and GRO-alpha in preeclampsia--possible role of platelet activation. Author(s): Mellembakken JR, Solum NO, Ueland T, Videm V, Aukrust P. Source: Thrombosis and Haemostasis. 2001 November; 86(5): 1272-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11816717&dopt=Abstract
Studies
51
•
Increased endothelial monocyte chemoattractant protein-1 and interleukin-8 in preeclampsia. Author(s): Kauma S, Takacs P, Scordalakes C, Walsh S, Green K, Peng T. Source: Obstetrics and Gynecology. 2002 October; 100(4): 706-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12383538&dopt=Abstract
•
Increased levels of macrophage colony-stimulating factor in the placenta and blood in preeclampsia. Author(s): Hayashi M, Hoshimoto K, Ohkura T, Inaba N. Source: American Journal of Reproductive Immunology (New York, N.Y. : 1989). 2002 January; 47(1): 19-24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11883744&dopt=Abstract
•
Increased plasma adenosine concentrations and the severity of preeclampsia. Author(s): Yoneyama Y, Suzuki S, Sawa R, Yoneyama K, Power GG, Araki T. Source: Obstetrics and Gynecology. 2002 December; 100(6): 1266-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12468172&dopt=Abstract
•
Increased risk of preeclampsia among nulliparous pregnant women with idiopathic hematuria. Author(s): Stehman-Breen CO, Levine RJ, Qian C, Morris CD, Catalano PM, Curet LB, Sibai BM. Source: American Journal of Obstetrics and Gynecology. 2002 September; 187(3): 703-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12237651&dopt=Abstract
•
Individual longitudinal patterns in biochemical and hematological markers for the early prediction of pre-eclampsia. Author(s): Mello G, Parretti E, Cioni R, Lagozio C, Mealli F, Pratesi M. Source: J Matern Fetal Neonatal Med. 2002 February;11(2):93-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12375550&dopt=Abstract
•
Induction or caesarean section for preterm pre-eclampsia? Author(s): Mashiloane CD, Moodley J. Source: Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology. 2002 July; 22(4): 353-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12521452&dopt=Abstract
•
Induction to delivery time interval in patients with and without preeclampsia: a retrospective analysis. Author(s): Griffiths AN, Hikary N, Sizer AR. Source: Acta Obstetricia Et Gynecologica Scandinavica. 2002 September; 81(9): 867-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12225304&dopt=Abstract
52
Eclampsia
•
Inflationary oscillometry provides accurate measurement of blood pressure in preeclampsia. Author(s): Golara M, Benedict A, Jones C, Randhawa M, Poston L, Shennan AH. Source: Bjog : an International Journal of Obstetrics and Gynaecology. 2002 October; 109(10): 1143-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12387468&dopt=Abstract
•
Influence of maternal preeclampsia on recombinant human granulocyte colonystimulating factor effect in neutropenic neonates with suspected sepsis. Author(s): Zuppa AA, Girlando P, Florio MG, Cota F, Romagnoli C, Tortorolo G. Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2002 May 10; 102(2): 131-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11950479&dopt=Abstract
•
Insulin sensitivity in pre-eclampsia. Author(s): Sharma A, Haldiya SS. Source: J Assoc Physicians India. 2002 August; 50: 1022-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12421023&dopt=Abstract
•
Interleukin-2 receptor serum concentrations in normal pregnancy and pre-eclampsia. Author(s): Romero-Adrian T, Ruiz A, Molina-Vilchez R, Estevez J, Atencio R. Source: Invest Clin. 2002 June; 43(2): 73-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12108028&dopt=Abstract
•
Interventionist versus expectant care for severe pre-eclampsia before term. Author(s): Churchill D, Duley L. Source: Cochrane Database Syst Rev. 2002; (3): Cd003106. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12137674&dopt=Abstract
•
Is a polymorphism of the apolipoprotein E gene associated with preeclampsia? Author(s): Francoual J, Audibert F, Trioche P, Chalas J, Capel L, Lindenbaum A, Labrune P, Frydman R. Source: Hypertension in Pregnancy : Official Journal of the International Society for the Study of Hypertension in Pregnancy. 2002; 21(2): 127-33. Erratum In: Hypertens Pregnancy. 2003; 22(2): 213. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12175441&dopt=Abstract
•
Is mid-trimester maternal serum inhibin-A a marker of preeclampsia or intrauterine growth restriction? Author(s): D'Anna R, Baviera G, Corrado F, Leonardi I, Buemi M, Jasonni VM. Source: Acta Obstetricia Et Gynecologica Scandinavica. 2002 June; 81(6): 540-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12047308&dopt=Abstract
Studies
53
•
Is there an increased maternal-infant prevalence of Factor V Leiden in association with severe pre-eclampsia? Author(s): Currie L, Peek M, McNiven M, Prosser I, Mansour J, Ridgway J. Source: Bjog : an International Journal of Obstetrics and Gynaecology. 2002 February; 109(2): 191-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11888101&dopt=Abstract
•
Isolated microparticles, but not whole plasma, from women with preeclampsia impair endothelium-dependent relaxation in isolated myometrial arteries from healthy pregnant women. Author(s): Vanwijk MJ, Svedas E, Boer K, Nieuwland R, Vanbavel E, Kublickiene KR. Source: American Journal of Obstetrics and Gynecology. 2002 December; 187(6): 1686-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12501084&dopt=Abstract
•
Lack of association of severe preeclampsia with maternal and fetal mutant alleles for tumor necrosis factor alpha and lymphotoxin alpha genes and plasma tumor necrosis factor alpha levels. Author(s): Livingston JC, Park V, Barton JR, Elfering S, Haddad B, Mabie WC, Quasney M, Sibai BM. Source: American Journal of Obstetrics and Gynecology. 2001 May; 184(6): 1273-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11349201&dopt=Abstract
•
L-arginine transport by the microvillous plasma membrane of the syncytiotrophoblast from human placenta in relation to nitric oxide production: effects of gestation, preeclampsia, and intrauterine growth restriction. Author(s): Ayuk PT, Theophanous D, D'Souza SW, Sibley CP, Glazier JD. Source: The Journal of Clinical Endocrinology and Metabolism. 2002 February; 87(2): 747-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11836315&dopt=Abstract
•
Late onset of cortical blindness in a patient with severe preeclampsia related to retained placental fragments. Author(s): Delefosse D, Samain E, Helias A, Regimbeau JM, Deval B, Farah E, Marty J. Source: Anesthesiology. 2003 January; 98(1): 261-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12503005&dopt=Abstract
•
Late onset postpartum eclampsia: a rare and difficult diagnosis. Author(s): Dziewas R, Stogbauer F, Freund M, Ludemann P, Imai T, Holzapfel C, Ringelstein PB. Source: Journal of Neurology. 2002 September; 249(9): 1287-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12242555&dopt=Abstract
54
Eclampsia
•
Late postpartum eclampsia: a preventable disease? Author(s): Chames MC, Livingston JC, Ivester TS, Barton JR, Sibai BM. Source: American Journal of Obstetrics and Gynecology. 2002 June; 186(6): 1174-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12066093&dopt=Abstract
•
Leptin and pre-eclampsia in black African parturients. Author(s): Kafulafula GE, Moodley J, Ojwang PJ, Kagoro H. Source: Bjog : an International Journal of Obstetrics and Gynaecology. 2002 November; 109(11): 1256-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12452464&dopt=Abstract
•
Leptin and preeclampsia. Author(s): Poston L. Source: Seminars in Reproductive Medicine. 2002 May; 20(2): 131-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12087498&dopt=Abstract
•
Leucocyte intracellular pH and Na+/H+ exchanger isoform-1 activity in postpartum women with pre-eclampsia. Author(s): Lee VM, Halligan AW, Ng LL. Source: Bjog : an International Journal of Obstetrics and Gynaecology. 2001 June; 108(6): 615-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11426897&dopt=Abstract
•
Levels of C-reactive protein in pregnant women who subsequently develop preeclampsia. Author(s): Savvidou MD, Lees CC, Parra M, Hingorani AD, Nicolaides KH. Source: Bjog : an International Journal of Obstetrics and Gynaecology. 2002 March; 109(3): 297-301. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11950185&dopt=Abstract
•
Levels of dimethylarginines and cytokines in mild and severe preeclampsia. Author(s): Ellis J, Wennerholm UB, Bengtsson A, Lilja H, Pettersson A, Sultan B, Wennergren M, Hagberg H. Source: Acta Obstetricia Et Gynecologica Scandinavica. 2001 July; 80(7): 602-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11437716&dopt=Abstract
•
Levels of plasminogen activators and their inhibitors in maternal and umbilical cord plasma in severe preeclampsia. Author(s): Roes EM, Sweep CG, Thomas CM, Zusterzeel PL, Geurts-Moespot A, Peters WH, Steegers EA. Source: American Journal of Obstetrics and Gynecology. 2002 October; 187(4): 1019-25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12388999&dopt=Abstract
Studies
55
•
Linkage and association studies of IL1B and IL1RN gene polymorphisms in preeclampsia. Author(s): Lachmeijer AM, Nosti-Escanilla MP, Bastiaans EB, Pals G, Sandkuijl LA, Kostense PJ, Aarnoudse JG, Crusius JB, Pena AS, Dekker GA, Arngrimsson R, ten Kate LP. Source: Hypertension in Pregnancy : Official Journal of the International Society for the Study of Hypertension in Pregnancy. 2002; 21(1): 23-38. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12044341&dopt=Abstract
•
Lipid hydroperoxides and free radical scavenging enzyme activities in preeclampsia and HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome: no evidence for circulating primary products of lipid peroxidation. Author(s): Diedrich F, Renner A, Rath W, Kuhn W, Wieland E. Source: American Journal of Obstetrics and Gynecology. 2001 July; 185(1): 166-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11483923&dopt=Abstract
•
Lipoprotein lipase gene mutations and the genetic susceptibility of preeclampsia. Author(s): Kim YJ, Williamson RA, Chen K, Smith JL, Murray JC, Merrill DC. Source: Hypertension. 2001 November; 38(5): 992-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11711487&dopt=Abstract
•
Lipoprotein(a): a longitudinal versus a cross-sectional study in normal pregnancy and its levels in preeclampsia. Author(s): Belo L, Caslake M, Santos-Silva A, Pereira-Leite L, Quintanilha A, Rebelo I. Source: Atherosclerosis. 2002 December; 165(2): 393-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12417294&dopt=Abstract
•
Loading dose versus standard regime of magnesium sulfate in the management of eclampsia: a randomized trial. Author(s): Begum MR, Begum A, Quadir E. Source: The Journal of Obstetrics and Gynaecology Research. 2002 June; 28(3): 154-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12214831&dopt=Abstract
•
Localization of hyaluronan with a hyaluronan-specific hyaluronic acid binding protein in the placenta in pre-eclampsia. Author(s): Matejevic D, Neudeck H, Graf R, Muller T, Dietl J. Source: Gynecologic and Obstetric Investigation. 2001; 52(4): 257-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11729340&dopt=Abstract
56
Eclampsia
•
Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. Author(s): Irgens HU, Reisaeter L, Irgens LM, Lie RT. Source: Bmj (Clinical Research Ed.). 2001 November 24; 323(7323): 1213-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11719411&dopt=Abstract
•
Long-term treatment with nicardipine for severe pre-eclampsia. Author(s): Seki H, Takeda S, Kinoshita K. Source: International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics. 2002 February; 76(2): 135-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11818107&dopt=Abstract
•
Low-density lipoprotein particle diameter in normal pregnancy and preeclampsia. Author(s): Ogura K, Miyatake T, Fukui O, Nakamura T, Kameda T, Yoshino G. Source: J Atheroscler Thromb. 2002; 9(1): 42-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12238637&dopt=Abstract
•
Magnesium for preventing and treating eclampsia: time for international action. Author(s): Sheth SS, Chalmers I. Source: Lancet. 2002 June 1; 359(9321): 1872-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12057545&dopt=Abstract
•
Magnesium sulfate compared with lytic cocktail for women with eclampsia. Author(s): Duley L, Gulmezoglu AM. Source: International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics. 2002 January; 76(1): 3-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11818087&dopt=Abstract
•
Magnesium sulfate for preeclampsia. Author(s): Greene MF. Source: The New England Journal of Medicine. 2003 January 23; 348(4): 275-6. Erratum In: N Engl J Med. 2003 Jan 23; 348(4): 1730. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12540639&dopt=Abstract
•
Marion's message. Preeclampsia and the placenta. Author(s): McLean MT. Source: Midwifery Today Int Midwife. 2001 Summer; (58): 7, 69. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12154730&dopt=Abstract
Studies
57
•
Massive ascites in severe pre-eclampsia: a rare complication. Author(s): Vaijyanath AM, Nayar B, Malhotra N, Deka D. Source: The Journal of Obstetrics and Gynaecology Research. 2002 August; 28(4): 199202. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12452261&dopt=Abstract
•
Maternal endothelial soluble cell adhesion molecules with isolated small for gestational age fetuses: comparison with pre-eclampsia. Author(s): Bretelle F, Sabatier F, Blann A, D'Ercole C, Boutiere B, Mutin M, Boubli L, Sampol J, Dignat-George F. Source: Bjog : an International Journal of Obstetrics and Gynaecology. 2001 December; 108(12): 1277-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11843391&dopt=Abstract
•
Maternal lymphocyte subpopulations (CD45RA+ and CD45RO+) in preeclampsia. Author(s): Chaiworapongsa T, Gervasi MT, Refuerzo J, Espinoza J, Yoshimatsu J, Berman S, Romero R. Source: American Journal of Obstetrics and Gynecology. 2002 October; 187(4): 889-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12388971&dopt=Abstract
•
Maternal outcome in eclampsia at Harare Maternity Hospital. Author(s): Majoko F, Mujaji C. Source: Cent Afr J Med. 2001 May; 47(5): 123-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11921670&dopt=Abstract
•
Maternal plasma adenosine and endothelin-1 levels in twin gestation complicated by preeclampsia. Author(s): Shinagawa T, Suzuki S, Sawa R, Yoneyama Y, Asakura H, Araki T. Source: Archives of Gynecology and Obstetrics. 2002 December; 267(2): 72-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12439550&dopt=Abstract
•
Maternal plasma cellular fibronectin concentrations in normal and preeclamptic pregnancies: a longitudinal study for early prediction of preeclampsia. Author(s): Chavarria ME, Lara-Gonzalez L, Gonzalez-Gleason A, Sojo I, Reyes A. Source: American Journal of Obstetrics and Gynecology. 2002 September; 187(3): 595601. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12237633&dopt=Abstract
58
Eclampsia
•
Maternal serum activin, inhibin, human chorionic gonadotrophin and alphafetoprotein as second trimester predictors of pre-eclampsia. Author(s): Davidson EJ, Riley SC, Roberts SA, Shearing CH, Groome NP, Martin CW. Source: Bjog : an International Journal of Obstetrics and Gynaecology. 2003 January; 110(1): 46-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12504935&dopt=Abstract
•
Maternal-fetal effects of magnesium sulfate on serum osmolality in pre-eclampsia. Author(s): van der Heyden JJ, Standley CA. Source: J Matern Fetal Neonatal Med. 2002 April;11(4):270-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12375684&dopt=Abstract
•
Matrix metalloprotease-9, placental syncytiotrophoblast and the endothelial dysfunction of pre-eclampsia. Author(s): de Jager CA, Linton EA, Spyropoulou I, Sargent IL, Redman CW. Source: Placenta. 2003 January; 24(1): 84-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12495663&dopt=Abstract
•
Measurement of plasma glutathione S-transferase in hepatocellular damage in preeclampsia. Author(s): Kumtepe Y, Borekci B, Aksoy H, Altinkaynak K, Ingec M, Ozdiller O. Source: J Int Med Res. 2002 September-October; 30(5): 483-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12449517&dopt=Abstract
•
Mechanism of increased maternal serum total activin a and inhibin a in preeclampsia. Author(s): Silver HM, Lambert-Messerlian GM, Reis FM, Diblasio AM, Petraglia F, Canick JA. Source: Journal of the Society for Gynecologic Investigation. 2002 September-October; 9(5): 308-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12383916&dopt=Abstract
•
Microarray analysis of differentially expressed genes in placental tissue of preeclampsia: up-regulation of obesity-related genes. Author(s): Reimer T, Koczan D, Gerber B, Richter D, Thiesen HJ, Friese K. Source: Molecular Human Reproduction. 2002 July; 8(7): 674-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12087083&dopt=Abstract
•
Microparticle subpopulations are increased in preeclampsia: possible involvement in vascular dysfunction? Author(s): VanWijk MJ, Nieuwland R, Boer K, van der Post JA, VanBavel E, Sturk A. Source: American Journal of Obstetrics and Gynecology. 2002 August; 187(2): 450-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12193942&dopt=Abstract
Studies
59
•
Mid-trimester triple test levels in early and late onset severe pre-eclampsia. Author(s): Shenhav S, Gemer O, Sassoon E, Volodarsky M, Peled R, Segal S. Source: Prenatal Diagnosis. 2002 July; 22(7): 579-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12124692&dopt=Abstract
•
Molecular epidemiology of preeclampsia. Author(s): Wilson ML, Goodwin TM, Pan VL, Ingles SA. Source: Obstetrical & Gynecological Survey. 2003 January; 58(1): 39-66. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12544785&dopt=Abstract
•
Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Author(s): Papageorghiou AT, Yu CK, Bindra R, Pandis G, Nicolaides KH; Fetal Medicine Foundation Second Trimester Screening Group. Source: Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2001 November; 18(5): 441-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11844162&dopt=Abstract
•
Neurologic aspects of eclampsia. Author(s): Kaplan PW. Source: Adv Neurol. 2002; 90: 41-9. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12068463&dopt=Abstract
•
Neutrophil intracellular pH and Na+/H+ exchanger activity in pre-eclampsia. Author(s): Lee VM, Halligan AW, Ng LL. Source: Metabolism: Clinical and Experimental. 2003 January; 52(1): 87-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12524667&dopt=Abstract
•
Neutrophil oxygen radical production in pre-eclampsia with HELLP syndrome. Author(s): Zusterzeel PL, Wanten GJ, Peters WH, Merkus HM, Steegers EA. Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2001 December 1; 99(2): 213-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11788174&dopt=Abstract
•
New scope in angiogenesis: role of vascular endothelial growth factor (VEGF), NO, lipid peroxidation, and vitamin E in the pathophysiology of pre-eclampsia among Egyptian females. Author(s): El-Salahy EM, Ahmed MI, El-Gharieb A, Tawfik H. Source: Clinical Biochemistry. 2001 June; 34(4): 323-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11440734&dopt=Abstract
60
Eclampsia
•
Newborn birth weight correlates with placental zinc, umbilical insulin-like growth factor I, and leptin levels in preeclampsia. Author(s): Diaz E, Halhali A, Luna C, Diaz L, Avila E, Larrea F. Source: Archives of Medical Research. 2002 January-February; 33(1): 40-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11825630&dopt=Abstract
•
Nifedipine or hydralazine as a first-line agent to control hypertension in severe preeclampsia. Author(s): Aali BS, Nejad SS. Source: Acta Obstetricia Et Gynecologica Scandinavica. 2002 January; 81(1): 25-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11942883&dopt=Abstract
•
Nitric oxide production increases during normal pregnancy and decreases in preeclampsia. Author(s): Choi JW, Im MW, Pai SH. Source: Ann Clin Lab Sci. 2002 Summer; 32(3): 257-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12175088&dopt=Abstract
•
Nitric oxide/endothelin-1 in preeclampsia. Author(s): Vural P. Source: Clinica Chimica Acta; International Journal of Clinical Chemistry. 2002 March; 317(1-2): 65-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11814459&dopt=Abstract
•
No difference in structure between omental small arteries isolated from women with preeclampsia, intrauterine growth restriction, and normal pregnancies. Author(s): Ong SS, Baker PN, Mayhew TM, Dunn WR. Source: American Journal of Obstetrics and Gynecology. 2002 September; 187(3): 606-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12237635&dopt=Abstract
•
No evidence for lipid peroxidation in severe preeclampsia. Author(s): Poston L, Mallet A. Source: American Journal of Obstetrics and Gynecology. 2002 October; 187(4): 1118; Author Reply 1119-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12389014&dopt=Abstract
•
No evidence for lipid peroxidation in severe preeclampsia. Author(s): Regan CL, Levine RJ, Baird DD, Ewell MG, Martz KL, Sibai BM, Rokach J, Lawson JA, Fitzgerald GA. Source: American Journal of Obstetrics and Gynecology. 2001 September; 185(3): 572-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11568780&dopt=Abstract
Studies
61
•
Normalization of vasoactive changes in preeclampsia precedes clinical recovery. Author(s): Makkonen N, Heinonen S, Hongisto T, Penttila I, Kirkinen P. Source: Hypertension in Pregnancy : Official Journal of the International Society for the Study of Hypertension in Pregnancy. 2002; 21(1): 51-64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12044343&dopt=Abstract
•
Not pre-eclampsia. Author(s): Saeed SA, Dean S, deGiovanni JV. Source: Journal of the Royal Society of Medicine. 2001 July; 94(7): 351-3. Erratum In: J R Soc Med 2001 October; 94(10): 556. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11418710&dopt=Abstract
•
Novel chemiluminescence assay for serum periostin levels in women with preeclampsia and in normotensive pregnant women. Author(s): Sasaki H, Roberts J, Lykins D, Fujii Y, Auclair D, Chen LB. Source: American Journal of Obstetrics and Gynecology. 2002 January; 186(1): 103-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11810094&dopt=Abstract
•
Obesity and preeclampsia: the potential role of inflammation. Author(s): Wolf M, Kettyle E, Sandler L, Ecker JL, Roberts J, Thadhani R. Source: Obstetrics and Gynecology. 2001 November; 98(5 Pt 1): 757-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11704165&dopt=Abstract
•
On the prevention of preeclampsia: nutritional factors back in the spotlight? Author(s): Alexander S. Source: Epidemiology (Cambridge, Mass.). 2002 July; 13(4): 382-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12094091&dopt=Abstract
•
Outcome of infants delivered between 24 and 28 weeks' gestation in women with severe pre-eclampsia. Author(s): Hiett AK, Brown HL, Britton KA. Source: The Journal of Maternal-Fetal Medicine. 2001 October; 10(5): 301-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11730491&dopt=Abstract
•
Oxidative stress in pre-eclampsia. Author(s): Bowen RS, Moodley J, Dutton MF, Theron AJ. Source: Acta Obstetricia Et Gynecologica Scandinavica. 2001 August; 80(8): 719-25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11531614&dopt=Abstract
62
Eclampsia
•
Oxidative stress reproduces placental abnormalities of preeclampsia. Author(s): Vaughan JE, Walsh SW. Source: Hypertension in Pregnancy : Official Journal of the International Society for the Study of Hypertension in Pregnancy. 2002; 21(3): 205-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12517328&dopt=Abstract
•
Paternal age and preeclampsia. Author(s): Harlap S, Paltiel O, Deutsch L, Knaanie A, Masalha S, Tiram E, Caplan LS, Malaspina D, Friedlander Y. Source: Epidemiology (Cambridge, Mass.). 2002 November; 13(6): 660-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12410007&dopt=Abstract
•
Paternal contribution to the risk for pre-eclampsia. Author(s): Zusterzeel PL, te Morsche R, Raijmakers MT, Roes EM, Peters WH, Steegers EA. Source: Journal of Medical Genetics. 2002 January; 39(1): 44-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11826024&dopt=Abstract
•
Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparas. Author(s): Hnat MD, Sibai BM, Caritis S, Hauth J, Lindheimer MD, MacPherson C, VanDorsten JP, Landon M, Miodovnik M, Paul R, Meis P, Thurnau G, Dombrowski M; National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine-Units. Source: American Journal of Obstetrics and Gynecology. 2002 March; 186(3): 422-6. Erratum In: Am J Obstet Gynecol. 2003 July; 189(1): 244. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11904601&dopt=Abstract
•
Perinatal outcomes in preeclampsia that is complicated by massive proteinuria. Author(s): Newman MG, Robichaux AG, Stedman CM, Jaekle RK, Fontenot MT, Dotson T, Lewis DF. Source: American Journal of Obstetrics and Gynecology. 2003 January; 188(1): 264-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12548227&dopt=Abstract
•
Plasma anti-oxidant status and lipid profile in non-gravida women with a history of pre-eclampsia. Author(s): Ozan H, Ilcol Y, Kimya Y, Cengiz C, Ediz B. Source: The Journal of Obstetrics and Gynaecology Research. 2002 October; 28(5): 274-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12428698&dopt=Abstract
Studies
63
•
Possible activation of the renin-angiotensin system in the feto-placental unit in preeclampsia. Author(s): Ito M, Itakura A, Ohno Y, Nomura M, Senga T, Nagasaka T, Mizutani S. Source: The Journal of Clinical Endocrinology and Metabolism. 2002 April; 87(4): 1871-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11932332&dopt=Abstract
•
Pre-eclampsia and expression of heparin-binding EGF-like growth factor. Author(s): Leach RE, Romero R, Kim YM, Chaiworapongsa T, Kilburn B, Das SK, Dey SK, Johnson A, Qureshi F, Jacques S, Armant DR. Source: Lancet. 2002 October 19; 360(9341): 1215-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12401248&dopt=Abstract
•
Preeclampsia and fetal triploidy: a rarely reported association in nephrologic literature. Author(s): Giannattasio M, Gernone G, Pannarale G, Gesualdo L, Schena FP. Source: Journal of Nephrology. 2002 January-February; 15(1): 74-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11936431&dopt=Abstract
•
Preeclampsia disrupts the normal physiology of leptin. Author(s): Gursoy T, Aliefendioglu D, Aslan AT, Gunduz M, Haberal A, Senes M, Cakmak FN, Laleli YR. Source: American Journal of Perinatology. 2002 August; 19(6): 303-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12357421&dopt=Abstract
•
Preeclampsia in multiple gestation: the role of assisted reproductive technologies. Author(s): Lynch A, McDuffie R Jr, Murphy J, Faber K, Orleans M. Source: Obstetrics and Gynecology. 2002 March; 99(3): 445-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11864672&dopt=Abstract
•
Pre-eclampsia in pregnancy and subsequent risk for breast cancer. Author(s): Vatten LJ, Romundstad PR, Trichopoulos D, Skjaerven R. Source: British Journal of Cancer. 2002 October 21; 87(9): 971-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12434286&dopt=Abstract
•
Preeclampsia is associated with altered Ca2+ regulation and NO production in human fetal venous endothelial cells. Author(s): Steinert JR, Wyatt AW, Poston L, Jacob R, Mann GE. Source: The Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology. 2002 May; 16(7): 721-3. Epub 2002 March 26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11923225&dopt=Abstract
64
Eclampsia
•
Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Author(s): Wimalasundera RC, Larbalestier N, Smith JH, de Ruiter A, McG Thom SA, Hughes AD, Poulter N, Regan L, Taylor GP. Source: Lancet. 2002 October 12; 360(9340): 1152-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12387967&dopt=Abstract
•
Pre-eclampsia, diagnosis and treatment. Author(s): Sunanda GV, Johanson R. Source: Expert Opinion on Pharmacotherapy. 2001 November; 2(11): 1817-24. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11825319&dopt=Abstract
•
Preeclampsia: a multifactorial disease resulting from the interaction of the fetomaternal HLA genotype and HCMV infection. Author(s): Carreiras M, Montagnani S, Layrisse Z. Source: American Journal of Reproductive Immunology (New York, N.Y. : 1989). 2002 September; 48(3): 176-83. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12443029&dopt=Abstract
•
Pregnancy-associated and placental proteins in the placental tissue of normal pregnant women and patients with pre-eclampsia at term. Author(s): Bersinger NA, Groome N, Muttukrishna S. Source: European Journal of Endocrinology / European Federation of Endocrine Societies. 2002 December; 147(6): 785-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12457454&dopt=Abstract
•
Presentation of a PTHrP-secreting pancreatic neuroendocrine tumour, with hypercalcaemic crisis, pre-eclampsia, and renal failure. Author(s): Abraham P, Ralston SH, Hewison M, Fraser WD, Bevan JS. Source: Postgraduate Medical Journal. 2002 December; 78(926): 752-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12509695&dopt=Abstract
•
Preventing and treating eclamptic seizures. Will magnesium sulphate for preeclampsia really help? Author(s): Moran NF. Source: Bmj (Clinical Research Ed.). 2003 January 4; 326(7379): 50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12511469&dopt=Abstract
Studies
65
•
ProC Global assay in the evaluation of women with history of severe preeclampsia or HELLP syndrome. Author(s): Heilmann L, von Tempelhoff GF, Pollow K. Source: Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2002 October; 8(4): 319-24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12518722&dopt=Abstract
•
Production of human mast cell chymase in human myometrium and placenta in cases of normal pregnancy and preeclampsia. Author(s): Mitani R, Maeda K, Fukui R, Endo S, Saijo Y, Shinohara K, Kamada M, Irahara M, Yamano S, Nakaya Y, Aono T. Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2002 March 10; 101(2): 155-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11858891&dopt=Abstract
•
Recent Insights into the pathogenesis of pre-eclampsia. Author(s): Roberts JM, Lain KY. Source: Placenta. 2002 May; 23(5): 359-72. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12061851&dopt=Abstract
•
Receptor double-trouble in preeclampsia. Author(s): Lodwick D. Source: Nature Medicine. 2001 September; 7(9): 999-1000. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11533700&dopt=Abstract
•
Recurrence risk of preterm birth due to preeclampsia. Author(s): Koike T, Minakami H, Izumi A, Watanabe T, Matsubara S, Sato I. Source: Gynecologic and Obstetric Investigation. 2002; 53(1): 22-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11803224&dopt=Abstract
•
Reduced function of endothelial prostacyclin in human omental resistance arteries in pre-eclampsia. Author(s): Suzuki Y, Hattori T, Kajikuri J, Yamamoto T, Suzumori K, Itoh T. Source: The Journal of Physiology. 2002 November 15; 545(Pt 1): 269-77. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12433966&dopt=Abstract
•
Reduced red blood cell deformability, an indicator for high fetal or maternal risk, is found in preeclampsia and IUGR. Author(s): Schauf B, Lang U, Stute P, Schneider S, Dietz K, Aydeniz B, Wallwiener D. Source: Hypertension in Pregnancy : Official Journal of the International Society for the Study of Hypertension in Pregnancy. 2002; 21(2): 147-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12175443&dopt=Abstract
66
Eclampsia
•
Regulation of trophoblast invasion: from normal implantation to pre-eclampsia. Author(s): Goldman-Wohl D, Yagel S. Source: Molecular and Cellular Endocrinology. 2002 February 22; 187(1-2): 233-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11988332&dopt=Abstract
•
Relation between adenosine and T-helper 1/T-helper 2 imbalance in women with preeclampsia. Author(s): Yoneyama Y, Suzuki S, Sawa R, Yoneyama K, Power GG, Araki T. Source: Obstetrics and Gynecology. 2002 April; 99(4): 641-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12039127&dopt=Abstract
•
Relation between adenosine deaminase activities and cytokine-producing T cells in women with preeclampsia. Author(s): Yoneyama Y, Sawa R, Suzuki S, Miura A, Kobayashi H, Doi D, Yoneyama K, Araki T. Source: Clinical Biochemistry. 2002 June; 35(4): 303-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12135693&dopt=Abstract
•
Relation between plasma endothelin 1 levels and T helper 1: T helper 2 cell immunity in women with preeclampsia. Author(s): Kuwajima T, Suzuki S, Yoneyama Y, Sawa R, Asakura H, Araki T. Source: Gynecologic and Obstetric Investigation. 2001; 52(4): 260-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11729341&dopt=Abstract
•
Relation between serum uric acid and plasma adenosine levels in women with preeclampsia. Author(s): Suzuki S, Yoneyama Y, Sawa R, Otsubo Y, Takeuchi T, Araki T. Source: Gynecologic and Obstetric Investigation. 2001; 51(3): 169-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11306903&dopt=Abstract
•
Relationship between plasma malondialdehyde levels and adenosine deaminase activities in preeclampsia. Author(s): Yoneyama Y, Sawa R, Suzuki S, Doi D, Yoneyama K, Otsubo Y, Araki T. Source: Clinica Chimica Acta; International Journal of Clinical Chemistry. 2002 August; 322(1-2): 169-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12104097&dopt=Abstract
•
Relationship of insulin-like growth factor-I and insulin-like growth factor binding proteins in umbilical cord plasma to preeclampsia and infant birth weight. Author(s): Vatten LJ, Odegard RA, Nilsen ST, Salvesen KA, Austgulen R. Source: Obstetrics and Gynecology. 2002 January; 99(1): 85-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11777516&dopt=Abstract
Studies
67
•
Relationship of twin zygosity and risk of preeclampsia. Author(s): Maxwell CV, Lieberman E, Norton M, Cohen A, Seely EW, Lee-Parritz A. Source: American Journal of Obstetrics and Gynecology. 2001 October; 185(4): 819-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11641658&dopt=Abstract
•
Remote prognosis of primiparous women with preeclampsia. Author(s): Dukler D, Porath A, Bashiri A, Erez O, Mazor M. Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2001 May; 96(1): 69-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11311764&dopt=Abstract
•
Resistance artery smooth muscle function in pregnancy and preeclampsia. Author(s): VanWijk MJ, Boer K, van der Meulen ET, Bleker OP, Spaan JA, VanBavel E. Source: American Journal of Obstetrics and Gynecology. 2002 January; 186(1): 148-54. Erratum In: Am J Obstet Gynecol 2002 April; 186(4): 722. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11810101&dopt=Abstract
•
Retinal detachment in preeclampsia. Author(s): Prado RS, Figueiredo EL, Magalhaes TV. Source: Arquivos Brasileiros De Cardiologia. 2002 August; 79(2): 183-6. English, Portuguese. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12219193&dopt=Abstract
•
Retinal disorders in preeclampsia studied with optical coherence tomography. Author(s): Theodossiadis PG, Kollia AK, Gogas P, Panagiotidis D, Moschos M, Theodossiadis GP. Source: American Journal of Ophthalmology. 2002 May; 133(5): 707-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11992874&dopt=Abstract
•
Reversible cortical blindness in preeclampsia. Author(s): Do DV, Rismondo V, Nguyen QD. Source: American Journal of Ophthalmology. 2002 December; 134(6): 916-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12470768&dopt=Abstract
•
Review of eclampsia at the Nnamdi Azikiwe University teaching hospital, Nnewi (January 1996-December 2000). Author(s): Ikechebelu JI, Okoli CC. Source: Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology. 2002 May; 22(3): 287-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12521501&dopt=Abstract
68
Eclampsia
•
Risk factors in Mozambican women with eclampsia: a case-referent study. Author(s): Bugalho A, Bacci A, Bergstrom S. Source: Afr J Reprod Health. 2001 August; 5(2): 30-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12471911&dopt=Abstract
•
Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler at 11-14 weeks of gestation. Author(s): Martin AM, Bindra R, Curcio P, Cicero S, Nicolaides KH. Source: Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2001 December; 18(6): 583-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11844193&dopt=Abstract
•
Screening for pre-eclampsia and fetal growth restriction in twin pregnancies at 23 weeks of gestation by transvaginal uterine artery Doppler. Author(s): Yu CK, Papageorghiou AT, Boli A, Cacho AM, Nicolaides KH. Source: Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2002 December; 20(6): 535-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12493040&dopt=Abstract
•
Searching for preeclampsia genes: the current position. Author(s): Lachmeijer AM, Dekker GA, Pals G, Aarnoudse JG, ten Kate LP, Arngrimsson R. Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2002 November 15; 105(2): 94-113. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12381470&dopt=Abstract
•
Selected local and peripheral intereactions of some cytokines in etiopathogenesis of preeclampsia. Author(s): Bielecki DA, Terlikowski SJ, Poludniewski G, Bielecki M. Source: Rocz Akad Med Bialymst. 2002; 47: 5-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12533944&dopt=Abstract
•
Selective termination of a twin pregnancy as a treatment of severe pre-eclampsia. Author(s): Audibert F, Salomon LJ, Castaigne-Meary V, Alves K, Frydman R. Source: Bjog : an International Journal of Obstetrics and Gynaecology. 2003 January; 110(1): 68-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12504939&dopt=Abstract
•
Serial assessment in eclampsia of cerebrohemodynamics by combined transcranial Doppler and magnetic resonance angiography. Author(s): Ikeda T, Urabe H, Matsukage S, Sameshima H, Ikenoue T. Source: Gynecologic and Obstetric Investigation. 2002; 53(1): 65-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11803232&dopt=Abstract
Studies
69
•
Serum activin A, inhibin A, and follistatin concentrations in preeclampsia or small for gestational age pregnancies. Author(s): Keelan JA, Taylor R, Schellenberg JC, Groome NP, Mitchell MD, North RA. Source: Obstetrics and Gynecology. 2002 February; 99(2): 267-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11814508&dopt=Abstract
•
Severe preeclampsia and cerebral blood volume response to postural change. Author(s): Chipchase J, Peebles D, Rodeck C. Source: Obstetrics and Gynecology. 2003 January; 101(1): 86-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12517651&dopt=Abstract
•
Severe preeclampsia and the very-low-birth-weight infant. The controversy over delivery mode continues. Author(s): Chibber RM. Source: J Reprod Med. 2002 November; 47(11): 925-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12497682&dopt=Abstract
•
Severe pre-eclampsia remote from term: what to expect of expectant management. Author(s): Blackwell SC, Redman ME, Tomlinson M, Berry SM, Sorokin Y, Cotton DB. Source: J Matern Fetal Neonatal Med. 2002 May;11(5):321-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12389673&dopt=Abstract
•
Skin capillary density changes in normal pregnancy and pre-eclampsia. Author(s): Hasan KM, Manyonda IT, Ng FS, Singer DR, Antonios TF. Source: Journal of Hypertension. 2002 December; 20(12): 2439-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12473869&dopt=Abstract
•
Soluble adhesion molecule profile in normal pregnancy and pre-eclampsia. Author(s): Chaiworapongsa T, Romero R, Yoshimatsu J, Espinoza J, Kim YM, Park K, Kalache K, Edwin S, Bujold E, Gomez R. Source: J Matern Fetal Neonatal Med. 2002 July;12(1):19-27. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12422905&dopt=Abstract
•
Soluble adhesion molecules: marker of pre-eclampsia and intrauterine growth restriction. Author(s): Coata G, Pennacchi L, Bini V, Liotta L, Di Renzo GC. Source: J Matern Fetal Neonatal Med. 2002 July;12(1):28-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12422906&dopt=Abstract
70
Eclampsia
•
Spinal anaesthesia or CSE are the preferred techniques of anaesthesia for caesarean section in pre-eclampsia. Author(s): Cooper G. Source: Acta Anaesthesiol Belg. 2002; 53(4): 289-93. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12503352&dopt=Abstract
•
Spinal anesthesia is the preferred technique for cesarean section in severe preeclampsia: proponent position. Author(s): Hood DD. Source: Acta Anaesthesiol Belg. 2002; 53(4): 305-10. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12503355&dopt=Abstract
•
Spontaneously beating neonatal rat heart myocyte culture-a model to characterize angiotensin II at(1) receptor autoantibodies in patients with preeclampsia. Author(s): Wallukat G, Nissen E, Neichel D, Harris J. Source: In Vitro Cellular & Developmental Biology. Animal. 2002 July-August; 38(7): 376-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12534336&dopt=Abstract
•
Subfecundity as a correlate of preeclampsia: a study within the Danish National Birth Cohort. Author(s): Basso O, Weinberg CR, Baird DD, Wilcox AJ, Olsen J; Danish National Birth Cohort. Source: American Journal of Epidemiology. 2003 February 1; 157(3): 195-202. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12543618&dopt=Abstract
•
Surgically obtained sperm, and risk of gestational hypertension and pre-eclampsia. Author(s): Wang JX, Knottnerus AM, Schuit G, Norman RJ, Chan A, Dekker GA. Source: Lancet. 2002 February 23; 359(9307): 673-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11879865&dopt=Abstract
•
Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in Finnish families. Author(s): Laivuori H, Lahermo P, Ollikainen V, Widen E, Haiva-Mallinen L, Sundstrom H, Laitinen T, Kaaja R, Ylikorkala O, Kere J. Source: American Journal of Human Genetics. 2003 January; 72(1): 168-77. Epub 2002 December 09. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12474145&dopt=Abstract
Studies
71
•
Syncytin, a novel human endogenous retroviral gene in human placenta: evidence for its dysregulation in preeclampsia and HELLP syndrome. Author(s): Knerr I, Beinder E, Rascher W. Source: American Journal of Obstetrics and Gynecology. 2002 February; 186(2): 210-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11854637&dopt=Abstract
•
Temporary blindness as a complication of eclampsia: observations on three cases. Author(s): Rahman J, Rahman W. Source: Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology. 2002 January; 22(1): 87-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12521740&dopt=Abstract
•
The changes of trace elements, malondialdehyde levels and superoxide dismutase activities in pregnancy with or without preeclampsia. Author(s): Ilhan N, Ilhan N, Simsek M. Source: Clinical Biochemistry. 2002 July; 35(5): 393-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12270770&dopt=Abstract
•
The elevated plasma lipoprotein(a) concentrations in preeclampsia do not precede the development of the disorder. Author(s): Bar J, Harell D, Bardin R, Pardo J, Chen R, Hod M, Sullivan M. Source: Thrombosis Research. 2002 January 1; 105(1): 19-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11864702&dopt=Abstract
•
The endocrinology of pre-eclampsia. Author(s): Page NM. Source: Clinical Endocrinology. 2002 October; 57(4): 413-23. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12354123&dopt=Abstract
•
The neurology of eclampsia : some observations. Author(s): Chakravarty A, Chakrabarti SD. Source: Neurology India. 2002 June; 50(2): 128-35. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12134173&dopt=Abstract
•
The partner's role in the etiology of preeclampsia. Author(s): Dekker G. Source: Journal of Reproductive Immunology. 2002 October-November; 57(1-2): 203-15. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12385843&dopt=Abstract
72
Eclampsia
•
The plasma and placental levels of malondialdehyde, glutathione and superoxide dismutase in pre-eclampsia. Author(s): Madazli R, Benian A, Aydin S, Uzun H, Tolun N. Source: Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology. 2002 September; 22(5): 477-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12521411&dopt=Abstract
•
The possible role of prolactin in preeclampsia: 2001, a hypothesis revisited a quarter of century later. Author(s): Parra A, Ramirez-Peredo J. Source: Medical Hypotheses. 2002 October; 59(4): 378-84. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12208175&dopt=Abstract
•
The power to terrify: eclampsia in 19th-century American practice. Author(s): Moss SW. Source: Journal of Obstetric, Gynecologic, and Neonatal Nursing : Jognn / Naacog. 2002 September-October; 31(5): 514-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12353729&dopt=Abstract
•
The relationships between leptin and inflammatory cytokines in women with preeclampsia. Author(s): Bartha JL, Romero-Carmona R, Escobar-Llompart M, Comino-Delgado R. Source: Bjog : an International Journal of Obstetrics and Gynaecology. 2001 December; 108(12): 1272-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11843390&dopt=Abstract
•
The role of hyperglycosylated hCG in trophoblast invasion and the prediction of subsequent pre-eclampsia. Author(s): Bahado-Singh RO, Oz AU, Kingston JM, Shahabi S, Hsu CD, Cole L. Source: Prenatal Diagnosis. 2002 June; 22(6): 478-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12116306&dopt=Abstract
•
The role of intravenous volume expansion in moderate pre-eclampsia. Author(s): Heilmann L, Gerhold S, von Tempelhoff GF, Pollow K. Source: Clinical Hemorheology and Microcirculation. 2001; 25(3-4): 83-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11847411&dopt=Abstract
Studies
73
•
The 'Severe Hypertensive Illness in Pregnancy' (SHIP) audit: promoting quality care using a high risk monitoring chart and eclampsia treatment pack. Author(s): Baldwin KJ, Leighton NA, Kilby MD, Wyldes M, Churchill D, Jones PW, Johanson RB; SHIP Steering Committee. Source: Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology. 2002 July; 22(4): 346-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12521451&dopt=Abstract
•
The upper airway in pregnancy and pre-eclampsia. Author(s): Izci B, Riha RL, Martin SE, Vennelle M, Liston WA, Dundas KC, Calder AA, Douglas NJ. Source: American Journal of Respiratory and Critical Care Medicine. 2003 January 15; 167(2): 137-40. Epub 2002 October 31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12411285&dopt=Abstract
•
Thrombomodulin Ala455Val dimorphism is not associated with pre-eclampsia in Australian and New Zealand women. Author(s): Borg AJ, Higgins JR, Brennecke SP, Moses EK. Source: Gynecologic and Obstetric Investigation. 2002; 54(1): 43-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12297717&dopt=Abstract
•
Thrombophilia, preeclampsia, and fetal demise: a case report. Author(s): Vallejo MC, Abdullah RS, Kaul B, Ramanathan S. Source: Journal of Clinical Anesthesia. 2002 September; 14(6): 449-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12393115&dopt=Abstract
•
Transcranial doppler measurement of cerebral velocity indices as a predictor of preeclampsia. Author(s): Riskin-Mashiah S, Belfort MA, Saade GR, Herd JA. Source: American Journal of Obstetrics and Gynecology. 2002 December; 187(6): 1667-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12501081&dopt=Abstract
•
Transforming growth factor beta(1) levels in platelet depleted plasma in African women with pre-eclampsia. Author(s): Naicker T, Khedun SM, Moodley J. Source: Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology. 2002 May; 22(3): 279-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12521499&dopt=Abstract
74
Eclampsia
•
Transforming growth factor-beta 1 does not relate to hypertension in pre-eclampsia. Author(s): Hennessy A, Orange S, Willis N, Painter DM, Child A, Horvath JS. Source: Clinical and Experimental Pharmacology & Physiology. 2002 November; 29(11): 968-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12366387&dopt=Abstract
•
Two exonic single nucleotide polymorphisms in the microsomal epoxide hydrolase gene are jointly associated with preeclampsia. Author(s): Laasanen J, Romppanen EL, Hiltunen M, Helisalmi S, Mannermaa A, Punnonen K, Heinonen S. Source: European Journal of Human Genetics : Ejhg. 2002 September; 10(9): 569-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12173035&dopt=Abstract
•
Ultrastructure of human umbilical vessels in pre-eclampsia. Author(s): Cetin A, Kukner A, Ozturk F. Source: J Matern Fetal Neonatal Med. 2002 September;12(3):178-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12530615&dopt=Abstract
•
Umbilical cord plasma interleukin-6 and fetal growth restriction in preeclampsia: a prospective study in Norway. Author(s): Odegard RA, Vatten LJ, Nilsen ST, Salvesen KA, Vefring H, Austgulen R. Source: Obstetrics and Gynecology. 2001 August; 98(2): 289-94. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11506847&dopt=Abstract
•
Umbilical cord plasma leptin is increased in preeclampsia. Author(s): Odegard RA, Vatten LJ, Nilsen ST, Salvesen KA, Austgulen R. Source: American Journal of Obstetrics and Gynecology. 2002 March; 186(3): 427-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11904602&dopt=Abstract
•
Update on Pre-eclampsia. Author(s): Haddad T. Source: International Anesthesiology Clinics. 2002 Fall; 40(4): 115-35. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12409937&dopt=Abstract
•
Urinary heparan sulfate proteoglycan excretion in black African women with preeclampsia. Author(s): Khedun SM, Naicker T, Moodley J, Gathiram P. Source: Acta Obstetricia Et Gynecologica Scandinavica. 2002 April; 81(4): 308-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11952459&dopt=Abstract
Studies
75
•
Urinary protein excretion and expectant management of early onset, severe preeclampsia. Author(s): Hall DR, Odendaal HJ, Steyn DW, Grove D. Source: International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics. 2002 April; 77(1): 1-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11929649&dopt=Abstract
•
Using village theatre to increase knowledge about eclampsia in Bangladesh. Author(s): Islam KS, Sachchu SA, Sandani R, Bullough C, Siraj N, Dimmock P, Johanson RB. Source: The Journal of Obstetrics and Gynaecology Research. 2001 August; 27(4): 199204. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11721730&dopt=Abstract
•
Uterine artery Doppler flow and uteroplacental vascular pathology in normal pregnancies and pregnancies complicated by pre-eclampsia and small for gestational age fetuses. Author(s): Aardema MW, Oosterhof H, Timmer A, van Rooy I, Aarnoudse JG. Source: Placenta. 2001 May; 22(5): 405-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11373150&dopt=Abstract
•
Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Author(s): Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, Alitalo K, Damsky C, Fisher SJ. Source: American Journal of Pathology. 2002 April; 160(4): 1405-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11943725&dopt=Abstract
•
Vasoactive diadenosine polyphosphates in human placenta: possible candidates in the pathophysiology of pre-eclampsia? Author(s): Jankowski J, Yoon MS, Stephan N, Zidek W, Schluter H. Source: Journal of Hypertension. 2001 March; 19(3 Pt 2): 567-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11327631&dopt=Abstract
•
Vasospasms are characteristic in cases with eclampsia/preeclampsia and HELLP syndrome: proposal of an angiospastic syndrome of pregnancy. Author(s): Kobayashi T, Tokunaga N, Isoda H, Kanayama N, Terao T. Source: Seminars in Thrombosis and Hemostasis. 2001; 27(2): 131-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11372766&dopt=Abstract
76
Eclampsia
•
Vitamin C and E supplementation in women at risk of preeclampsia is associated with changes in indices of oxidative stress and placental function. Author(s): Chappell LC, Seed PT, Kelly FJ, Briley A, Hunt BJ, Charnock-Jones DS, Mallet A, Poston L. Source: American Journal of Obstetrics and Gynecology. 2002 September; 187(3): 777-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12237663&dopt=Abstract
•
Vitamin C and the risk of preeclampsia--results from dietary questionnaire and plasma assay. Author(s): Zhang C, Williams MA, King IB, Dashow EE, Sorensen TK, Frederick IO, Thompson ML, Luthy DA. Source: Epidemiology (Cambridge, Mass.). 2002 July; 13(4): 409-16. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12094095&dopt=Abstract
77
CHAPTER 2. NUTRITION AND ECLAMPSIA Overview In this chapter, we will show you how to find studies dedicated specifically to nutrition and eclampsia.
Finding Nutrition Studies on Eclampsia The National Institutes of Health’s Office of Dietary Supplements (ODS) offers a searchable bibliographic database called the IBIDS (International Bibliographic Information on Dietary Supplements; National Institutes of Health, Building 31, Room 1B29, 31 Center Drive, MSC 2086, Bethesda, Maryland 20892-2086, Tel: 301-435-2920, Fax: 301-480-1845, E-mail:
[email protected]). The IBIDS contains over 460,000 scientific citations and summaries about dietary supplements and nutrition as well as references to published international, scientific literature on dietary supplements such as vitamins, minerals, and botanicals.7 The IBIDS includes references and citations to both human and animal research studies. As a service of the ODS, access to the IBIDS database is available free of charge at the following Web address: http://ods.od.nih.gov/databases/ibids.html. After entering the search area, you have three choices: (1) IBIDS Consumer Database, (2) Full IBIDS Database, or (3) Peer Reviewed Citations Only. Now that you have selected a database, click on the “Advanced” tab. An advanced search allows you to retrieve up to 100 fully explained references in a comprehensive format. Type “eclampsia” (or synonyms) into the search box, and click “Go.” To narrow the search, you can also select the “Title” field.
7 Adapted from http://ods.od.nih.gov. IBIDS is produced by the Office of Dietary Supplements (ODS) at the National Institutes of Health to assist the public, healthcare providers, educators, and researchers in locating credible, scientific information on dietary supplements. IBIDS was developed and will be maintained through an interagency partnership with the Food and Nutrition Information Center of the National Agricultural Library, U.S. Department of Agriculture.
78
Eclampsia
The following information is typical of that found when using the “Full IBIDS Database” to search for “eclampsia” (or a synonym): •
A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. Author(s): Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.
[email protected] Source: Belfort, M A Anthony, J Saade, G R Allen, J C Jr N-Engl-J-Med. 2003 January 23; 348(4): 304-11 1533-4406
•
A new treatment of severe pre-eclampsia by long-term epidural anaesthesia. Author(s): Department of Obstetrics and Gynecology, Hamamastu University School of Medicine, Hamamatsu city, Japan. Source: Kanayama, N Belayet, H M Khatun, S Tokunaga, N Sugimura, M Kobayashi, T Terao, T J-Hum-Hypertens. 1999 March; 13(3): 167-71 0950-9240
•
Abnormalities in intracellular Ca2+ regulation in fetal vascular smooth muscle in preeclampsia: enhanced sensitivity to arachidonic acid. Author(s): Centre for Cardiovascular Biology and Medicine, GKT Schools of Biomedical Sciences and Medicine, King's College London, Guy's Campus, London SE1 1UL, UK. Source: Steinert, J R Poston, L Mann, G E Jacob, R FASEB-J. 2003 February; 17(2): 307-9 1530-6860
•
Activation of endothelial cells by plasma from women with preeclampsia: differential effects on four endothelial cell types. Author(s): Department of Obstetrics and Gynaecology, Nottingham City Hospital, UK. Source: Wellings, R P Brockelsby, J C Baker, P N J-Soc-Gynecol-Investig. 1998 JanFebruary; 5(1): 31-7 1071-5576
•
An imbalance between prostacyclin and thromboxane in relation to cerebral blood flow in neonates with maternal preeclampsia. Author(s): Department of Pediatrics, Yokohama City University School of Medicine, Kanagawa, Japan.
[email protected] Source: Nishimaki, S Seki, K Prostaglandins-Other-Lipid-Mediat. 1999 August; 58(1): 439 1098-8823
•
Anti-convulsant therapy in eclampsia. Source: Maheshwari, J R Desai, S V Hansotia, M D Walvekar, V R J-Postgrad-Med. 1989 April; 35(2): 66-9 0022-3859
•
C4 deficiency state in antiphospholipid antibody-related recurrent preeclampsia evolving into systemic lupus erythematosus. Author(s): Hospital Central de Asturias, Oviedo-Asturias, Spain.
[email protected] Source: Queiro, R Weruaga, A Riestra, J L Rheumatol-Int. 2002 July; 22(3): 126-8 01728172
•
Calcium, nitric oxide, and preeclampsia. Author(s): Instituto Colombiano de Investigaciones Biomedicas, Bucaramanga, Colombia.
[email protected] Source: Lopez Jaramillo, P Semin-Perinatol. 2000 February; 24(1): 33-6 0146-0005
•
Circulating factors as markers and mediators of endothelial cell dysfunction in preeclampsia. Author(s): Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco 94143, USA. Source: Taylor, R N de Groot, C J Cho, Y K Lim, K H Semin-Reprod-Endocrinol. 1998; 16(1): 17-31 0734-8630
Nutrition
79
•
Correlation between oral sex and a low incidence of preeclampsia: a role for soluble HLA in seminal fluid? Author(s): Department of Immunohematology and Blood Bank, Leiden University Medical Centre, PO Box 9600, 2300 RC, Leiden, The Netherlands. Source: Koelman, C A Coumans, A B Nijman, H W Doxiadis, I I Dekker, G A Claas, F H J-Reprod-Immunol. 2000 March; 46(2): 155-66 0165-0378
•
Counseling for women with preeclampsia or eclampsia. Author(s): Department of Obstetrics and Gynecology, the University of Texas Medical Branch, Galveston, USA. Source: Witlin, A G Semin-Perinatol. 1999 February; 23(1): 91-8 0146-0005
•
Deficient detoxifying capacity in the pathophysiology of preeclampsia. Author(s): Department of Obstetrics and Gynaecology, University Hospital, Nijmegen, The Netherlands. Source: Roes, E M Raijmakers, M T Zusterzeel, P L Knapen, M C Peters, W H Steegers, E A Med-Hypotheses. 2000 November; 55(5): 415-8 0306-9877
•
Dietary risk factors for pre-eclampsia among women attending Harare Maternity Hospital, Zimbabwe. Author(s): Department of Epidemiology, University of Washington, School of Public Health and Community Medicine, Seattle, USA. Source: Atkinson, J O Mahomed, K Williams, M A Woelk, G B Mudzamiri, S Weiss, N S Cent-Afr-J-Med. 1998 April; 44(4): 86-92 0008-9176
•
Effects of calcium antagonists on contractions of chorionic arteries in normal and preeclampsia placenta. Author(s): Department of Pharmacology, Chonnam University Medical School, Kwangju, Korea. Source: Kook, H Yoon, Y D Baik, Y H J-Korean-Med-Sci. 1996 June; 11(3): 250-7 10118934
•
Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: A systematic review. Author(s): Obstetrical Medicine Programme, Department of Medicine, University of Toronto, Ontario.
[email protected] Source: Ray, J G Laskin, C A Placenta. 1999 September; 20(7): 519-29 0143-4004
•
Functional characteristics of chorionic plate placental arteries from normal pregnant women and women with pre-eclampsia. Author(s): The MRC Development Group, School of Human Development, University of Nottingham, City Hospital, Nottingham NG5 1PB, UK.
[email protected] Source: Ong, S S Crocker, I P Warren, A Y Baker, P N Hypertens-Pregnancy. 2002; 21(3): 175-83 1064-1955
•
Glutathione and glutathione-related enzymes in decidua and placenta of controls and women with pre-eclampsia. Author(s): Department of Obstetrics/Gynaecology, University Hospital St Radboud, Nijmegen, The Netherlands. Source: Knapen, M F Peters, W H Mulder, T P Merkus, H M Jansen, J B Steegers, E A Placenta. 1999 September; 20(7): 541-6 0143-4004
•
Hypertensive diseases and eclampsia. Author(s): Maternal and Fetal Health Research Centre, St Mary's Hospital, Manchester, UK.
[email protected]
80
Eclampsia
Source: Myers, Jenny E Baker, Philip N Curr-Opin-Obstet-Gynecol. 2002 April; 14(2): 119-25 1040-872X •
Inadequate reducing systems in pre-eclampsia: a complementary role for vitamins C and E with thioredoxin-related activities. Author(s): Department of Medical Microbiology, University of Wales College of Medicine, Cardiff, UK. Source: Stark, J M BJOG. 2001 April; 108(4): 339-43 1470-0328
•
Lower circulating insulin-like growth factor I and 1,25-dihydroxyvitamin D levels in preeclampsia. Author(s): Depto. de Fisiologia de la Nutricion, Instituto Nacional de la Nutricion, Mexico, D.F. Source: Halhali, A Bourges, H Carrillo, A Garabedian, M Rev-Invest-Clin. 1995 JulAugust; 47(4): 259-66 0034-8376
•
Magnesium taurate for the prevention and treatment of pre-eclampsia/eclampsia. Author(s): Nutrition 21, San Diego, CA 92109, USA. Source: McCarty, M F Med-Hypotheses. 1996 October; 47(4): 269-72 0306-9877
•
Mechanisms of endothelium-dependent relaxation in myometrial resistance vessels and their alteration in preeclampsia. Author(s): Department of Obstetrics and Gynaecology, City Hospital, Nottingham, United Kingdom. Source: Ashworth, J R Baker, P N Warren, A Y Johnson, I R Hypertens-Pregnancy. 1999; 18(1): 57-71 1064-1955
•
Methylenetetrahydrofolate reductase polymorphism, folate, and susceptibility to preeclampsia. Author(s): Magee-Women's Research Institute, Pittsburgh, PA 15213, USA. Source: Powers, R W Minich, L A Lykins, D L Ness, R B Crombleholme, W R Roberts, J M J-Soc-Gynecol-Investig. 1999 Mar-April; 6(2): 74-9 1071-5576
•
Nitric oxide dysfunction in the pathophysiology of preeclampsia. Author(s): 375th Medical Group, Scott Air Force Base, Illinois 62225, USA.
[email protected] Source: Lowe, D T Nitric-Oxide. 2000 August; 4(4): 441-58 1089-8603
•
Non-medical prevention of pre-eclampsia. Author(s): Department of Obstetrics and Gynecology, University of Tartu, Estonia. Source: Ehrenberg, A Acta-Obstet-Gynecol-Scand-Suppl. 1997; 164108-10 0300-8835
•
Omega-3 fatty acids in maternal erythrocytes and risk of preeclampsia. Author(s): Center for Perinatal Studies, Swedish Medical Center/Seattle, WA 981140999, USA. Source: Williams, M A Zingheim, R W King, I B Zebelman, A M Epidemiology. 1995 May; 6(3): 232-7 1044-3983
•
On the prevention of preeclampsia: nutritional factors back in the spotlight? Author(s): Reproductive Health Unit, School of Public Health, Universite Libre de Bruxelles 808, Route de Lennik, 1070 Brussels, Belgium.
[email protected] Source: Alexander, Sophie Epidemiology. 2002 July; 13(4): 382-3 1044-3983
•
Oxidative stress reproduces placental abnormalities of preeclampsia. Author(s): Department of Obstetrics, Virginia Commonwealth University, Richmond, VA 23298-0034, USA. Source: Vaughan, J E Walsh, S W Hypertens-Pregnancy. 2002; 21(3): 205-23 1064-1955
Nutrition
81
•
Perceived causes of eclampsia in four ethnic groups in Borno State, Nigeria. Author(s): Department of Obstetrics and Gynaecology, University of Maiduguri, Borno State, Nigeria. Source: el Nafaty, A U Omotara, B A Afr-J-Reprod-Health. 1998 April; 2(1): 20-5
•
Physiology of low-dose aspirin therapy for the prevention of preeclampsia. Author(s): Department of Obstetrics, Gynecology, University of Texas Medical School, Houston. Source: Walsh, S W Semin-Perinatol. 1990 April; 14(2): 152-70 0146-0005
•
Placental mitochondria as a source of oxidative stress in pre-eclampsia. Author(s): Department of Obstetrics and Gynecology, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298-0034, USA. Source: Wang, Y Walsh, S W Placenta. 1998 November; 19(8): 581-6 0143-4004
•
Plasma and urinary endothelin 1, prostacyclin metabolites and platelet consumption in pre-eclampsia and essential hypertensive pregnancy. Author(s): University Department of Medicine, Royal Perth Hospital, Australia. Source: Barden, A Beilin, L J Ritchie, J Walters, B N Michael, C A Blood-Press. 1994 March; 3(1-2): 38-46 0803-7051
•
Possible beneficial effect of exercise, by reducing oxidative stress, on the incidence of preeclampsia. Author(s): The University of Michigan, School of Nursing Division of Health Promotion and Risk Reduction, Ann Arbor, Michigan, USA. Source: Yeo, S Davidge, S T J-Womens-Health-Gend-Based-Med. 2001 December; 10(10): 983-9 1524-6094
•
Pre-eclampsia and hypertension. Author(s): Institute of Health Sciences, Oxford, UK. Source: Duley, L Clin-Evid. 2002 June; (7): 1296-309 1462-3846
•
Pre-eclampsia does not change the adhesion molecule status in the placental bed. Author(s): National Public Health Institute and MediCity Research Laboratory, University of Turku, Tykistokatu 6 a, Turku, FIN-20520, Finland. Source: Jaakkola, K Jokimaa, V Kallajoki, M Jalkanen, S Ekholm, E Placenta. 2000 MarApril; 21(2-3): 133-41 0143-4004
•
Pre-eclampsia, diagnosis and treatment. Author(s): Academic Department of Obstetrics and Gynaecology, North Staffordshire Hospital Trust, Maternity Building, Newcastle Road, Stoke On Trent, ST4 6QG, UK. Source: Sunanda, G V Johanson, R Expert-Opin-Pharmacother. 2001 November; 2(11): 1817-24 1465-6566
•
Prevention of preeclampsia. Author(s): Johns Hopkins University School of Medicine, Baltimore, Maryland. Source: Repke, J T Clin-Perinatol. 1991 December; 18(4): 779-92 0095-5108
•
Reduced excretion of vasodilator prostaglandins in preeclampsia. Author(s): Clinica Medica dell'Universita, Policlinico di Borgo Roma, Verona, Italy. Source: Minuz, P Covi, G Corsato, M Probitzer, P Spiazzi, L Paluani, F Degan, M Lechi, C Lechi, A Agents-Actions-Suppl. 1987; 22175-81 0379-0363
•
Serum and placental lipid peroxides in chronic hypertension during pregnancy with and without superimposed preeclampsia. Author(s): Department d'Obstetricia i Ginecologia, Hospital Clinic de Barcelona, Universitat de Barcelona, Catalonia, Spain.
[email protected]
82
Eclampsia
Source: Gratacos, E Casals, E Deulofeu, R Gomez, O Cararach, V Alonso, P L Fortuny, A Hypertens-Pregnancy. 1999; 18(2): 139-46 1064-1955 •
Serum antibodies to oxidized low-density lipoprotein in pregnant women with preeclampsia and chronic hypertension: lack of correlation with lipid peroxides. Author(s): Department d'Obstetricia i Ginecologia, Hospital Cliinic de Barcelona, Universitat de Barcelone, Catalunya, Spain.
[email protected] Source: Gratacos, E Casals, E Deulofeu, R Gomez, O Cararach, V Alonso, P L Fortuny, A Hypertens-Pregnancy. 2001; 20(2): 177-83 1064-1955
•
Sulprostone for pregnancy termination in women with severe (pre-) eclampsia. Author(s): Department of Obstetrics, Albinusdreef 2, 2333 ZA Leiden University Medical Center, Leiden, The Netherlands.
[email protected] Source: van Gemund, N de Boer, M A van Selm, M Scherjon, S A Kanhai, H H Hypertens-Pregnancy. 2002; 21(2): 115-22 1064-1955
•
The effect of acute volume expansion and vasodilatation with verapamil on uterine and umbilical artery Doppler indices in severe preeclampsia. Author(s): Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas. Source: Belfort, M Akovic, K Anthony, J Saade, G Kirshon, B Moise, K J-ClinUltrasound. 1994 June; 22(5): 317-25 0091-2751
•
The renin-angiotensin-aldosterone system in preeclampsia. A review. Author(s): Department of Obstetrics and Gynecology, Free University Hospital, Amsterdam, The Netherlands. Source: de Jong, C L Dekker, G A Sibai, B M Clin-Perinatol. 1991 December; 18(4): 683711 0095-5108
•
The vascular endothelium in normal pregnancy and pre-eclampsia. Author(s): Department of Obstetrics and Gynaecology, University of Glasgow, Glasgow Royal Infirmary, UK. Source: Lyall, F Greer, I A Rev-Reprod. 1996 May; 1(2): 107-16 1359-6004
•
Treatment for postdural puncture headache associated with late postpartum eclampsia. Author(s): Department of Anaesthesiology, University Hospitals Gasthuisberg, UZ Leuven, Belgium. Source: Van de Velde, M Corneillie, M Vanacker, B Stevens, E Verhaeghe, J Van Assche, A Vandermeersch, E Acta-Anaesthesiol-Belg. 1999; 50(2): 99-102 0001-5164
•
Vitamin C and the risk of preeclampsia--results from dietary questionnaire and plasma assay. Author(s): Department of Epidemiology, University of Washington School of Public Health and Community Medicine, 1959 NE Pacific Avenue, Seattle, WA 98195, USA.
[email protected] Source: Zhang, Cuilin Williams, Michelle A King, Irena B Dashow, Edward E Sorensen, Tanya K Frederick, Ihunnaya O Thompson, Mary Lou Luthy, David A Epidemiology. 2002 July; 13(4): 409-16 1044-3983
Nutrition
83
Federal Resources on Nutrition In addition to the IBIDS, the United States Department of Health and Human Services (HHS) and the United States Department of Agriculture (USDA) provide many sources of information on general nutrition and health. Recommended resources include: •
healthfinder®, HHS’s gateway to health information, including diet and nutrition: http://www.healthfinder.gov/scripts/SearchContext.asp?topic=238&page=0
•
The United States Department of Agriculture’s Web site dedicated to nutrition information: www.nutrition.gov
•
The Food and Drug Administration’s Web site for federal food safety information: www.foodsafety.gov
•
The National Action Plan on Overweight and Obesity sponsored by the United States Surgeon General: http://www.surgeongeneral.gov/topics/obesity/
•
The Center for Food Safety and Applied Nutrition has an Internet site sponsored by the Food and Drug Administration and the Department of Health and Human Services: http://vm.cfsan.fda.gov/
•
Center for Nutrition Policy and Promotion sponsored by the United States Department of Agriculture: http://www.usda.gov/cnpp/
•
Food and Nutrition Information Center, National Agricultural Library sponsored by the United States Department of Agriculture: http://www.nal.usda.gov/fnic/
•
Food and Nutrition Service sponsored by the United States Department of Agriculture: http://www.fns.usda.gov/fns/
Additional Web Resources A number of additional Web sites offer encyclopedic information covering food and nutrition. The following is a representative sample: •
AOL: http://search.aol.com/cat.adp?id=174&layer=&from=subcats
•
Family Village: http://www.familyvillage.wisc.edu/med_nutrition.html
•
Google: http://directory.google.com/Top/Health/Nutrition/
•
Healthnotes: http://www.healthnotes.com/
•
Open Directory Project: http://dmoz.org/Health/Nutrition/
•
Yahoo.com: http://dir.yahoo.com/Health/Nutrition/
•
WebMD®Health: http://my.webmd.com/nutrition
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
84
Eclampsia
The following is a specific Web list relating to eclampsia; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
Vitamins Folic Acid Source: Healthnotes, Inc.; www.healthnotes.com Vitamin B12 Source: Healthnotes, Inc.; www.healthnotes.com Vitamin B2 Source: Healthnotes, Inc.; www.healthnotes.com Vitamin B6 Source: Healthnotes, Inc.; www.healthnotes.com Vitamin C Source: Healthnotes, Inc.; www.healthnotes.com Vitamin C Source: Prima Communications, Inc.www.personalhealthzone.com Vitamin E Source: Healthnotes, Inc.; www.healthnotes.com Vitamin E Source: Prima Communications, Inc.www.personalhealthzone.com
•
Minerals Calcium Source: Healthnotes, Inc.; www.healthnotes.com Calcium Source: Integrative Medicine Communications; www.drkoop.com Calcium Source: Prima Communications, Inc.www.personalhealthzone.com Magnesium Source: Healthnotes, Inc.; www.healthnotes.com Magnesium Source: Integrative Medicine Communications; www.drkoop.com Magnesium Source: Prima Communications, Inc.www.personalhealthzone.com Zinc Source: Healthnotes, Inc.; www.healthnotes.com
Nutrition
•
Food and Diet Low-Salt Diet Source: Healthnotes, Inc.; www.healthnotes.com Trans-fats Source: Healthnotes, Inc.; www.healthnotes.com Water Source: Healthnotes, Inc.; www.healthnotes.com Weight Loss and Obesity Source: Healthnotes, Inc.; www.healthnotes.com
85
87
CHAPTER 3. ALTERNATIVE MEDICINE AND ECLAMPSIA Overview In this chapter, we will begin by introducing you to official information sources on complementary and alternative medicine (CAM) relating to eclampsia. At the conclusion of this chapter, we will provide additional sources.
National Center for Complementary and Alternative Medicine The National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (http://nccam.nih.gov/) has created a link to the National Library of Medicine’s databases to facilitate research for articles that specifically relate to eclampsia and complementary medicine. To search the database, go to the following Web site: http://www.nlm.nih.gov/nccam/camonpubmed.html. Select “CAM on PubMed.” Enter “eclampsia” (or synonyms) into the search box. Click “Go.” The following references provide information on particular aspects of complementary and alternative medicine that are related to eclampsia: •
24-hour blood pressure monitoring to evaluate the effects of nifedipine in preeclampsia and in chronic hypertension in pregnancy. Author(s): Benedetto C, Zonca M, Giarola M, Maula V, Chiarolini L, Carandente F. Source: British Journal of Obstetrics and Gynaecology. 1997 June; 104(6): 682-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9197871&dopt=Abstract
•
A case of primary antiphospholipid syndrome who developed acute myocardial infarction followed by early-onset pre-eclampsia. Author(s): Kurum T, Soy M, Karahasanoglu E, Ozbay G, Sayin NC. Source: Clinical Rheumatology. 2003 May; 22(2): 160-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12740688&dopt=Abstract
•
A possible preventive effect of low-dose fish oil on early delivery and pre-eclampsia: indications from a 50-year-old controlled trial. Author(s): Olsen SF, Secher NJ.
88
Eclampsia
Source: The British Journal of Nutrition. 1990 November; 64(3): 599-609. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2265175&dopt=Abstract •
A study of milk and calcium supplement intake and subsequent preeclampsia in a cohort of pregnant women. Author(s): Richardson BE, Baird DD. Source: American Journal of Epidemiology. 1995 April 1; 141(7): 667-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7702042&dopt=Abstract
•
Absence of enhanced systemic inflammatory response at 18 weeks of gestation in women with subsequent pre-eclampsia. Author(s): Djurovic S, Clausen T, Wergeland R, Brosstad F, Berg K, Henriksen T. Source: Bjog : an International Journal of Obstetrics and Gynaecology. 2002 July; 109(7): 759-64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12135211&dopt=Abstract
•
Attempts at dietary alteration of prostaglandin pathways in the management of preeclampsia. Author(s): Moodley J, Norman RJ. Source: Prostaglandins, Leukotrienes, and Essential Fatty Acids. 1989 September; 37(3): 145-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2608693&dopt=Abstract
•
Calcium Metabolism in Preeclampsia: Supplementation May Help. Author(s): Hojo M, August P. Source: Medscape Women's Health [electronic Resource]. 1997 January; 2(1): 5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9746671&dopt=Abstract
•
Calcium supplementation and the risk of preeclampsia in Ecuadorian pregnant teenagers. Author(s): Lopez-Jaramillo P, Delgado F, Jacome P, Teran E, Ruano C, Rivera J. Source: Obstetrics and Gynecology. 1997 August; 90(2): 162-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9241285&dopt=Abstract
•
Calcium supplementation in mild preeclampsia remote from term: a randomized double-blind clinical trial. Author(s): Sanchez-Ramos L, Adair CD, Kaunitz AM, Briones DK, Del Valle GO, Delke I. Source: Obstetrics and Gynecology. 1995 June; 85(6): 915-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7770260&dopt=Abstract
•
Calcium supplementation in nulliparous women for the prevention of pregnancyinduced hypertension, preeclampsia and preterm birth: an Australian randomized
Alternative Medicine 89
trial. FRACOG and the ACT Study Group. Author(s): Crowther CA, Hiller JE, Pridmore B, Bryce R, Duggan P, Hague WM, Robinson JS. Source: The Australian & New Zealand Journal of Obstetrics & Gynaecology. 1999 February; 39(1): 12-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10099740&dopt=Abstract •
Calcium supplementation in pre-eclampsia. Author(s): Wanchu M, Malhotra S, Khullar M. Source: J Assoc Physicians India. 2001 August; 49: 795-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11837466&dopt=Abstract
•
Calcium supplementation to prevent pre-eclampsia--a systematic review. Author(s): Hofmeyr GJ, Roodt A, Atallah AN, Duley L. Source: South African Medical Journal. Suid-Afrikaanse Tydskrif Vir Geneeskunde. 2003 March; 93(3): 224-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12768949&dopt=Abstract
•
Chlormethiazole in the treatment of pre-eclampsia. Author(s): Varma T. Source: J Obstet Gynaecol Br Commonw. 1972 June; 79(6): 513-7. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5033001&dopt=Abstract
•
Decreased levels of polyunsaturated fatty acids in preeclampsia. Author(s): Wang YP, Kay HH, Killam AP. Source: American Journal of Obstetrics and Gynecology. 1991 March; 164(3): 812-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1900662&dopt=Abstract
•
Diet, pre-eclampsia, and intrauterine growth retardation. Author(s): Andersen HJ, Andersen LF, Fuchs AR. Source: Lancet. 1989 May 20; 1(8647): 1146. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2566093&dopt=Abstract
•
Dietary supplementation with L-arginine or placebo in women with pre-eclampsia. Author(s): Staff AC, Berge L, Haugen G, Lorentzen B, Mikkelsen B, Henriksen T. Source: Acta Obstetricia Et Gynecologica Scandinavica. 2004 January; 83(1): 103-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14678093&dopt=Abstract
•
Eclampsia 1963-1966. Evaluation of the treatment of 107 cases. Author(s): Lopez-Llera M.
90
Eclampsia
Source: J Obstet Gynaecol Br Commonw. 1967 June; 74(3): 379-84. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6026615&dopt=Abstract •
Eclampsia. Author(s): Lawson J. Source: Clin Obstet Gynaecol. 1982 December; 9(3): 711-21. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6756754&dopt=Abstract
•
Effect of calcium supplementation on pregnancy-induced hypertension and preeclampsia: a meta-analysis of randomized controlled trials. Author(s): Bucher HC, Guyatt GH, Cook RJ, Hatala R, Cook DJ, Lang JD, Hunt D. Source: Jama : the Journal of the American Medical Association. 1996 April 10; 275(14): 1113-7. Erratum In: Jama 1996 November 6; 276(17): 1388. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8601931&dopt=Abstract
•
Effect of oral magnesium supplementation on experimental pre-eclampsia induced by prolonged blockade of nitric oxide synthesis in pregnant rats. Author(s): Pandhi P, Saha L, Malhotra S. Source: Indian J Exp Biol. 2002 March; 40(3): 349-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12635709&dopt=Abstract
•
Effects of a combination of evening primrose oil (gamma linolenic acid) and fish oil (eicosapentaenoic + docahexaenoic acid) versus magnesium, and versus placebo in preventing pre-eclampsia. Author(s): D'Almeida A, Carter JP, Anatol A, Prost C. Source: Women & Health. 1992; 19(2-3): 117-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1492408&dopt=Abstract
•
Effects of folic acid and vitamin B6 supplementation on women with hyperhomocysteinemia and a history of preeclampsia or fetal growth restriction. Author(s): Leeda M, Riyazi N, de Vries JI, Jakobs C, van Geijn HP, Dekker GA. Source: American Journal of Obstetrics and Gynecology. 1998 July; 179(1): 135-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9704778&dopt=Abstract
•
Fulminating pre-eclampsia with cesarean section performed under hypnosis; a case report. Author(s): WINKELSTEIN LB, LEVINSON J. Source: American Journal of Obstetrics and Gynecology. 1959 August; 78(2): 420-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=13670218&dopt=Abstract
Alternative Medicine 91
•
High intake of energy, sucrose, and polyunsaturated fatty acids is associated with increased risk of preeclampsia. Author(s): Clausen T, Slott M, Solvoll K, Drevon CA, Vollset SE, Henriksen T. Source: American Journal of Obstetrics and Gynecology. 2001 August; 185(2): 451-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11518908&dopt=Abstract
•
Influence of preeclampsia or maternal intake of omega-3 fatty acids on the vasoactive effect of prostaglandin F-two-alpha in human umbilical arteries. Author(s): Haugen G, Helland I. Source: Gynecologic and Obstetric Investigation. 2001; 52(2): 75-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11586032&dopt=Abstract
•
Magnesium supplementation in pregnancy-induced hypertension and preeclampsia. Author(s): Rudnicki M, Frolich A, Fischer-Rasmussen W. Source: Acta Obstetricia Et Gynecologica Scandinavica. 1994 February; 73(2): 95-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8116360&dopt=Abstract
•
NADPH oxidase activity in preeclampsia with immortalized lymphoblasts used as models. Author(s): Lee VM, Quinn PA, Jennings SC, Ng LL. Source: Hypertension. 2003 April; 41(4): 925-31. Epub 2003 March 10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12629036&dopt=Abstract
•
Non-medical prevention of pre-eclampsia. Author(s): Ehrenberg A. Source: Acta Obstetricia Et Gynecologica Scandinavica. Supplement. 1997; 164: 108-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9225653&dopt=Abstract
•
Omega-3 fatty acids in maternal erythrocytes and risk of preeclampsia. Author(s): Williams MA, Zingheim RW, King IB, Zebelman AM. Source: Epidemiology (Cambridge, Mass.). 1995 May; 6(3): 232-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7619928&dopt=Abstract
•
Plasma cortisol and adrenocorticotrophic hormone in normal men and non-pregnant women, normal pregnant women and women with pre-eclampsia. Author(s): Mukherjee K, Swyer GI. Source: J Obstet Gynaecol Br Commonw. 1972 June; 79(6): 504-12. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4338172&dopt=Abstract
•
Possible dietary measures in the prevention of pre-eclampsia and eclampsia. Author(s): Baker PN.
92
Eclampsia
Source: Baillieres Clin Obstet Gynaecol. 1995 September; 9(3): 497-507. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8846552&dopt=Abstract •
Preeclampsia and reproductive performance in a community of vegans. Author(s): Carter JP, Furman T, Hutcheson HR. Source: Southern Medical Journal. 1987 June; 80(6): 692-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3589760&dopt=Abstract
•
Pre-eclampsia. III: The role of aspirin in prevention. Author(s): de Swiet M. Source: Mod Midwife. 1994 December; 4(12): 20-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7697403&dopt=Abstract
•
Preeclampsia: a hyperdynamic disease model. Author(s): Easterling TR, Benedetti TJ. Source: American Journal of Obstetrics and Gynecology. 1989 June; 160(6): 1447-53. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2567574&dopt=Abstract
•
Preeclampsia: from epidemiological observations to molecular mechanisms. Author(s): Lopez-Jaramillo P, Casas JP, Serrano N. Source: Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas / Sociedade Brasileira De Biofisica. [et Al.]. 2001 October; 34(10): 1227-35. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11593296&dopt=Abstract
•
Pregnant women with a low milk intake have an increased risk of developing preeclampsia. Author(s): Duvekot EJ, de Groot CJ, Bloemenkamp KW, Oei SG. Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2002 October 10; 105(1): 11-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12270557&dopt=Abstract
•
Prevention of preeclampsia by linoleic acid and calcium supplementation: a randomized controlled trial. Author(s): Herrera JA, Arevalo-Herrera M, Herrera S. Source: Obstetrics and Gynecology. 1998 April; 91(4): 585-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9540946&dopt=Abstract
•
Prevention of preeclampsia with calcium supplementation and its relation with the Larginine:nitric oxide pathway. Author(s): Lopez-Jaramillo P.
Alternative Medicine 93
Source: Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas / Sociedade Brasileira De Biofisica. [et Al.]. 1996 June; 29(6): 731-41. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9070385&dopt=Abstract •
Prevention of preeclampsia with calcium supplementation and vitamin D3 in an antenatal protocol. Author(s): Ito M, Koyama H, Ohshige A, Maeda T, Yoshimura T, Okamura H. Source: International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics. 1994 November; 47(2): 115-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7843479&dopt=Abstract
•
Prevention of preeclampsia. Author(s): Mattar F, Sibai BM. Source: Semin Perinatol. 1999 February; 23(1): 58-64. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10102171&dopt=Abstract
•
Prevention of preeclampsia: a big disappointment. Author(s): Sibai BM. Source: American Journal of Obstetrics and Gynecology. 1998 November; 179(5): 1275-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9822515&dopt=Abstract
•
Prevention of preeclampsia: is it possible? Author(s): Norwitz ER, Robinson JN, Repke JT. Source: Clinical Obstetrics and Gynecology. 1999 September; 42(3): 436-54. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10451763&dopt=Abstract
•
Relationship between elevated lipid peroxides, vitamin E deficiency and hypertension in preeclampsia. Author(s): Jain SK, Wise R. Source: Molecular and Cellular Biochemistry. 1995 October 4; 151(1): 33-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8584011&dopt=Abstract
•
Supplementary calcium in prevention of pre-eclampsia. Author(s): Niromanesh S, Laghaii S, Mosavi-Jarrahi A. Source: International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics. 2001 July; 74(1): 17-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11430936&dopt=Abstract
•
The effect of garlic tablet on plasma lipids and platelet aggregation in nulliparous pregnants at high risk of preeclampsia. Author(s): Ziaei S, Hantoshzadeh S, Rezasoltani P, Lamyian M.
94
Eclampsia
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2001 December 1; 99(2): 201-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11788172&dopt=Abstract •
The holistic management of the patient with pre-eclampsia. Author(s): Turner A. Source: Nursing in Critical Care. 1997 July-August; 2(4): 169-73. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9873319&dopt=Abstract
•
The influence of pre-eclampsia and diabetes mellitus on plasma free amino acids in maternal, umbilical vein and infant blood. Author(s): Cockburn F, Blagden A, Michie EA, Forfar JO. Source: J Obstet Gynaecol Br Commonw. 1971 March; 78(3): 215-31. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5558838&dopt=Abstract
•
The Parkland Memorial Hospital protocol for treatment of eclampsia: evaluation of 245 cases. Author(s): Pritchard JA, Cunningham FG, Pritchard SA. Source: American Journal of Obstetrics and Gynecology. 1984 April 1; 148(7): 951-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6711634&dopt=Abstract
•
Vitamin C and E supplementation in women at risk of preeclampsia is associated with changes in indices of oxidative stress and placental function. Author(s): Chappell LC, Seed PT, Kelly FJ, Briley A, Hunt BJ, Charnock-Jones DS, Mallet A, Poston L. Source: American Journal of Obstetrics and Gynecology. 2002 September; 187(3): 777-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12237663&dopt=Abstract
•
Vitamin E supplementation in preeclampsia. Author(s): Stratta P, Canavese C, Porcu M, Dogliani M, Todros T, Garbo E, Belliardo F, Maina A, Marozio L, Zonca M. Source: Gynecologic and Obstetric Investigation. 1994; 37(4): 246-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8050728&dopt=Abstract
Additional Web Resources A number of additional Web sites offer encyclopedic information covering CAM and related topics. The following is a representative sample: •
Alternative Medicine Foundation, Inc.: http://www.herbmed.org/
•
AOL: http://search.aol.com/cat.adp?id=169&layer=&from=subcats
Alternative Medicine 95
•
Chinese Medicine: http://www.newcenturynutrition.com/
•
drkoop.com®: http://www.drkoop.com/InteractiveMedicine/IndexC.html
•
Family Village: http://www.familyvillage.wisc.edu/med_altn.htm
•
Google: http://directory.google.com/Top/Health/Alternative/
•
Healthnotes: http://www.healthnotes.com/
•
MedWebPlus: http://medwebplus.com/subject/Alternative_and_Complementary_Medicine
•
Open Directory Project: http://dmoz.org/Health/Alternative/
•
HealthGate: http://www.tnp.com/
•
WebMD®Health: http://my.webmd.com/drugs_and_herbs
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
•
Yahoo.com: http://dir.yahoo.com/Health/Alternative_Medicine/
The following is a specific Web list relating to eclampsia; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
General Overview Diabetes Mellitus Source: Integrative Medicine Communications; www.drkoop.com Edema Source: Healthnotes, Inc.; www.healthnotes.com Gestational Hypertension Source: Healthnotes, Inc.; www.healthnotes.com High Blood Pressure Source: Integrative Medicine Communications; www.drkoop.com High Homocysteine Source: Healthnotes, Inc.; www.healthnotes.com Obesity Source: Integrative Medicine Communications; www.drkoop.com Preeclampsia Source: Healthnotes, Inc.; www.healthnotes.com Preeclampsia Source: Integrative Medicine Communications; www.drkoop.com Pregnancy and Postpartum Support Source: Healthnotes, Inc.; www.healthnotes.com
96
•
Eclampsia
Alternative Therapy Naturopathy Source: Integrative Medicine Communications; www.drkoop.com
•
Chinese Medicine Gouteng Alternative names: Gambir Plant; Ramulus Uncariae cum Uncis Source: Chinese Materia Medica
•
Herbs and Supplements Aesculus Alternative names: Horse Chestnut; Aesculus hippocastanum L. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Glycyrrhiza Alternative names: Licorice; Glycyrrhiza glabra L. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Lobelia Source: The Canadian Internet Directory for Holistic Help, WellNet, Health and Wellness Network; www.wellnet.ca
General References A good place to find general background information on CAM is the National Library of Medicine. It has prepared within the MEDLINEplus system an information topic page dedicated to complementary and alternative medicine. To access this page, go to the MEDLINEplus site at http://www.nlm.nih.gov/medlineplus/alternativemedicine.html. This Web site provides a general overview of various topics and can lead to a number of general sources.
97
CHAPTER 4. PATENTS ON ECLAMPSIA Overview Patents can be physical innovations (e.g. chemicals, pharmaceuticals, medical equipment) or processes (e.g. treatments or diagnostic procedures). The United States Patent and Trademark Office defines a patent as a grant of a property right to the inventor, issued by the Patent and Trademark Office.8 Patents, therefore, are intellectual property. For the United States, the term of a new patent is 20 years from the date when the patent application was filed. If the inventor wishes to receive economic benefits, it is likely that the invention will become commercially available within 20 years of the initial filing. It is important to understand, therefore, that an inventor’s patent does not indicate that a product or service is or will be commercially available. The patent implies only that the inventor has “the right to exclude others from making, using, offering for sale, or selling” the invention in the United States. While this relates to U.S. patents, similar rules govern foreign patents. In this chapter, we show you how to locate information on patents and their inventors. If you find a patent that is particularly interesting to you, contact the inventor or the assignee for further information. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical patents that use the generic term “eclampsia” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on eclampsia, we have not necessarily excluded non-medical patents in this bibliography.
Patents on Eclampsia By performing a patent search focusing on eclampsia, you can obtain information such as the title of the invention, the names of the inventor(s), the assignee(s) or the company that owns or controls the patent, a short abstract that summarizes the patent, and a few excerpts from the description of the patent. The abstract of a patent tends to be more technical in nature, while the description is often written for the public. Full patent descriptions contain much more information than is presented here (e.g. claims, references, figures, diagrams, etc.). We will tell you how to obtain this information later in the chapter. The following is an 8Adapted
from the United States Patent and Trademark Office: http://www.uspto.gov/web/offices/pac/doc/general/whatis.htm.
98
Eclampsia
example of the type of information that you can expect to obtain from a patent search on eclampsia: •
Adrenomedullin receptor polynucleotides Inventor(s): Gout; Bernard Emile Joseph (Rennes, FR), Krief; Stephane Clement (Montgermont, FR), Mahe; Eve (La Chapelle des Fougeretz, FR), Poste; George Henry (Dover, PA), Robert; Philippe Laurent (Pace, FR), Souchet; Michel Louis (Rennes, FR) Assignee(s): Smithkline Beecham Corporation (philadelphia, Pa), Smithkline Beecham Laboratoires Pharmaceutiques (cedex, Fr) Patent Number: 6,197,069 Date filed: September 3, 1998 Abstract: Putative Adrenomedullin Receptor polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Putative Adrenomedullin Receptor polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; diabetes, obesity; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension, urinary retention, osteoporosis; angina pectoris; myocardial infarction, ulcers; asthma; allergies; benign prostatic hypertrophy; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome; and preeclampsia, among others and diagnostic assays for such conditions. Excerpt(s): This invention relates to newly identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to G-protein coupled receptor family, hereinafter referred to as Putative Adrenomedullin Receptor. The invention also relates to inhibiting or activating the action of such polynucleotides and polypeptides. It is well established that many medically significant biological processes are mediated by proteins participating in signal transduction pathways that involve G-proteins and/or second messengers, e.g., cAMP (Lefkowitz, Nature, 1991, 351:353-354). Herein these proteins are referred to as proteins participating in pathways with G-proteins or PPG proteins. Some examples of these proteins include the GPC receptors, such as those for adrenergic agents and dopamine (Kobilka, B. K., et al., Proc. Natl Acad. Sci., U.S.A., 1987, 84:46-50; Kobilka, B. K., et al., Science, 1987, 238:650-656; Bunzow, J. R, et al., Nature, 1988, 336:783-787), Gproteins themselves, effector proteins, e.g., phospholipase C, adenyl cyclase, and phosphodiesterase, and actuator proteins, e.g., protein kinase A and protein kinase C (Simon, M. I., et al., Science, 1991, 252:802-8). For example, in one form of signal transduction, the effect of hormone binding is activation of the enzyme, adenylate cyclase, inside the cell. Enzyme activation by hormones is dependent on the presence of the nucleotide GTP. GTP also influences hormone binding. A G-protein connects the hormone receptor to adenylate cyclase. G-protein was shown to exchange GTP for bound GDP when activated by a hormone receptor. The GTP carrying form then binds to activated adenylate cyclase. Hydrolysis of GTP to GDP, catalyzed by the G-protein itself; returns the G-protein to its basal, inactive form. Thus, the G-protein serves a dual role, as an intermediate that relays the signal from receptor to effector, and as a clock that controls the duration of the signal.
Patents 99
Web site: http://www.delphion.com/details?pn=US06197069__ •
Compositions, kits, and methods for modulating survival and differentiation of multi-potential hematopoietic progenitor cells Inventor(s): Cohen; Isaac (Wilmette, IL), Lefebvre; Phil (Chicago, IL), Lin; Jiandie (Evanston, IL), Linzer; Daniel (Evanston, IL) Assignee(s): The Board of Trustees of Northwestern University (evanston, Il) Patent Number: 6,261,841 Date filed: June 23, 2000 Abstract: The invention includes compositions, kits, and methods for modulating survival and differentiation of mammalian multi-potential hematopoietic progenitor cells using a placental glycoprotein hormone of the murine prolactin family, namely either murine prolactin-like protein E or murine prolactin-like protein F. The compositions, kits, and methods described herein can be used, for example, for in vitro or ex vivo expansion of hematopoietic precursor cells or to treat a disorder associated with aberrant hematopoiesis (e.g., pre-eclampsia and thrombocytopenia). Excerpt(s): The invention relates generally to the field of maintaining and expanding populations of hematopoietic cells ex vivo. Blood cells of all types derive from hematopoietic progenitor cells, which are multipotential (i.e., capable of differentiating into any of a variety of types of blood cells) at early stages of development. At later stages of development, a hematopoietic progenitor cell can become one of only certain types of cells, depending on the developmental path the cell has undergone. By way of example, a hematopoietic stem cell can differentiate to become either a myelo-erythroid progenitor cell or a lymphoid stem cell. If the cell becomes a myelo-crythroid progenitor cell, it can become an erythroid progenitor (and subsequently an erythrocyte) or a myeloid progenitor cell. A myeloid progenitor cell, in turn, can differentiate to become a megakaryocyte (MK), or one of several other types of blood cells. Platelets are derived from MKs. Thus, MKs and the physiological processes by which hematopoietic progenitor cells differentiate into MKs are involved in disorders associated with aberrant formation and activation of platelets. Many pregnancy-associated diseases (e.g., pregnancy-induced hypertension, pre-eclampsia, and diabetes) result from aberrant modulation of maternal physiology. For example, although the platelet count has been observed to decrease slightly during human pregnancy in some studies (Fay et al., 1983, Obst. Gynecol. 61:238-240), the rate of platelet production apparently increases to compensate for the dramatic increase in blood volume during pregnancy (Davison et al., 1989, Baillieres Clin. Endocrinol. Metab. 3:451-472). Aberrantly high rates of platelet activation in plasma have been clinically associated with pre-eclampsia, and antiplatelet treatment is widely used to treat pregnant women afflicted with this disorder (Beaufils et al., 1985, Lancet 1:840-842; Steyn et al., 1997, Lancet 350:1267-1271; Konijnenberg et al., 1997, Am. J. Obst. Gynecol. 176:461-469). Disorders associated with aberrantly low rates of platelet production include thrombocytopenia (e.g., that associated with leukemia and alcohol-induced thrombocytopenia). Web site: http://www.delphion.com/details?pn=US06261841__
100
•
Eclampsia
Determining pregnancy induced hypertension and eclampsia by immunoassay of cellular fibronectin Inventor(s): Senyei; Andrew E. (Santa Ana, CA), Teng; Nelson N. H. (Hillsborough, CA) Assignee(s): Adeza Biomedical Corporation (sunnyvale, Ca) Patent Number: 5,079,171 Date filed: January 27, 1989 Abstract: Preeclampisa, pregnancy induced hypertension (PIH) and eclampsia are determined by identifying the presence of an endothelial cell marker in a sample of blood, plasma or serum of a pregnant woman using a sandwich or competition immunoassay. Cellular fibronectin marker in a sample is determined by binding with an anti-(cellular fibronectin) antibody. Reagents for these methods are also an aspect of the invention. Excerpt(s): This invention relates to methods, reagents and kits for detection of pregnancy induced hypertension (PIH) or preeclampsia during pregnancy. In particular, this invention is directed to the determination of PIH or preeclampsia by testing whole blood, serum or plasma samples for the presence of a marker for endothelial cell injury, for example cellular fibronectin. Preeclampsia, eclampsia and pregnancy induced hypertension (PIH) are characterized by elevated blood pressure, proteinuria, and edema. The cause and nature of these disorders is only partially understood. Preeclampsia and PIH are often used to designate the same disorders. The term "preeclampsia" is used hereinafter, for purposes of clarity of explanation, not by way of limitation, to broadly include preeclampsia, pregnancy induced hypertension, and eclampsia. Although considered to be relatively rare in the United States, preeclampsia occurs worldwide in from 2 to 35 percent of pregnancies, depending on diagnostic criteria and study population. Deaths from preeclampsia are nearly equal to those from eclampsia in a recent report by Redman, C. Brit.Med.J. 296:1209-1210 (April, 1988). However, tests for these conditions are often ambiguous, and diagnosis of these conditions have often not been possible until the condition had progressed. A reliable test for early diagnosis of this condition is critically needed. A review of the role of prostaglandins in preeclampsia was published by Friedman, S. Obstet.Gynecol.71:122137 (1988). Examination of maternal fluids for metabolic markers for PIH and preeclampsia has revealed that urine levels of 2,3-dinor-6-keto PG F.sub.1.alpha. increase during this condition, Ob/Gyn Topics, 2:5 (1987). Levels of other substances in the blood have also been studied. Web site: http://www.delphion.com/details?pn=US05079171__
•
Method for lowering abdominal pressure Inventor(s): Sugerman; Harvey J. (Richmond, VA) Assignee(s): Virginia Commonwealth University (richmond, Va) Patent Number: 5,893,368 Date filed: May 15, 1996 Abstract: An abdominal decompression apparatus is used to treat a variety of disorders including acute abdominal compartment syndrome, increased intra-abdominal pressure related morbidity in severely obese persons, and pre-eclampsia and other complications associated with increased abdominal pressure in pregnancy. The abdominal
Patents 101
decompression apparatus is worn for an extended period of time (e.g., 6-12 hours at a time), with relatively low levels of pressure being applied (e.g., -20 to -45 mm Hg). Preferably, abdominal decompression is performed on a continuous basis with the final pressure being gradually achieved. In a preferred embodiment, the patient's urinary bladder pressure is used as a measure of intra-abdominal pressure. The sensed urinary bladder pressure can be used to gauge the effectiveness of treatment as well as to control parameters of the abdominal decompression device (e.g., time of use, pressure utilized, etc.). Excerpt(s): The invention is generally related to medical devices used for lowering intraabdominal pressure (IAP) in patients. Abdominal decompression has been investigated for a number of years in connection with the treatment of pregnant women. Specifically, studies have been conducted to evaluate the ability of abdominal decompression to ease the pain of labor, to increase intra-uterine fetal growth, or treat toxemia of pregnancy. In all previous investigations, abdominal decompression was performed intermittently at high negative pressures for short periods of time (e.g., -70 mm Hg for 30 seconds every minute for 30 minutes, twice daily). Heyns, Obstet. Gynaecol. Br. Commonw., 66:220-228, 1959, discloses a study wherein intermittent abdominal decompression is used for the treatment of labor pains during the first stage of labor. Eight patients were used in the study, and the patients controlled the negative pressure themselves by placing a finger over a vent tube to bring the pressure down to around 50 mm Hg in most instances for about sixty seconds. However, in some cases the pressure was brought down to as low as 150 mm Hg. The article reports that the labor pains were relieved in all eight patients, and that the treatment did not interfere with diagnosing the second stage of labor (actual commencement of delivery). Web site: http://www.delphion.com/details?pn=US05893368__ •
Method of treating preeclampsia Inventor(s): Killian; Anthony (Libertyville, IL) Assignee(s): Tap Pharmaceuticals, Inc. (deerfield, Il) Patent Number: 5,534,548 Date filed: May 3, 1994 Abstract: Straight-chain alkanoic acids, substituted at the.OMEGA.-carbon atom by a substituted phenyl, naphthyl, furyl, or thienyl group and by a substituted 1,4benzoquinon-2-yl group are effective in the therapy or prophylaxis of conditions associated with lipid peroxide injury to vascular endothelium particularly preeclampsia and eclampsia in pregnant females. Excerpt(s): The present invention relates to medical methods of treatment. More particularly, the present invention concerns the use of a class of substituted.OMEGA.(1,4-benzoquinon-2-yl)alkanoic acids for the therapy or prophylaxis of conditions associated with excess production of lipid peroxides which may lead to vascular endothelial injury, particularly the conditions of preeclampsia and eclampsia. Preeclampsia is the development of hypertension with proteinuria or edema in pregnant women between the twentieth week of pregnancy and the end of the first week following delivery without apparent cause. Preeclampsia develops in roughly 5% of pregnant women, typically in women with a prior history of hypertension or vascular disease. If left untreated, preeclampsia can often rapidly progress to eclampsia which is fatal if untreated and which occurs in about 1 out of every 200 women who develop
102
Eclampsia
preeclampsia. Mild preeclampsia is typically treated with bed rest. If the condition persists or develops into eclampsia, the usual treatment is the immediate induction of labor and delivery of the fetus. Web site: http://www.delphion.com/details?pn=US05534548__ •
Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor Inventor(s): Wimalawansa; Sunil J. (Friendswood, TX), Yallampalli; Chandrasekhar (Houston, TX) Assignee(s): Board of Regents, the University of Texas System (austin, Tx) Patent Number: 5,910,482 Date filed: March 19, 1996 Abstract: The present invention provides a method for counteracting preeclampsia, eclampsia of pregnancy and preterm labor in a pregnant female mammal treated by administering thereto calcitonin gene-related peptide (CGRP) or its analogues including CGRP/adrenomedullin or their peptide or receptor-based analogues, or in combination with a progestin, and with or without a nitric oxide substrate, or a nitric oxide donor or both, optionally in further combination with one or more of a cyclooxygenase inhibitor, a PGI.sub.2 -mimetic, a thromboxane (TXA.sub.2) inhibitor, a compound possessing TXA.sub.2 -agonistic, and TXA.sub.2 -inhibiting properties, a compound possessing TXA.sub.2 -antagonistic and PGI.sub.2 -mimetic activities, and a TXA.sub.2 antagonist. CGRP, progesterone and some of the nitric oxide substrate and donor compounds are naturally occurring compounds. As such these agents do not have the same toxicity and allergy problems as the foreign substances that are currently used for similar purposes. During pregnancy uterine blood vessels and the uterine muscles are particularly sensitive to CGRP as well as nitric oxide. Therefore, one could administer a very small quantities of these drugs (i.e., intravenously, subcutaneous, or Implants), the effects are then seen mainly in the uterine muscle and blood vessels, namely increase the blood supply to the uteroplacental unit (hence nutrients and oxygen supply to the fetus through the improved placental circulation), and uterine muscular relaxation thereby ameliorate the signs and symptoms of preeclampsia, and eclampsia, and prevent preterm labor. At these dosages, virtually no systemic effects are induced, making CGRP (which is an endogenous natural product present in human body) extremely safe and effective. Excerpt(s): This invention relates to a method for the treatment of preeclampsia and of preterm labor with calcitonin gene-related peptide (CGRP) or CGRP/CGRP receptorbased analogue and combinations with a progestational agent (with or without a nitric oxide synthase substrate such as L-arginine, a nitric oxide donor or both), alone or in further combination with one or more of a cyclooxygenase inhibitor, a PGI.sub.2 mimetic, a thromboxane (TXA.sub.2) inhibitor, A compound possessing TXA.sub.2 agonistic and TXA.sub.2 -inhibiting properties, a compound possessing TXA.sub.2 antagonistic and PGI.sub.2 -mimetic activities, and a TXA.sub.2 antagonist, and to pharmaceutical compositions comprising such a combination. Preeclampsia, toxemia, or eclampsia of pregnancy can be significant health problems during pregnancy and are the leading causes of fetal growth retardation, fetal mortality, premature birth, and maternal mortality. The etiology of this pathology is largely unknown and effective therapy is not available. Preeclampsia of pregnancy is characterized by a triad of
Patents 103
hypertension, pathological edema and proteinuria. This disease affects 6 to 10% of all pregnancies. Nitric oxide (NO) has been shown to be the endothelium derived relaxing factor (EDRF) generated from the endothelium of blood vessels. Nitric oxide is a major mediator in the control of vascular relaxation. Nitric oxide is synthesized from Larginine by nitric oxide synthase located in endothelial and other cells. Nitric oxide can also be generated by application of various nitric oxide donors such as sodium nitroprusside, nitroglycerin, SIN-1, isosorbid mononitrate, isosorbid dinitrate, and the like. Web site: http://www.delphion.com/details?pn=US05910482__ •
Use of fibronectin having a variable included type III repeat sequence as a marker for toxemia in pregnancy Inventor(s): Lockwood; Charles J. (210 Hobart, Hingham, MA 02043), Peters; John H. (3290-58 Via Marin, La Jolla, CA 92037) Assignee(s): None Reported Patent Number: 5,108,898 Date filed: January 18, 1989 Abstract: The elevation of human cellular fibronectin monomers having a variably included Type III repeat in a pregnant woman, as early as the first trimester, has been found to precede the onset of the clinical manifestations of toxemia and correlate with the severity of the disease state. The present invention provides a means of detection for and the monitoring of the toxemias of pregnancy, particularly preeclampsia and eclampsia, by the use a marker, human fibronectin having a variably included Type III repeat sequence, ED1 or ED2. Excerpt(s): The present invention relates to a method for the detection and monitoring of toxemia, particularly preeclampsia, in a pregnant woman by use of a marker, human fibronectin having a variably included Type III repeat (ED1+Fn or ED2+Fn). More specifically, it relates to a method for the determination of the concentration of the fibronectin in a body sample from a pregnant woman, which concentration has been found to correlate with the disease state. Preeclampsia and eclampsia are toxemias associated with pregnancy. Preeclampsia is classically defined as the triad of hypertension, proteinuria, and edema associated with pregnancy. Other manifestations of preeclampsia are vascular prostenoid and platelet derangements, vasospasm, uteroplacental vascular lesions, and in severe cases, convulsions and coma (eclampsia). Walsh et al., Am. J. Obstet. Gynecol., 151:100-15 (1985); Goodman et al., Am. J. Obstet. Gynecol., 142:817-22 (1982); Kitzmiller et al., Am. J. Obstet. Gynecol., 118:362-8 (1974); Giles et al., Br. J. Obstet. Gynecol., 88:1115-19(1981); and Gant et al., J. Clin Invest., 52:2682-89 (1973). Toxemia occurs more often in women pregnant for the first time and in those over the age of thirty-five. Toxemia is especially frequent in patients with prior renal and vascular disease. A significant percentage of pregnant women with preexisting hypertension are also likely to have a toxemic episode. Web site: http://www.delphion.com/details?pn=US05108898__
104
Eclampsia
Patent Applications on Eclampsia As of December 2000, U.S. patent applications are open to public viewing.9 Applications are patent requests which have yet to be granted. (The process to achieve a patent can take several years.) The following patent applications have been filed since December 2000 relating to eclampsia: •
Assays Inventor(s): Bord, Stephanie; (Marseille, FR), Rademacher, Thomas William; (Oxford, GB) Correspondence: Dann, Dorfman, Herrell & Skillman; 1601 Market Street; Suite 2400; Philadelphia; PA; 19103-2307; US Patent Application Number: 20040038295 Date filed: August 4, 2003 Abstract: Assays, kits and methods for determining the presence or amount inositol phosphoglycans (IPG) analytes in samples are disclosed based on the finding that IPG antigens are capable of binding to gelatin. These assays can be used in the diagnosis of conditions where the presence or amount of these analytes is a diagnostic marker for a condition. Methods for the diagnosis of pre-eclampsia, distinguishing different type of pre-eclampsia, are disclosed and also methods for determining the onset of labour in a patient. Excerpt(s): The present invention relates to materials and methods for use in assays for determining the presence or amount of an IPG analyte in a sample, and in particular for the diagnosis of pre-eclampsia, distinguishing different types of pre-eclampsia and predicting the onset of labour. Many of the actions of growth factors on cells are thought to be mediated by a family of inositol phosphoglycan (IPG) second messengers (Rademacher et al, 1994). It is thought that the source of IPGs is a "free" form of glycosyl phosphatidylinositol (GPI) situated in cell membranes. IPGs are thought to be released by the action of phosphatidylinositol-specific phospholipases following ligation of growth factors to receptors on the cell surface. There is evidence that IPGs mediate the action of a large number of growth factors including insulin, nerve growth factor, hepatocyte growth factor, insulin-like growth factor I (IGF-I), fibroblast growth factor, transforming growth factor.beta., the action of IL-2 on B-cells and T-cells, ACTH signalling of adrenocortical cells, IgE, FSH and hCG stimulation of granulosa cells, thyrotropin stimulation of thyroid cells, cell proliferation in the early developing ear and rat mammary gland. Soluble IPG fractions have been obtained from a variety of animal tissues including rat tissues (liver, kidney, muscle brain, adipose, heart) and bovine liver. IPG biological activity has also been detected in malaria parasitized red blood cells (RBC) and mycobacteria. We have divided the family of IPG second messengers into distinct A and P-type subfamilies on the basis of their biological activities. In the rat, release of the A and P-type mediators has been shown to be tissuespecific (Kunjara et al, 1995). Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
9
This has been a common practice outside the United States prior to December 2000.
Patents 105
•
Determining existence of complications in pregnancies by measuring levels of bioactive lipids Inventor(s): Parrott, Jeff A.; (Irvine, CA) Correspondence: Orrick, Herrington & Sutcliffe, Llp; 4 Park Plaza; Suite 1600; Irvine; CA; 92614-2558; US Patent Application Number: 20030068653 Date filed: October 8, 2002 Abstract: The present invention relates generally to methods for detecting complications, or abnormal conditions occurring during pregnancy, including placental abnormalities, eclampsia, or preelcampsia. The present invention comprises the steps of obtaining a sample from a patient, assaying the specimen to determine the level of bioactive lipids and comparing levels in the sample to control values or levels in normal samples, and correlating alterations to disease. The invention includes measuring panels of bioactive lipids to screen patients for disease and to monitor the progress of disease for diagnostic or therapeutic purposes. Excerpt(s): This application is a continuation-in-part of co-pending application Ser. No. 09/585,138 filed on Jun. 1, 2000, U.S. Pat. No. 6,461,830. The priority of this prior application is expressly claimed, and the disclosure is hereby incorporated by reference in their entirety. The present invention relates to methods for the early detection of complications in pregnancy, including placental abnormalities and other conditions based on the detection of bioactive lipids. Specifically, the present invention relates to methods for early detection of pregnancy related disorders such as eclampsia and preeclampsia by detecting levels of bioactive lipids including phospholipids, sphingolipids, glycerophosphatidyl compounds, and lysophospholipids, as well as byproducts and molecular species of these compounds in sample specimens obtained from pregnant women. Pregnancy is accompanied by a broad variety of physiological changes and complex metabolic processes that occur in the mother. These processes include lipid synthesis and several cellular mechanisms that involve lipid turnover. In some cases, pregnancy-related disorders affect lipid levels in the body and, when reflective of an underlying abnormality or disease, these lipid levels can be measured to detect the diseases. Many disorders that occur during pregnancy are also accompanied by abnormalities in the structure or function of the placenta including specifically eclampsia, preeclampsia, small gestational age, and others. The placenta is the key organ through which blood and nutrients flow from the mother to the infant and provides an essential lifeline for the developing fetus. When the placenta is abnormal, the result is a virtually unavoidable stress on the mother and infant. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Diagnosis of pre-eclampsia Inventor(s): Groome, Nigel Patrick; (Oxford, GB), Knight, Philip Gerald; (Reading, GB), Ledger, William Leigh; (Sheffield, GB), Muttukrishna, Shanthi; (Oxford, GB), Redman, Christopher Willard George; (Oxford, GB) Correspondence: Wenderoth, Lind & Ponack, L.L.P.; 2033 K Street N. W.; Suite 800; Washington; DC; 20006-1021; US Patent Application Number: 20010055781 Date filed: April 25, 2001
106
Eclampsia
Abstract: A method for diagnosis of pre-eclampsia is disclosed, which comprises measuring the hormone inhibin A in a biological sample such as maternal serum. The method allows non-invasive, early diagnosis and can be used to predict the onset of secondary symptoms. Excerpt(s): This invention relates to detection of pre-eclampsia. In particular, it relates to early diagnosis of pre-eclampsia by detecting elevated levels of the hormone inhibin A. Pre-eclampsia, otherwise known as gestational proteinuric hypertension (GPH) is a multisystem disease of pregnancy of unknown cause. The maternal syndrome is characterised by various abnormalities: increased blood pressure, oedema, proteinuria and abnormal clotting, liver and renal function. The cause of pre-eclampsia is believed to lie in the placenta and there is evidence for a circulating endothelial cell "toxic" factor which is most likely to originate from the syncytiotrophoblast. The syncytiotrophoblast provides the surface of contact between the placenta and the maternal blood and is a multi-nucleated syncytium with an extensive microvillous brush border. Pre-eclampsia is a relatively common condition, occuring in approximately one in ten pregnant women. Around 10% of cases will be severe. In severe cases, early delivery may be necessary and there is therefore the risk of the child being handicapped. Pre-eclampsia also remains a danger to the lives of both babies and mothers. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Diagnosis of pre-eclampsia Inventor(s): Chappell, Luey Charlotte; (London, GB), Hunt, Beverley Jane; (London, GB), Poston, Lucilla; (London, GB), Seed, Paul Townsend; (London, GB) Correspondence: Banner & Witcoff; 1001 G Street N W; Suite 1100; Washington; DC; 20001; US Patent Application Number: 20040038305 Date filed: September 4, 2003 Abstract: The present invention relates to a method of predicting pre-eclampsia (PE). The present invention also relates to a diagnostic kit for performing a method of predicting PE. In particular, the method determining the level of two or more markers selected from placenta growth factor (PIGF), plasminogen activator inhibitor-1 (PAI-1) plasminogen activator inhibitor-2 (PAI-2) and leptin. Excerpt(s): The present invention relates to a method of predicting pre-eclampsia (PE). The present invention also relates to a diagnostic kit for performing a method of predicting PE. PE is defined according to the guidelines of the International Society for the Study of Hypertension in Pregnancy (Davey et al., Am. J. Obstet Gynecol; 158: 89298, 1988). Gestational hypertension is defined as two recordings of diastolic blood pressure of 90 mm Hg or higher at least 4 h apart, and severe pressure of 110 mm Hg or higher at least 4 h apart or one recording of diastolic blood pressure of at least 120 mm Hg. Proteinuria is defined as excretion of 300 mg or more in 24 h or two readings of 2+or higher on dipstick analysis of midstream or catheter urine specimens if no 24 h collection was available. Women are classified as previously normotensive or with chronic hypertension before 20 weeks' gestation. For previously normotensive women, PE is defined as gestational hypertension with proteinuria and severe PE as severe gestational hypertension with proteinuria. For women with chronic hypertension, superimposed PE is defined by the new development of proteinuria. PE affects approximately 4% of all pregnancies and is a leading cause of maternal death in the UK.
Patents 107
This disease, or the threat of onset, is the commonest cause of elective premature delivery, accounting for approximately 15% of all premature births. The measurement of blood pressure and testing for proteinuria in all pregnant women is carried out predominantly for the detection of PE. These procedures and the care of affected women and of the premature children make considerable demands on healthcare resources. Accurate identification of women at risk could dramatically reduce costs of antenatal care. Although, there is no widely used treatment for PE (other than premature delivery), we have recently reported a significant reduction in PE in high risk women given supplements of vitamin C and vitamin E (see Chappell et al., The Lancet, 354, 810816, 1999). Risk was assessed by a test of relatively low sensitivity. More accurate and robust identification of women at risk would target those women most likely to benefit from this, or alternative, prophylactic therapies. Those identified at lower risk could be provided with less intensive and less expensive antenatal care. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Dihydroxy unsaturated fatty acid levels as diagnostic markers Inventor(s): Gee, Shirley; (US), Hammock, Bruce; (US), Newman, John William; (US), Zurek, Gabriela; (US) Correspondence: Townsend And Townsend And Crew, Llp; Two Embarcadero Center; Eighth Floor; San Francisco; CA; 94111-3834; US Patent Application Number: 20030113824 Date filed: May 29, 2001 Abstract: The invention provides methods of using dihydroxy unsaturated fatty acids as markers for identifying patients with a disorder associated with abnormal regulation of the cytochrome P450 metabolism or oxidation of unsaturated fatty acids. In preferred embodiments, linoleic acid diols, including, but not limited to, leukotoxindiol, are used as a diagnostic tool for identifying patients with pre-eclampsia, eclampsia, and pregnancy-induced hypertension. Excerpt(s): This application is related to U.S. Ser. No. 09/721,261, filed Nov. 21, 2000, which is a continuation in part of U.S. Pat. No. 6,150,415, the entire disclosures of both which are incorporated herein by reference. The present invention generally relates to methods of treating hypertension using inhibitors of epoxide hydrolases. Preferred inhibitors include compounds, such as ureas, amides, and carbamates that can interact with the enzyme catalytic site and mimic transient intermediates. Other useful inhibitors include glycodiols and chalcone oxides which can interact with the enzyme as irreversible inhibitors. The invention also relates to methods of identifying patients with disorders or at risk for disorders with abnormal regulation of the cytochrome P450 metabolism or other oxidation of polyunsaturated fatty acids by assaying levels of dihydroxy unsaturated fatty acids. The leukotoxin pathway appears to be involved in regulation of vascular permeability, and failure to regulate vascular permeability is associated with a variety of vascular diseases including adult respiratory distress syndrome (ARDS). ARDS is a pulmonary disease that has a mortality rate of 50% and results from lung lesions that are caused by a variety of conditions found in trauma patients and in severe burn victims. Ingram, R. H. Jr., Harrison's Principals of Internal Medicine, 13:1240 (1995). In ARDS there is an acute inflammatory reaction with high numbers of neutrophils that migrate into the interstitium and alveoli. If this progresses there is increased inflammation, edema, cell proliferation, and the end result is impaired ability to extract oxygen. The exact cause of ARDS is not known. However it has been
108
Eclampsia
hypothesized that over-activation of neutrophils leads to the release of linoleic acid in high levels via phospholipase A.sub.2 activity. Linoleic acid in turn is converted to 9,10epoxy-12-octadecenoate enzymatically by neutrophil cytochrome P-450 epoxygenase and/or a burst of active oxygen. This lipid epoxide, or leukotoxin, is found in high levels in burned skin and in the serum and bronchial lavage of burn patients. Furthermore, when injected into rats, mice, dogs, and other mammals it causes ARDS. With the possible exception of glucocorticoids, there have not been therapeutic agents known to be effective in preventing or ameliorating the tissue injury, such as microvascular damage, associated with acute inflammation that occurs during the early development of ARDS. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Materials and methods relating to the diagnosis and treatment of pre-eclampsia and diabetes Inventor(s): McLean, Patricia; (Surrey, GB), Rademacher, Thomas William; (Oxford, GB) Correspondence: Quine Intellectual Property Law Group, P.C.; P O Box 458; Alameda; CA; 94501; US Patent Application Number: 20030091581 Date filed: May 8, 2002 Abstract: The present invention relates to materials and methods for the diagnosis and treatment of pre-eclampsia, and more particularly to the role of P-type inositolphosphoglycans (IPGs) in the occurrence of pre-eclampsia. Methods of diagnosing pre-eclampsia by determining the level of P-type IPGs and uses of antagonists of P-type IPGs in the treatment of pre-eclampsia are disclosed, together with a method for screening for P-type IPG antagonists. Excerpt(s): The present invention relates to materials and methods for the diagnosis and treatment of pre-eclampsia and diabetes, and more particularly to the role of P-type inositolphosphoglycans (IPGs) in the occurrence of pre-eclampsia, methods of diagnosing pre-eclampsia and uses of antagonists of P-type IPGs in the treatment of pre-eclampsia. Pre-eclampsia is a placental disease [1] characterised by insufficiency of the uteroplacental circulation [2], and which affects 10-12% of all pregnancies and is a major factor in the perinatal mortality rate. There is evidence that one or more placentally-derived factors are released into the maternal circulation which either directly or indirectly cause maternal endothelial dysfunction and ensuing maternal problems with activation of the clotting system increased vascular permeability and ischaemia in maternal organs secondary to vasoconstriction [3]. The present invention arises from investigations to determine whether there is a correlation between preeclampsia and its degree of severity and the profile of inositol phosphoglycans (IPGs) in the pre-eclamptic subjects and their normal age and parity-matched controls. In order to gain information on the significance of the disordered carbohydrate metabolism in the placenta in pre-eclampsia, as previously revealed by the massive increase in glycogen accumulation [4], comparison has been made with diabetic pregnant women in which placental glycogen accumulation is also a prominent feature [4,5], although not accompanied by the same degree of the life-threatening sequelae of pre-eclampsia. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Patents 109
•
Method for controlling preeclampsia and eclampsia Inventor(s): Adair, Charles David; (Signal Mountain, TN) Correspondence: Husch & Eppenberger, Llc; 190 Carondelet Plaza; Suite 600; ST. Louis; MO; 63105-3441; US Patent Application Number: 20040018201 Date filed: July 25, 2002 Abstract: A method of controlling preeclampsia includes the steps of providing a supply of digoxin immune Fab (ovine), calculating an appropriate dosage of the digoxin immune Fab (ovine) based on a patient's weight and using an assumed endogenous digitalis-like factor level, administering the appropriate dosage as an intravenous bolus, and repeating the administ